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General introduction
In 2007, WHO estimated that there are 33.2 million HIV-infected subjects worldwide whereby 
Sub-Sahara Africa is the most affected region. Before Highly Active Antiretroviral Treatment 
(HAART) became available, HIV infection mostly resulted in the Acquired ImmunoDeficiency 
Syndrome (AIDS) and death. HAART has greatly improved the prognosis of seropositive 
patients to the extent that an adequately treated HIV infection is presently considered a 
chronic condition like diabetes mellitus. Precondition is however that patients have access 
to HAART and are able to adhere and tolerate chronic treatment. In developing countries, 
access to HAART has its limitations and many HIV-infected subjects will consult traditional 
docters and are treated with herbal medicines. Herbal medicines, like “Western medicines”, 
can be considered as xenobiotics and may be metabolized by specialized enzymatic systems 
like Cytochrome P450 (CYP450). Apart from xenobiotics, also endogenous compounds may 
be metabolized by this enzymatic metabolizing system. Vitamin D for example is extensively 
metabolized by different enzymes of CYP450.
The first part of this thesis focuses on CYP450 and the metabolism of antiretrovirals (ARV), 
herbal medicines and vitamin D in the HIV-1-infected patient. We hypothesized that 
insufficient vitamin D levels may develop in HIV-infected subjects, among others, as a result 
of Cytochrome P450 interactions. The second part of this study explores this hypothesis and 
the consequences of vitamin D deficiency in HIV infection.
Cytochrome P450
The cytochrome P450 enzyme system (CYP450) is a superfamily of hemethiolate-containing 
enzymes (CYP) that catalyzes the oxidative metabolism of lipophylic xenobiotics and 
endogenous compounds. The antiretroviral classes of protease inhibitors (PI) and non-
nucleoside reverse transcriptase inhibitors (NNRTI), as well as other xenobiotics like herbal 
medicines, are metabolized by CYP450. CYPs are also involved in the biosynthesis and 
metabolism of endogenous compounds such as Vitamin D3. 
The expression of CYP is regulated by nuclear receptors. Members of the nuclear receptor 
group include, among others, Glucocorticoid Receptor (GR), Retinoid X Receptor (RXR), 
Vitamin D Receptor (VDR) , Peroxisome proliferator-activated Receptor (PPAR), Pregnane X 
Receptor (PXR) and Constitutive Androstane Receptor (CAR). Nuclear receptors contain a 
ligand binding domain (LBD) and a DNA binding domain (DBD). The DBD links the receptor 
to specific hormone responsive elements located in the promoter of the target genes and 
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is involved in dimerization of nuclear receptors. Between the nuclear receptors “Cross-talk” 
is common and indicates that individual response elements can be activated by more 
than a single receptor and that one receptor may induce several CYP sub forms. Through 
binding of their corresponding nuclear receptor or by binding directly to the CYP, drugs as 
well as herbal medicines, can respectively induce or inhibit CYPs, thereby giving potential for 
pharmacokinetic drug-drug or drug-herb interactions. 
Cytochrome P450 interaction between medicinal herbs and ARVs
Herbal medicines are commonly used by HIV-infected individuals1, 2. The concomitant use of 
herbal medications with NNRTIs and/or PIs can lead to significant interactions on the level of 
CYP450. Especially since PIs and NNRTIs have a small therapeutic range. 
PIs and NNRTIs are mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 and 
CYP2C93. Induction of these CYPs by herbal medicines may result in subtherapeutic ARV 
plasma levels and in consequence treatment failure and development of resistant HIV, while 
inhibition will lead to higher ARV plasma levels and hence toxicity. In chapter 2 we review 
the available data to answer the question whether the most commonly used African and 
Western herbal medicines and ARVs interact.
Oral candidiasis is one of the commonest opportunistic fungal infection in HIV- infected 
patients in Sub-Saharan African countries, such as Tanzania4. Many of these patients consult a 
traditional healer for their treatment. Herbal medications can offer cheap alternative treatment 
opportunities, although there is limited scientific support for their use in treatment of fungal 
infections. During a field study, as described in Chapter 3, we explored which medicinal 
plants are used by traditional healers for treatment of fungal infections and determined 
their in vitro antifungal activities. Fortunately, the access to antiretroviral agents in Tanzania 
is growing, however this is also increasing the risk of herb-ARV interactions. Therefore we 
investigated the CYP450 enzymatic competition and CYP3A4 inducing effects of the twelve 
most antifungal effective Tanzanian plant extracts in Chapter 4. In addition we wondered 
whether the genotoxicity and cytotoxicity of these twelve herbs was studied. Theoretically 
many herbs can interact with ARVs but little is known from daily clinical practice, apart 
from the interaction between SJW and ARVs. In Chapter 5 we describe a significant clinical 
interaction between the ARV lopinavir and herbal medicines in a HIV-1-infected patient.
Cytochrome P450 and Vitamin D metabolism
The vitamin D metabolism is regulated by several CYP enzymes, although it is not clear which 
exact CYP enzymes are involved in the different hydroxylation steps. Vitamin D is taken up in 
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the body by dietary intake of vitamin D or by formation of pre-vitamin D in the skin trough 
conversion of 7-dehydrocholesterol under influence of sunlight. Thereafter, pre-Vitamin D3 is 
25-hydroxylised in the liver to 25-hydroxy Vitamin D3 (25(OH)D3) and is then 1α-hydroxylized 
to the active metabolite 1α,25-dihydroxy Vitamin D3 (1α,25(OH)2D3) occurring mainly in 
the kidneys (Figure1). The latter hydroxylation step can also occur in macrophages, which 
also express 1α-hydroxylase. Hydroxylation in the kidney is regulated closely by parathyroid 
hormone (PTH), hypocalcaemia, and hypophosphatemia and is inhibited by 1α,25(OH)2D3. 
PTH, stimulated mainly by hypocalcaemia (and low 1α,25(OH)2D3), increases plasma calcium 
levels by stimulating vitamin D synthesis and the renal 1α-hydroxylation, increasing bone 
resorption and renal tubular calcium reabsorption. 
Inactivation of the vitamin D metabolites occurs mainly by 24-hydroxylase, forming 
24,25(OH)2D3 and 1α,24,25(OH)3D3, which is regulated by high 1α,25(OH)2D3 levels and 
hypercalcaemia (Figure1).
Vitamin D in HIV infection
Low 25(OH)D3 levels have been reported among HIV-infected patients5. In a pilot study at 
our hospital, we found that about 40% of the HIV-infected patients had vitamin D deficiency. 
25(OH)D3 is the best indicator of the vitamin D status and reflects levels from dietary 
intake and synthesis in the skin6. Beside the common risk factors, including low sunlight 
exposure, high skin pigmentation and low dietary intake, both HIV itself and highly active 
antiretroviral therapy (HAART) may contribute to a low vitamin D status.  HIV can inhibit 
the 1α-hydroxylation in the kidney, probably caused by an inhibitory effect of TNFα or other 
cytokines7, 8. PIs and NNRTIs can respectively inhibit or induce CYPs and as such interfere with 
vitamin D metabolism. In Chapter 6 we investigated the prevalence and causes of vitamin D 
deficiency in HIV-1-infected patients and  focused, in specific, on effects of ARVs on vitamin 
D metabolism.
Functions of Vitamin D and possible consequences of vitamin D deficiency in HIV 
infection
The active metabolite 1α,25(OH)2D3 exerts its functions through binding of VDR, which are 
expressed on several tissues including skin, bone, kidney and parathyroid as well as pancreas, 
fat and immune system9-11. 
Vitamin D is originally known as the vitamin for optimal bone status. By regulation of the 
calcium and phosphate homeostasis it maintains the bone mineral density (BMD). A low 
vitamin D status results in decreased bone mineralization, which may lead to rickets in 
1general introduction
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children and osteomalacia in adults. In HIV-infected patients, bone disorders, as osteopenia 
and osteoporosis are increasingly observed12, 13. The underlying mechanism of changed bone-
turnover in HIV infected persons is probably multifactorial, but a role for HIV itself, HAART and 
lipodistrophy have been postulated12. Given the fact that HAART interacts with vitamin D 
metabolism, the vitamin D status may have a crucial role in HIV-associated bone disorders.
Beside its role in bone metabolism, vitamin D can also exert effects on adipocyte function 
and glucose metabolism. Several in vitro studies indicate that 1α,25(OH)2D3 inhibits adipocyte 
differentiation, which results in stimulation of adipogenesis and inhibition of lipolysis14-16. 
Glucose metabolism may be affected by 1α,25(OH)2D3  binding to VDR on pancreas cells 
or other mechanisms17. Studies in animals and vitamin-D-deficient patients suggest that 
vitamin D treatment may increase insulin secretion17. In addition, genetic polymorphisms 
in VDR and low 25(OH)D3 levels have been associated with insulin resistance and diabetes 
mellitus type 1 and 2.
A well-known problem after initiation of HAART in HIV-1-infected patients is the lipodystrophy 
syndrome, which is characterized by altered fat distribution (central fat accumulation and 
peripheral fat loss: lipoatrophy) and metabolic alterations (dislipidemia, insulin resistance and 
diabetes). Interestingly, insulin resistance and diabetes are even more prevalent in patients 
chapter 1
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with lipodystrophy disorders. The effects of 1α,25(OH)2D3 on adipocyte differentiation and 
in glucose metabolism and the effect of HAART on vitamin D levels may be relevant in the 
development of  the lipodystrophy syndrome. Therefore, we hypothesized that an adequate 
vitamin D status is beneficial for HIV-1-infected patients. We conducted a prospective 
colecalciferol intervention study in 20 HIV-1-infected patients with vitamin D deficiency. In 
chapter 7 we explored whether supplementation of colecalciferol will lead to normalization 
of the vitamin D levels and studied the effects on bone mineral density, fat distribution and 
insulin resistance in vitamin D deficient HIV-1-infected patients.
Vitamin D has also important immunomodulatory properties. The discovery of VDR expression 
on several mononuclear cells and the finding that 1α-hydroxylase is expressed by activated 
macrophages, suggest a role for vitamin D in immune regulation11. Through its action on 
antigen-presenting cells and T-lymphocytes, 1α,25(OH)2D3 diminishes the pro-inflammatory 
T helper 1 (Th1) immune response and induces Th2 immune responses and regulatory 
T-cells (Treg)11, 18-20. Treg further suppress Th1 immune response and the shift from Th1 to Th2 
immune response results in a more tolerogenic immune system. 
Vitamin D deficiency might lead to a higher susceptibility to infections such as tuberculosis 
and has also been correlated with auto-immune diseases, such as diabetes mellitus. It was 
shown in HIV-infected patients that low 1α,25(OH)2D3 was associated with lower CD4+ 
counts and immunological hyperactivity7, 21. These results indicate that vitamin D status 
affects the host defense in HIV-infected patients. In chapter 8, we studied the effects of 
colecalciferol supplementation on the circulating CD4+CD25high regulatory T-cells numbers 
in vitamin D deficient HIV-1-infected patients. To date, with regard to human Treg, there is 
no unique marker. Most Treg reside in the CD4+CD25high T-cell population, but a number 
of other markers have been described. In contrast to most markers, FoxP3, a transcription 
factor, is clearly associated with the immunosuppressive functions of Treg and is at present, 
in combination with lack of CD127 expression, considered to be an accurate marker for Treg. 
FoxP3 and CD127 where therefore measured in a subpopulation as well.
Finally, a Summary and Discussion is presented in chapter 9.
1general introduction
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Abstract
Herbal medicines are widely used by HIV patients. Several herbal medicines have been 
shown to interact with antiretroviral drugs, which might lead to drug failure. We have aimed 
to provide an overview of the modulating effects of Western and African herbal medicines 
on antiretroviral drug-metabolizing and transporting enzymes, focussing on potential herb-
antiretroviral drug interactions. Echinacea, garlic, ginkgo, milk thistle and St John’s wort have 
the potential to cause significant interactions. In vitro and in vivo animal studies also indicated 
other herbs with a potential for interactions; however, most evidence is based on in vitro 
studies. Further pharmacokinetic studies to unveil potential Western and especially African 
herb-antiretroviral drug interactions are urgently required and the clinical significance these 
interactions should be assessed.
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Introduction
The use of herbal medicines has been the primary form of healthcare for centuries, and is 
nowadays becoming more and more reutilized in Western medicine. Results of a follow up 
national survey in the US that compared results from 1990 and 1997, showed that the use of 
herbal medicines among adults increased significantly from 2.5% in 1990 to 12.1% in 1997 
1. The Slone survey conducted from 1998-1999 among adults in the US reported the use 
of herbal medicines among 10.9% of the adults2. By 2002, the use of natural products by 
US citizens had (even) grown to almost 19%3. In Europe, Germany and France are leading 
countries with an estimated use of unconventional therapies of approximately 50%4. The 
percentage of the German population who had used herbal medicines during the previous 
12 months was 27% ( 33% of women and 20% of men)5. An Italian survey showed that 4.8% 
of the patients used herbal medicines in the period of 1997-1999 4. In Africa, up to 80% of 
the population uses traditional medicine for primary health care6-9. One report of a survey 
performed in Dar es Salaam, Tanzania, showed that 21% of the people that went to seek care 
from public services had first consulted a traditional healer10. In South Africa up to 60% of the 
population consults a traditional healer 11. 
The use of complementary and alternative medicines, including herbal medicines, is 
common among individuals with HIV 12, 13. The reported prevalence of herbal remedies use 
by HIV-infected individuals in the US varies between 12 and 27.2%12-14. Echinacea, garlic, 
St John’s wort, tea tree oil and milk thistle are (all) herbal medicines commonly used by HIV-
infected patients12, 15. The reasons for using herbal medicines are mostly to fight infections 
or boost immunity, but also to treat weight loss, nausea and diarrhea12, 14. In Africa, the 
reported prevalence of herbal medicine use by HIV patients ranged from 37% in Malawi to 
79% in Zimbabwe and up to 83% in Tanzania 16-18.  The African herbal medicines Hypoxis and 
Sutherlandia, are commonly used by HIV patients 19, 20.
The use of herbal remedies complementary to antiretroviral (ARV) medicine may cause 
clinically significant interactions, especially because two important groups of ARVs (non-
nucleoside reverse transcriptase inhibititors (NNRTI) and protease inhibitors (PI)) are CYP 
substrates and have a small therapeutic range21. In a survey among 100 HIV-infected patients 
in the US, it was found that 54% used complementary and alternative medicines in addition to 
ARVs13. It is to be expected that in Africa, where almost 80% of the inhabitants use traditional 
medicine and access to antiretroviral agents is growing, the risk for herb-ARV interactions 
may even be higher 6, 9. It was found in a study among 150 HIV patients in Gabon that 17% 
used traditional medicines concomitant to conventional therapy22. 
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Herbs can influence the ARV drug metabolism in different ways: 1) interactions at the level 
of cytochrome P450 (CYP450), 2) interactions with UDP-glucuronosyltransferases (UGT) 3) 
interactions with P-glycoprotein (Pgp). The antiretroviral therapy received by HIV-infected 
individuals usually consists of either a NNRTI or PI with a backbone of two nucleoside reverse 
transcriptase inhibitors (NRTI). NRTIs are predominantly excreted trough renal clearance and 
interactions based upon CYP are not regularly encountered23. On the other hand, both PIs and 
NNRTIs are mainly metabolized by CYP3A4 and to a lesser extent CYP2B6, 2C9, 2C19 and 2D6 
(see Table 1). The consequences of inhibition of these CYPs by herbal medicines would be 
higher antiretroviral plasma levels, thus putting patients at greater risk of serious side effects, 
whereas induction of CYP would lead to subtherapeutic plasma levels, leading to therapeutic 
failure and an enhanced risk of developing antiviral drug resistance. Furthermore all NNRTI’s 
and PIs are substrates of Pgp23. Pgp is encoded by the human MDR1 gene and is present at 
high levels on the apical surfaces of epithelial cells in the liver, kidney and intestine24-27. Pgp 
is also vulnerable to induction, activation and inhibition by constituents of herbal medicines. 
The induction of intestinal Pgp leads to decreased drug absorption by stimulating the drug’s 
active efflux back into the intestinal lumen and thus lowering the systemic bioavailability. 
When Pgp is inhibited, the clearance of Pgp substrates through biliary excretion and renal 
secretion can be significantly decreased. Consequently the systemic bioavailability increases, 
which may lead to toxicity27.
The ARVs abacavir and zidovudine are metabolized by the phase II-enzymes UGTs23. UGT 
enzymes catalyze the glucuronidation of endogenous and exogenous substances, making 
them more hydrophilic and thus more easily excreted28, 29. UGTs can be induced and inhibited 
by xenobiotics. Inhibition of UGT leads to decreased glucuronidation and subsequently high 
ARV plasma levels, whereas induction of UGT leads to increased excretion and subtherapeutic 
ARV plasma concentrations28.
Case reports, clinical trials and in vitro studies showed the existence of a number of important 
interaction risks of herbal medicines with antiretroviral agents. Seen that worldwide many HIV 
patients utilize herbal medication in combination with antiretroviral therapy, more awareness 
and further research on the possible side effects of this practice are highly necessary. 
With this review we want to provide an overview of the modulating effects of the most 
commonly used Western herbal medicines on drug-metabolizing and transporting enzymes 
involved in antiretroviral drug metabolism. The potential interaction risks of these herbs will 
be given, with particular focus on antiretroviral drugs. Furthermore we want to compare 
this overview with the available data on the ARV drug interaction risks of African herbal 
medicines. 
chapter 2
VandenBout.1044-Proefschrift.indd   22 02-03-2009   14:53:48
23
Methods
The herbs included in this article were selected per continent. The twenty top-selling herbal 
dietary supplements in the United States Food, Drug and Mass market retail channels in 2004 
are listed in Table 2. There is no European herb top 20 available; therefore the German top-20 
of most popular reimbursed herbal medicines in 2003 has been taken as a proxy (Table 2). 
2
drug-metabolism interactions of medicinal herbs with antiretrovirals
Table 1  Metabolism of Antiretroviral agents.
Antiretroviral Metabolism Induction of Inhibition of References
agent  CYP CYP
Nucleoside reverse transcriptase inhibitors
Abacavir ADH, UGT   
Didanosine    
lamivudine    
Stavudine    
Zalcitabine    
Zidovudine UGT, Pgp   Antonelli, 1992
Non-nucleoside reverse transcriptase inhibitors
Efavirenz 3A4, 2B6, Pgp 3A4 2C9/19, 3A4  
Nevirapine 3A4, 2B6, Pgp 3A4, 2B6  
Protease inhibitors
Amprenavir 3A4, Pgp  3A4 
Atazanavir 3A4, 2C9, Pgp Pgp 3A4, Pgp 
Indinavir 3A4, Pgp  3A4 
Lopinavir 3A4, Pgp UGT 3A4, 2D6 
Nelfinavir 3A4, 2C9/19,   3A4
 2D6, Pgp138   
Ritonavir 3A, 2D6, Pgp138  UGT, 1A2, 3A,  3A, 2D6 Kim et al., 1998
  2C9, Pgp   
saquinavir 3A468, Pgp68, 138   3A4 Kim et al., 1998
Compiled from de Maat et al., 2003 139.
ADH, alcohol dehydrogenase; CYP, cytochrome P450; UGT, UDP-glucuronosyltransferase;  
Pgp, P-glycoprotein.
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Furthermore we adapted a list of 53 African Medicinal Plants selected by the Medicinal Plants 
Forum for Commonwealth Africa (Table 3)30, 31. This list includes most of the important African 
Medicinal Plants presently traded as well as others judged to be of sustainable long-term 
importance30.  
A literature search was performed using Pubmed (up to October 2005). Also, extensive literature 
searches were made using five recently published reviews on herb-drug interactions27, 32-35. 
To search for interactions between alternative agents and antiretrovirals the following 
search terms were used: (Dietary Supplements OR Phytotherap* OR Plant Preparations 
OR Plants,Medicinal OR Plant Extracts OR Vitamin* OR Mineral* OR Complementary OR 
Alternative OR Unconventional OR Herb OR Herbal OR Herbs OR Traditional Medicine* OR 
each individual herb) AND (“Antiviral Agents”[MeSH] OR “Anti-Retroviral Agents”[MeSH] OR 
Abacavir OR adefovir OR amprenavir OR atazanavir OR delavirdine OR didanosine OR efavirenz 
OR emtricitabine OR enfuvirtide OR fosamprenavir OR indinavir OR lamivudine OR lopinavir OR 
nelfinavir OR nevirapine OR ritonavir OR saquinavir OR stavudine OR tenofovir OR zalcitabine 
OR zidovudine). Additionally, for each individual herb, we searched for interactions with the 
cytochrome P450 enzyme system, P-glycoprotein, UDP-glucuronosyltransferase and drugs 
with the same metabolic route as ARVs. Search terms were for example: (“Hypericum” OR 
“St John´s wort”) AND (CYP450 OR cytochrome P450 OR cytochrome P450 enzyme system 
OR cytochrome*) AND (“drug interactions” OR “adverse effects”). Results from human studies, 
including case reports, case series and clinical trials, as well as from animal studies and in 
vitro studies regarding herb interactions with CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, 
Pgp and UGTs involved in ARV metabolism, ARVs or drugs with the same metabolic route as 
ARVs, were included.  
Results 
Tables 4a and 4b provides an overview of the effects of the Western and African herbs 
on CYP450 and the drug transporters P-glycoprotein and UDP-glucuronosyltransferases 
involveld in ARV metabolism. The known pharmacokinetic interactions between the herbs 
and antiretroviral agents or drugs with the same metabolic route are described below.
chapter 2
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Table 3  African herbs selected by medicinal plants forum for 
Commonwealth Africa held in Cape Town in 2000 to prepare  
product profiles.
Herb (latin name – local name)
1. Agathosma betulina – Buchu 
2. Aloe ferox – Aloes
3.  Antidesma madagascariensis –  
 Bois bigaignon
4. Aphloia theformis - Fandamane
5. Aspalathus linearis -  Rooibos
6. Balantes aegyptica – Desert Date
7. Boswellia sp. – Frankincense
8. Cola sp. – Kola Nut
9. Cyclopia genistoides – Honeybush 
10. Danais fragrans – Liane
11. Griffonia simplicifolia – Griffonia 
12. Harungana madagascariensis - 
 Haronga
13. Hypargophytum procumbens – 
 Devils Claw
14. Hypoxis hemerocallidea – 
 African Potato
15. Kigelia africana – African Sausage Tree
16. Moringa oleifera - Moringa
17. Pelargonium sidoides – Umckaloabo
18. Prunus africana – African Plum Tree
19. Sceletium tortuosum – Sceletium
20. Siphonochilus aethiopicus – 
 African Ginger
21. Sutherlandia frutescens – Cancer Bush
22. Warburgia salutaris – Warburgia
23. Xysmalobium undulatum – Uzara
24. Hibiscus sabdariffa 
25. Rauwolfia vomitoria
26. Voacanga africana 
27. Hoodia gordonii 
28. Catharanthus roseus
29. Centella asiatica 
30. Enantia chorantha
31. Ipomoea pescaprae
32. Terminalia sericea
33. Garcinia kola
34. Acacia senegal
35. Adansonia digitata
36. Veronia amygdalina
37. Veronia kotschyana
38. Crossopteryx febrifuga
39. Mondia whittei
40. Euphorbia hirta
41. Artemesia afra
42. Bulbine frutescens
43. Xylopia aethiopica
44. Combretum micranthum
45. Commiphora myrrha
46. Strophanthus gratus
47. Toddalia asiatica
48. Cajanus cajan
49. Trichilia emetica
50. Aframomum melegueta
51. Carissa edulis
52. Asparagus africanus
53. Ravenala madagascariensis
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Known or suspected herb-drug interactions of Western herbal medicines
American and Asian ginseng
American Ginseng (Panax quinquefolius roots) and Asian Ginseng (Panax ginseng roots) are 
popular herbal medicines, because of their anti-hypertensive, anti-fatigue, neuroprotective, 
anti-oxidative, anti-cancer, hypolipidemic, cognition enhancing, immuno-enhancing, ulcer-
healing, anti-cancer and other pharmacological effects 32, 34. 
It was shown in vitro that ginsenoside Re and Rf (200µmol/L) increased the activity of CYP2C9 
and CYP3A4 respectively, whereas ginsenoside Rd showed weak inhibitory activity against 
recombinant CYP3A4, CYP2D6, CYP2C19 and CYP2C9 36. Furthermore, He et al. reported that 
ginsenosides Rb1, Rb2, Rc and Rd showed marked inhibition of CYP2C9 and CYP3A4 37, 38. 
However, a crude extract of ginseng (type not stated) at concentrations of 0,5 mg/ml did 
not inhibit CYP3A4 activity in vitro in human hepatocytes39. In vitro, using human and mouse 
multidrug-resistant cell lines, it was shown that many ginsenosides inhibit Pgp activity 27. 
Furthermore, protopanaxatriol ginsenosides (>200µg/ml) inhibited P-glycoprotein activity 
in vitro 27. 
Administration of Asian ginseng to rats for five days did not significantly alter the 
pharmacokinetics of warfarin, which is mainly metabolized by CYP2C9 and 3A440, 41. 
However, there were two case studies reporting a substantial decrease in the anticoagulant 
effect of warfarin after Asian ginseng consumption by patients on stable warfarin 
therapy42, 43. In contrast, no significant changes in warfarin pharmacokinetics and 
pharmacodynamics were found after administration of Asian ginseng (1.0g , 3 times daily) for 
7 days in healthy volunteers32. In a clinical trial, however, administration of American ginseng 
(1 g daily) to healthy volunteers for 3 weeks significantly reduced the INR, Cmax and AUC 
of warfarin44. Interaction with warfarin might be due to induction of CYP3A4 or CYP2C9, 
although ginsenosides were also found to have antiplatelet effects 45.
Furthermore, no effect of Asian ginseng (500 mg, 3 times daily) administered for 14-28 days 
to young and elderly healthy volunteers, was found on CYP3A4 activity, using midazolam as 
probe drug46, 47. However,  Asian ginseng treatment (200 mg for 18 days)  significantly increased 
the Cmax of the CYP3A4 substrate nifedipine in healthy volunteers33. In the elderly, a significant 
inhibition of CYP2D6 activity, as measured by the debrisoquin urinary ratio, was found, although 
the magnitude of this effect (+/-7%), did not appear to be clinically relevant 47. 
These in vivo and in vitro results indicate that Ginseng has the potential to interact with 
antiretrovirals metabolized trough CYP3A4, CYP2C9 and Pgp. Further human studies are 
necessary to investigate this.
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Bilberry
Bilberry (Vaccinium myrtillus) has been used for the treatment of diabetic retinopathy, 
diarrhea, dysentery, throat inflammations and chronic fatigue syndrome33. 
Bilberries contain a small amount of quercetin, which has the ability to modulate CYP3A4 
activity in vivo; however, it’s circulating concentration is probably too low to cause a clinical 
significant interaction33, 48, 48. 
Pharmacokinetic interactions of bilberry with conventional drugs are currently unknown.
Black cohosh
Black cohosh (Actaea racemosa, formerly cimicifuga racemosa) is a popular drug in the US, because 
of its purported ability to help alleviate menopausal symptoms and premenstrual syndrome33, 49.
In vitro, six triterpene glycosides fractionated from black cohosh were found to have potent 
inhibitory activity on CYP3A4 as measured by nifedipine oxidation 50.
In vivo, administration of black cohosh (1090 mg, twice daily, standardized to 0.2% triterpene 
glycosides) to healthy volunteers did not affect CYP3A4 activity, while a weak, though 
statistically significant, inhibition of CYP2D6 was found, which appears to be of little clinical 
relevance47. In another trial in healthy volunteers, administration of black cohosh (20 mg, twice 
daily, standardized to 2,5% triterpene glycosides) had no effect on digoxin pharmacokinetics, 
suggesting that black cohosh does not interact with Pgp in vivo51. 
Currently, interactions of black cohosh with antiretrovirals are unknown. Based on the above results 
no risk of clinically significant  Pgp or CYP-mediated herb-ARV interactions is to be expected.
Cranberry
American cranberry (Vaccinium macrocarpon) is used as a prophylaxis against urinary tract 
infections33. 
Izzo et al. describe a total of 8 cases of interaction between cranberry juice and warfarin, 
leading to changes in international normalized ratio (INR) values or bleeding and even death 
in one case 52. The mechanism behind this interaction might be the inhibition of CYP3A4 
and/or CYP2C9 enzymes, responsible of warfarin metabolism, by cranberry flavonoids 34, 41, 52. 
Caution should be taken when cranberries are used concomitantly with antiretrovirals 
metabolized by CYP3A4 or CYP2C9.
Devil’s claw
Devil’s claw (Harpagophytum procumbens) is an African traditional medicine, whose popularity 
has increased in Europe since its use in reducing pain sensation and improving mobility/
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flexibility in patients with rheumatic diseases was approved 53. 
In vitro, crude devil’s claw root extract moderately inhibited the activity of CYP2C9, CYP2C19 
and CYP3A4 with IC50 values in the range of 100-350 µg/ml, whereas the inhibitory activity 
on CYP2D6 was low (IC50>900 µg/ml)54.
In vivo, one case was reported of an increased INR value when devil’s claw was used 
concomitantly to warfarin52.
These data indicate that devil’s claw root extract may give interactions with ARVs that 
are substrates of CYP2C9/19 or CYP3A4. Clinical studies are necessary to investigate the 
interaction potential of devil’s claw with ARVs. 
Echinacea
Echinacea is the second best-selling herb in the US and is used for treatment of cold and 
influenza symptoms and inflammation of mouth and pharynx. The most common three 
species of Echinacea are E. purpurea, E. angustifolia and E. pallida. Most research has been 
conducted on E. purpurea preparations 33.
In vitro, both E. purpurea extract and its constituent quercetin have been shown to significantly 
inhibit the activity of CYP3A4 and CYP2C9, whereas no effect on CYP2D6 was found 33, 55-57. 
Coadministration of E. purpurea (root) to human healthy volunteers was shown to inhibit 
intestinal, and induce hepatic CYP3A4, using midazolam as probe substrate58. Furthermore, 
E. purpurea (root) significantly increased the AUC of tolbutamide, a CYP2C9 substrate, and 
non-significantly inhibited the CYP2D6 activity as measured by the dextromethorphan-
dextrorphan urinary metabolic ratio58.
In vitro and in vivo results indicate that Echinacea products of E.purpurea extracts are likely 
to interact with ARVs that are substrates for CYP3A4 and CYP2C9. In the case of CYP3A 
substrates, the type of drug-interaction observed with E. purpurea will depend on the relative 
extraction of these drugs at hepatic and intestinal sites33, 58. 
Eucalyptus oil 
Eucalyptus oil (Eucalyptus globulus) is used in the treatment of bronchitis and other respiratory 
inflammatory diseases59, 60. 
The inhibitory activities of cineole, the bioactive component of Eucalyptus oil, on CYP2C9/19, 
CYP2D6 and CYP3A4 in vitro were low (IC50 values>100µg/ml);  therefore only a weak 
influence on the metabolism of simultaneously ingested drugs is to be expected54.
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Evening Primrose
Evening primrose (Oenothera biennis)  is used to treat premenstrual syndrome, chronic 
mastalgia, diabetic peripheral neuropathy, atopic eczema, rheumatoid arthritis and 
schizophrenia33.
In vitro, evening primrose moderately inhibits CYP3A4, CYP2C9, CYP2C19 and CYP2D633 . No 
cases are known of interactions between evening primrose and conventional medications. 
Therefore the clinical interaction potential of this herb seems to be low; however, in vivo 
studies need to be conducted to investigate this.
Garlic 
Garlic (Allium sativum) is most commonly used in HIV infected patients as a dietary supplement 
to improve their health and as a herbal complementary medicine to fight opportunistic 
infections61. 
In vitro, extracts of aged and fresh garlic inhibited CYP2C9, CYP2C19, CYP3A4 activities, as 
measured in human liver microsomes and cDNA expressed CYPs32, 33. Furthermore, raw garlic 
and garlic products were found to moderately inhibit Pgp activity32, 62.
Administration of various garlic constituents to rats led to enhanced CYP3A activity in rats32, 33. 
In vivo, two cases of garlic-warfarin interaction, resulting in increased INR, have been reported. 
This interaction is not likely to be due to inhibition of CYP, since some garlic constituents 
are known to have (direct) anticoagulant activity32. In healthy volunteers, administration of 
garlic extract (1800µg allicin, twice daily)  for 14 days had no significant effect on CYP2D6 
and CYP3A4 metabolism, using dextrometorphan and alprazolam as probe substrates, 
respectively 32, 33, 35, 63. Also, treatment with garlic oil for 28 days did not alter the activity of 
CYP3A4 using midazolam as a probe in healthy volunteers32, 33, 35, 46.
Pharmacokinetic interactions of garlic with saquinavir and ritonavir have been reported. In 
a case reported by Laroche et al., two HIV infected patients taking fresh or odourless soft 
liquid-filled garlic supplements for >2 weeks developed severe gastrointestinal toxicity after 
starting on ritonavir-containing antiretroviral therapy (400 or 600 mg twice daily)64. After 
discontinuing garlic or ritonavir the symptoms resolved. The symptoms recurred when the 
patients were rechallenged with low-dose ritonavir (100 mg twice daily) in the presence of 
garlic. This interaction could be due to the inhibitory effect of garlic constituents on CYP3A4 
or Pgp, resulting in an increased systemic concentration of ritonavir, which is a substrate of 
CYP3A4 and Pgp, and both an inhibitor and inducer of CYP65. 
However, in  a trial with ten healthy volunteers it was found that 4 days co-administration of 
garlic (2x 5 mg daily of Natural Source Odourless Garlic Life Brand) insignificantly reduced 
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the plasma concentrations of ritonavir by 17%62, 66. The lack of detectable pharmacokinetic 
interaction could have resulted from a transitory effect of induction followed by inhibition on 
the various drug disposition pathways of ritonavir. Most probably, the garlic therapy was too 
short to observe a significant decrease in ritonavir plasma levels. Further studies are required 
to explore the garlic-ritonavir interaction potential.
Interestingly, administration of garlic (mainly containing allicin) for 3 weeks in healthy 
volunteers decreased the mean saquinavir area-under-the-curve by 51%67. This interaction 
may be caused by the induction of CYP3A4 or Pgp, as Saquinavir is a known substrate of 
CYP3A4 and Pgp 68. The most likely mechanism for garlic-ritonavir or -saquinavir interaction 
is, however, the induction of Pgp or another CYP450 enzyme, since two studies reported 
no effect of garlic on CYP3A4 activity when alprazolam and midazolam were used as probe 
substrates32, 33, 46.
These in vitro and in vivo studies of garlic indicate that the effects of garlic constituents on 
CYP isoforms may have implications for interactions with ARVs metabolised trough CYP3A4 
and Pgp. Especially HIV patients receiving saquinavir as their sole protease inhibitor should 
avoid using garlic supplements.
Ginger
Ginger (Zingiber officinale) has been used for treatment of various ailments, including 
symptomatic relief of motion sickness and inflammation69. 
A study in rats showed that administration of ginger had no significant effects on warfarin-
induced changes in blood coagulation 70. Also, in healthy volunteers it was found that co-
administration of ginger (1.2 g ginger rhizome powder, 3 times daily) for 1 week had no 
effects on the pharmacokinetics or pharmacodynamics of warfarin, a substrate of CYP2C9 and 
CYP3A441, 69. However, one case has been reported of ginger- phenprocoumon interaction, 
another CYP3A4 and CYP2C9 substrate, resulting in elevated INR and epistaxis71. Therefore, 
care should be taken when ginger is used concomitantly with ARVs that are substrates of 
CYP3A4 or CYP2C9.
Ginkgo Biloba
Ginkgo (ginkgo biloba) is a very popular medicine in China, that has reached increasing 
popularity worldwide for a variety of ailments, due to its memory-enhancing, cognition-
improving and antiplatelet effects, amongst others32, 33. 
In vitro experiments showed that Gingkgolic acids, but not ginkgolide A,B and C, inhibit 
the activity of CYP2C9, CYP2C19, CYP2D6 and CYP3A432, 72. Whatismore, the constituent 
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kaempferol inhibits the Pgp mediated efflux of ritonavir in the Caco2 cell line by increasing 
its cellular uptake and inhibits CYP3A4 activity73. 
Consistent with in vitro results, administration of ginkgo leaf extract (20 mg/kg) to rats 
significantly increased the AUC and absolute bioavailability of diltiazem at concentrations 
of 50-182µg/ml, which was considered to be due to inhibition of intestinal and hepatic 
CYP3A432, 74. However, it was also shown in rats that ginkgo extract can significantly increase 
the mRNA expression and induce the activity of CYP3A475. Furthermore treatment of rats 
with 0,1% ginkgo extract for five days significantly enhanced the activity of CYP2C9, which is 
involved in tolbutamide metabolism 32, 76. 
No pharmacokinetic interactions have been reported between ginkgo and antiretroviral 
agents. However, in several clinical trials significant interactions of ginkgo with drugs with 
the same metabolic route as ARVs have been found, as recently reported by Hu et al, and 
Sparreboom et al. These drugs are omeprazole (CYP2C19), alprazolam, trazodone and 
nifedipine (CYP3A4); on the other hand, no significant interactions were reported between 
ginkgo and donepezil (CYP3A4 and CYP2D6), midazolam and warfarin (CYP3A4, 2C9), 
debrisoquin and dextrometorpham (CYP2D6) or digoxin (Pgp) 32, 33, 35. 
The above results suggest that interactions of ginkgo may occur with ARVs that are substrates 
of CYP2C9/19 and CYP3A4. 
Grape seed
Grape seed (Vitis vinifera) extracts are used in the treatment of circulatory disorders such 
as capillary fragility, peripheral chronic venous insufficiency and microangiopathy of the 
retina. Other uses include the treatment of respiratory conditions, allergic rhinitis and as a 
cardioprotectant 33. 
In vitro, grape seed extract inhibited the activities of CYP2C9, CYP2D6 and CYP3A4 
of microsomes prepared from human liver 77. However in another study using human 
hepatocytes, grape seed extract produced an increase in CYP3A4 mRNA expression of 270% 
compared to control CYP3A4 mRNA at a concentration of 0.6µg/ml 39.
After treatment of rats with grape seed extract (80mg /10mL / kg) for six days it was shown ex 
vivo that the activity of CYP3A4 in hepatic microsomes was non-significantly increased, whereas 
the activity of CYP3A4 in intestinal microsomes was not affected 77. Furthermore, no in vivo 
effect on the pharmacokinetics of midazolam, a CYP3A4 substrate, was found. This discrepancy 
with the in vitro results might be due to different mechanisms of gene regulation between 
humans and rats 77. Therefore, further studies are necessary before any final conclusions can be 
drawn on the clinical significance of the interactions between grape seed extract and ARVs. 
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Green tea
Green tea (Camellia sinensis) has been reported to promote weight loss and have antioxidant, 
anti-inflammatory and anti-cancer properties78-80. 
In human liver microsomes it was found that green tea extract inhibited the activities of 
CYP2C9, CYP2D6 and CYP3A4 77. 
In rats no change in hepatic CYP3A4 activities was found after drinking green tea for 6 days, 
although UGT activity was increased compared to water controls 81. In another study it was 
found that the activity of intestinal CYP3A4 was significantly inhibited and hepatic CYP3A4 
non-significantly increased, as measured in hepatic and intestinal microsomes isolated from 
rats treated with green tea extract (400 mg/ kg) for six days 77. 
Two recent studies investigated the effects of green tea extract on the pharmacokinetics of 
probe substrates. In a study in rats it was found that treatment with green tea extract (dosage 
400mg/kg) led to a significant change in the pharmacokinetics of midazolam, suggesting an 
induction of CYP3A4 activity 77.  
In healthy volunteers green tea extract (844 mg catechins/ day) did not alter CYP3A4 or 2D6 
activity, as measured with alprazolam and dextrometorphan, respectively. 82. 
Based on the above results it seems unlikely that green tea extract results in clinically 
significant interactions with ARVs that are metabolized by CYP3A4 and/or CYP2D6. Further 
studies on the drug interaction potential of green tea extract need to be conducted.
Hawthorn
Hawthorn (crataegus oxyacantha) is used for the prevention and treatment of heart 
failure, angina pectoris and hypertension. The major constituents of hawthorn are 
flavonoids, proanthocyanides, triterpenes and organic acids. Among these, flavonoids and 
proanthocyanides are the major group of bioactive components 27, 83. 
Tankanow et al. found that hawthorn caused no significant interaction with the Pgp substrate 
digoxin in healthy volunteers, which suggest that interactions with ARVs that are substrates 
of Pgp are unlikely 27, 84.
Milk thistle
Milk thistle (Silybum marianum) is a herbal medicine commonly taken by HIV infected patients 
for the prevention of HAART related hepatotoxicity and the treatment of hepatitis15. 
In vitro, only CYP3A4 and CYP2C9 were inhibited at concentrations similar to those observed 
in vivo27, 32.
In vivo, administration of milk thistle to healthy volunteers for 14 and 28 days had no effect on 
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the pharmacokinetics of either irinotecan, a substrate of CYP3A4 and UGT1A185, or midazolam, 
a CYP3A4 substrate, respectively86. In contrast, 9 days of silymarin supplementation (140mg 
daily) significantly reduced the AUC and Cmax of metronidazole, a substrate of CYP3A4 and 
Pgp87. Additionally,  milk thistle administration (300 mg, 3 times daily) for 14 days caused a 
borderline-significant (p = 0.06) reduction in the AUC(0-24) and AUC(0-3) of digoxin, a substrate 
of Pgp51. Consistent with this data, three other studies noted interactions of milk thistle with 
the antiretroviral agent indinavir. Two studies demonstrated that concomitant administration 
of milk thistle (175 mg 3 times daily) to healthy volunteers for 2-3 weeks caused respectively a 
non-significant 9%, and significant 25%, reduction in the mean trough level of indinavir 15, 88. 
Mills et al. found a non significant reduction in indinavir levels during concomitant use of milk 
thistle (450 mg/day) for 28 days by HIV patients89.  These in vivo results suggest that the minor 
reduction in drug levels might be due to a small to moderate induction of CYP3A4 or Pgp. 
Based on in vivo and in vitro data it seems that milk thistle has limited clinical impact on 
antiretroviral agents metabolised mainly by CYP2C9, CYP2D6 and CYP3A4. However, the data 
indicate that silimaryn and its metabolites inhibit Pgp-mediated cellular efflux, raising the 
potential for clinically significant interactions with PI´s and NNRTI´s that are substrates of 
Pgp32, 73.
Saw Palmetto
Saw palmetto (Serenoa repens) is used for the treatment of symptoms of benign prostatic 
hyperplasia. 
In vitro, saw palmetto inhibited the activity of CYP2C9, CYP2D6 and CYP3A455, 57. 
In contrast with the in vitro results, two in vivo studies failed to show an effect of saw palmetto 
supplementation on CYP activity. Markowitz et al. found that administration of saw palmetto 
(197 mg) for 14 days to 12 healthy volunteers had no effect on CYP2D6 and CYP3A4 activity, 
using dextrometorphan and alprazolam as probe substrates, respectively90. These results are 
confirmed by Gurley et al., who demonstrated that supplementation with saw palmetto 
(160mg twice daily) for 28 days in healthy volunteers had no significant effect on CYP2D6 
and CYP3A4 activity86.
Based on these results saw palmetto is an unlikely candidate for CYP-mediated herb-ARV 
interactions.
Siberian ginseng
Siberian ginseng, the roots of Eleutherococcus senticosus, should not be confused with 
Panax ginseng, which belongs to the same family (Araliaceae) but forms a different genus. 
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Eleutherosides are considered the major bioactive constituents responsible for the beneficial 
effect of reducing symptoms of stress. Other pharmacological effects of Siberian ginseng 
include anti-inflammatory, immunomodulatory and anti-cancer activity32.
In vitro, Siberian ginseng had no effect on CYP3A4 activity 55. However, Siberian ginseng 
extract inibited mouse hexobarbital metabolism in vitro whereas administration of Siberian 
ginseng to mice induced the metabolism of hexobarbital, a CYP2C9 substrate32. 
Consistent with the above, the results from a study in healthy volunteers indicated that 
treatment with Siberian ginseng (485mg, twice daily) did not significantly alter the activities 
of CYP2D6 and CYP3A4 32, 91. One case of interaction between Syberian ginseng and digoxin, a 
Pgp substrate, has been reported. A 74-year-old man on stable digoxin therapy for years was 
found to have an increased serum digoxin level. After it had been found that he was taking 
Siberian ginseng and the patient stopped taking the herb, digoxin serum concentrations 
returned to an acceptable level. When the use of Siberian ginseng was resumed, the serum 
digoxin concentration rose again, indicating that Siberian ginseng may be a Pgp inhibitor. 
However, recently it was suggested that Siberian ginseng contains digoxin-like constituents, 
which interfere with digoxin serum assay results32.
Based on these data, concomitant use of Siberian ginseng and ARV’s that are substrates of 
CYP2C9 is not advisable.
Soy
Soy (Glycine max) and soy-derived products are used by women for the treatment of 
menopausal symptoms. 
In vitro, the soy components genistein and daidzein have been shown to inhibit UGT in rat 
liver extract92. Genistein has also been shown to inhibit Pgp activity in rat liver 93. Furthermore, 
Anderson et al. showed in human liver microsomes that unhydrolized soy extract (containing 
genistein and daidzein at concentrations comparable to those reached in plasma in vivo (0.5-
1.0mg/ml)) significantly inhibited CYP2D6, while CYP2C9 and 3A4 activity were induced 94. 
The hydrolyzed soy extract inhibited CYP2C9, 2D6 and 3A494. The majority of soy isoflavones 
in plasma are in the unhydrolized form 20, 94.
In vivo, however, treatment of healthy volunteers with soy extract (100 mg isoflavones per 
day) for 14 days showed a trend to lower 6-β-hydroxycorticosol to corticosol ratio compared 
to baseline, suggesting a small induction of CYP3A4 activity94. 
Theses in vitro and in vivo results indicate that soy may alter PI and NNRTI metabolism in 
humans.
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St John’s wort 
St John’s wort (Hypericum perforatum; SJW) is a herbal medicine widely used for the treatment 
of mild to moderate depression95.  Hyperforin is the major constituent responsible for the 
antidepressant activity34.
Effect on CYP: Results of in vitro studies of SJW are conflicting. Some studies have indicated 
that SJW extract is a potent inducer of CYP2B696, CYP2C9, CYP2C1972 and CYP3A472, 96-98. 
However, using cDNA-expressed enzymes, crude SJW extracts have been shown to inhibit 
the activities of CYP2D6, CYP2C9, CYP2C19 and CYP3A499. The inductive effects on CYP2B6, 
CYP2C19 and CYP3A4 can be explained by binding of the SJW constituent hyperforin to the 
pregnane X receptor, an orphan nuclear receptor regulating the transcriptional expression 
of these genes96-98. 
In mouse and rat studies it was shown that long term treatment (14-21 days) with SJW (140-300 
mg/kg daily) led to induction of CYP3A434, 100-102, while short term treatment (<12 days) with SJW, 
hyperforin or hypericin failed to induce CYP3A4100, 103. However, Cantoni et al. found induction 
of CYP3A4 in mice treated for 4-12 days with SJW (300 mg/kg containing 4,5% hyperforin, twice 
daily)104. This discrepancy was possibly caused by the high dosage of SJW used in that study.
In clinical studies using probe drugs it has been shown that long term treatment with SJW 
(>12 days) significantly induces hepatic and intestinal CYP3A446, 101, 105-109, but had no effect 
on CYP2C9108 or CYP2D646, 108, 110. However, short administration (<8 days) had no significant 
effect on CYP3A4 109, 111, 112 or CYP2D6 activities109, 111, 112.
These in vivo animal and human studies indicate that long term  (>12 days) administration 
of St John´s wort can induce hepatic and intestinal CYP3A4, but has no effect on CYP2C9 or 
CYP2D6 activities. 
Effect on Pgp. Chronic incubation of LS-180 adenocarcinoma cells with SJW extract or 
hypericin led to increased expression of Pgp, while acute exposure had no effect on 
Pgp109, 111, 113. Quercetin has been found to inhibit MDR1 gene expression in multi-drug resistant 
cells 114[Kim et al., 1998]. Additionally, quercitin and hypericin have been shown to inhibit the 
Pgp-mediated efflux of ritonavir in Caco2 cells grown in the presence of 0.25 µmol/L 1α,25-
dihydroxy vitamin D3 73, resulting in an increased systemic availability. Prolonged exposure of 
the Caco2 cell line to quercetin resulted in a significant increase in mRNA expression levels 
of MDR1 73. Additionally, hyperforin caused downregulation of MDR1 expression whereas 
hypericin did not show much increase in MDR1 expression73.
Consistent with these in vitro results, administration of SJW (>12 days) to rats, mice and 
humans induces intestinal expression of Pgp101, 102, 106, 109 and expression of Pgp in peripheral 
blood mononuclear cells115. Administration of a single dose of SJW to healthy volunteers 
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resulted in significant inhibition of intestinal Pgp, while long-term administration led to an 
induction of intestinal P-glycoprotein108. 
These in vitro and in vivo studies also indicate that long term administration (>12 days) of SJW 
causes induction of intestinal Pgp, although a single dose resulted in significant inhibition of 
intestinal Pgp. Furthermore,  the expression of Pgp is induced by long-term administration, 
and short-term administration leads to decreased expression of Pgp.
Pharmacokinetic interactions of SJW. Case reports and several other clinical studies that 
followed these case reports, describe serious adverse interactions between SJW and 
medications with the same metabolic route as antiretroviral agents. It is beyond the scope 
of this article to describe all the clinical trials of St John’s wort-drug interactions; instead, we 
refer to the reviews by Hu et al. and Mills et al.32, 35. In the present review only the clinically 
significant interactions of St John’s wort with antiretroviral agents will be described.
Clinically significant interactions of antiretroviral agents and SJW wort have been reported. 
One patient was reported in the UK, who used SJW concomitantly with indinavir and 
lamivudine, which led to an increase in HIV RNA load32. Indinavir is a substrate of CYP3A4 
and Pgp, and reduced serum concentrations might lead to the development of resistance 
and treatment failure116. Furthermore, St John’s wort has been shown to decrease indinavir 
plasma concentrations with 57% in healthy volunteers117. In HIV patients the clearance of 
nevirapine was increased with 35% after concomitant use of St John’s wort 118. These clinical 
interactions are thought to be due to the inductive capacity of St John’s wort on CYP3A4 and 
Pgp97. Although PXR mediates both CYP3A4 and MDR1 expression, the extent of induction of 
an ARV by SJW depends on the relative contribution of CYP3A4 and MDR1 in the metabolism 
of that specific ARV. The use of SJW by HIV patients during treatment with PI’s, or NNRTI’s 
should be avoided. It has been recommended by the European Medicine Evaluation Agency 
that patients receiving protease inhibitors for treatment of HIV infection should avoid 
concomitant use of hypericum and other products that contain SJW32.
Valerian
Valerian (Valeriana officinalis) is used as a hypnotic and mild sedative33, 119.
In vitro, the isolated component valerenic acid at concentrations up to 200µmol/ml had no 
inhibitory effect on CYP3A4, and only weakly inhibited CYP2C9 and CYP2C19 33, 72. However, 
Lefebvre et al. and Budzinsky et al. showed that several valerian root extracts had a moderate 
to high inhibitory activity on CYP3A433, 55, 119. These results indicate that synergistic interactions 
might play an important role in the effects of Valerian on CYP3A4. Valerian root extract also 
has an inhibitory effect on Pgp119.
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A study in healthy volunteers showed that coadministration of valerian (root extract, 1000mg 
daily) for 14 days significantly increased the Cmax of alprazolam, a CYP3A4 substrate, whereas 
no effect on the pharmacokinetics of dextrometorpham, a CYP2D6 substrate, was found 120. 
Gurley et al. found no effect on CYP2D6 and CYP3A4 after 28 days treatment of healthy 
volunteers with valerian root extract (375 mg daily) 47. Discrepancies in the effect on CYP3A4 
might be due to the different concentrations used.
Currently no interactions between valerian and antiretroviral drugs or drugs with the same 
metabolic route have been reported. The above results indicate that pharmacokinetic 
interactions between valerian and antiretrovirals metabolized by CYP2C9,CYP2C19 or CYP3A4 
may occur. Further studies are necessary to explore the clinical drug interaction potential of 
this herb.
Known or suspected herb-drug interactions of African herbal medicines 
Catharanthus roseus
Catharanthus roseus is used worldwide for the treatment of many disorders including diabetes, 
malaria, constipation, cancer, lung congestion, inflammation, sore throat and hypertension. 
Isolated compounds of catharanthus roseus include ursolic acid, oleanolic acid, vindoline, 
ajmalicine and serpentine121. 
In vitro experiments with human liver microsomes showed that ajmalicine and serpentine 
have inhibitory activity against CYP2D6. All isolated compounds were found to have weak or 
no inhibitory effect on CYP3A4121.
In vivo studies need to be conducted to determine the clinical interaction potential of 
Catharanthus roseus with antiretrovirals.
Harungana madagascariencis
Leaves of Harungana madagascariencis are used for the treatment of gastrointestinal 
disorders, including diarrhea, thyphoid fever and dysentery, poor pancreatic function and 
abortifacient122. Isolated constituents of H. madagascariencis include tannins, steroids and 
terpens, saponins, alkaloids and anthraquinones 123.
In a caco-2 cell-line it has been shown that H. madagascariencis leaf extract has no inhibitory 
effect on Pgp 7.
No identified drug interactions have been associated with the use of Harungana 
madagascariencis leaf extracts.
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Hypoxis hemerocallidea
Hypoxis hemerocallidea (corms and roots) have been used in African traditional medicine 
for the treatment of urinary infections, heart weakness, tumors, nervous disorders and also 
immune related illnesses such as the common cold, flu, cancer and HIV/AIDS. The South 
African Ministry of Health and other non-governmental organizations endorse the use this 
herb by HIV/AIDS patients because of its immunostimulating properties19, 124. 
Chemical constituents of Hypoxis include hypoxiside, which in the human gut is converted 
into the bioactive compound rooperol. Furthermore the plant contains sterols and glycosides, 
including stigmastanol, which have also been reported to have biological activity 124.
In vitro testing of Hypoxis using cDNA expressed human liver microsomes showed that 
the herb inhibits normal CYP3A4 activity by 86%. Furthermore, Hypoxis showed 42-51% of 
the activity (strength) of the known Pgp inhibitor verapamil. Exposure to Hypoxis of PXR, a 
nuclear receptor that controls the activation of both Pgp and CYP3A4, resulted in a two-fold 
induction of its activity19. These findings suggest that the use of Hypoxis together with ARVs 
may lead to early inhibition of drug metabolism and transport followed by decreased drug 
exposure with more prolonged therapy19.  
More research is needed to investigate the true potential for clinically significant interactions 
of Hypoxis with antiretrovirals metabolized trough CYP3A4 and Pgp.
Kigelia Africana
Kigelia africana (synonym K. pinnata), also called sausage tree, is found throughout Africa and 
its fruits are traditionally used for the treatment of a variety of ailments including wounds and 
abscesses, dysentery, syphilis, diabetes and gonorrhea. The herb has also been reported to 
have antimicrobial activity125. Isolated constituents of Kigelia africana include naphthoquinons, 
coumarins, iridoids and flavonoids126-128.
Kigelia africana (stem bark) has been shown in vitro (caco-2 celline) to have no inhibitory 
effect on Pgp7.
No other studies on the effects of Kigelia on drug-metabolizing or transporting enzymes 
have been reported.
Sutherlandia frutescens
Sutherlandia frutescens has been used for the treatment of stress related maladies linked to 
the endocrine system, internal cancers (hence the African name cancer bush), tuberculosis, 
diabetes, influenza, rheumatoid arthritis, osteoarthritis, clinical depression and HIV infection124. 
The bioactive components of Sutherlandia include L-canavanine, GABA and D-pinitol. Despite 
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the lack of evidence for any anti-HIV activity of Sutherlandia, the South African Ministry of 
Health recommends the use of this herb as a HIV/AIDS remedy20.
In vitro Sutherlandia has been shown to almost completely inhibit CYP3A4 activity (96%)  and 
moderately inhibit Pgp activity, while PXR was significantly activated in a dose-dependent 
manner19.  
These results indicate that sutherlandia has the potential for clinically significant interactions 
with antiretrovirals metabolized through CYP3A4 or Pgp.
Herb-drug interactions per continent
Seventeen (85%) herbs on the American top 20 list of best-selling herbs, 8 (40%) of the 
German top 20 list and 6 (11%) out of 53 herbs on the African list have been investigated for 
interactions with drug-metabolizing or transporting enzymes involved in ARV metabolism or 
pharmacokinetic interactions with ARVs or drugs with the same metabolic route as ARVs.
Five herbs (St John’s wort, milk thistle, Saw Palmetto, ginkgo and black cohosh) feature on the 
American as well as the German list and 1 herb (devil’s claw) is on both the German and the 
African list. In total, 25 herbs have been investigated.
Discussion
Evidence from in vitro and in vivo studies indicate that many American and German as well 
as some African herbal medicines modulate activities of CYPs, Pgp or UGTs that are involved 
in ARV metabolism and thereby have potential for interactions with ARVs. The use of some 
of these herbal medicines by HIV patients on antiretroviral therapy may cause toxic ARV 
concentrations or subtherapeutic drug levels and the development of resistant HIV.
Investigations on potential herb-ARV interactions were performed for 25 herbal medicines: 
17 herbs on the American list, 8 herbs on the German list and 6 herbs on the African list. 
Table 5 shows the kind of studies that provided the evidence for potential herb-arv 
interactions. Clinical trials with ARVs form the highest quality evidence, followed by clinical 
trials with drugs with same metabolizing route as ARVs, case reports, animal studies and 
in vitro investigations129. Remarkably, all African herbal medicines have only been investigated 
in vitro, except for devil’s claw, of which one case was reported; however, this herb is also 
included on the German list.
The western herbal medicines garlic and SJW were shown to have the highest potential 
to significantly interact with ARVs, as indicated in clinical trials with ARVs. They may induce 
CYP3A4 or Pgp and may thereby lead to treatment failure and resistant HIV. Furthermore, 
it has been indicated in clinical trials using drugs with the same metabolic route as ARVs, 
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that the Western herbal medicines Echinacea, ginkgo and milk thistle have the potential 
to significantly interact with ARV metabolism through the modulation of CYPs and/or Pgp. 
Therefore, HIV patients on ARV treatment should avoid the use of allicin containing garlic 
supplements, SJW, Echinacea, ginkgo and milk thistle. Evidence from other clinical studies, 
case reports, animal and in vitro studies on some American, German and African herbal 
medicines indicate that they may have the potential for herb-ARV interactions. For these 
herbs, caution need to be taken when they are used by HIV patients on ARV treatment and 
therapeutic drug monitoring (TDM) should be used to follow the plasma concentrations of 
ARVs, so that the physician can act promptly to any changes.  Table 5 lists which American, 
German and African herbs have the potential to interact with ARVs and should therefore be 
avoided or used with caution by HIV patients receiving ARV treatment.
It should be noted that most evidence for the potential herb-ARV interactions is based 
on in vitro data. The in vitro effects of a herbal compound on CYP enzymes, Pgp and UGT 
depend on the type and chemical composition and dosage of the herbal supplement and 
the experimental system used (e.g. hepatocytes or liver microsomes). When a study uses 
an isolated compound, it is difficult to extrapolate results to the complex phytomedicine, 
since synergistic interactions may occur. When extrapolating in vitro data to the in vivo 
situation  several factors should be taken into account including the role of the metabolite 
and interindividual differences in clearance 130. 
Case reports are also not easily interpreted, since they often provide limited information and 
can represent outliers in a population23. 
The highest quality of evidence for interactions with ARVs is provided by controlled clinical 
trials which were only provided for garlic, SJW and milk thistle. These studies were conducted 
in healthy volunteers, instead of HIV patients, while it is known that HIV-seropositive patients 
metabolize drugs slower and have more variability in CYP3A4 activity than HIV-negative 
individuals21, 131. Furthermore, the healthy volunteers were exposed to one antiretroviral drug, 
while for treatment of HIV infection in clinical practice more complex multi-drug regimens 
are used. Thus evidence from studies using healthy volunteers should be extrapolated to 
HIV-infected individuals with care.
The chance that a herb produces a clinically significant interaction with ARVs depends on 
factors associated with the antiretroviral agent, such as type, dose, dosing regimen and 
administration route and with the concomitant herbal supplement, such as type, dosage, 
dosing regimen, administration route, duration of treatment and chemical composition. 
Beside the ARV and herbal product various patient-related factors, such as gender, age, drug 
compliance, disease factors, concomitant medications and genetic polymorphisms also 
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influence the chance of a clinical significant herb-ARV interaction. It should be kept in mind 
that there are differences in the prevalence of genetic polymorphisms between individuals 
from Africa, America and Europe, which can influence drug metabolism. For example, in the 
African population there are more individuals with a high CYP2D6 metabolisation rate than 
in the Caucasian population132. 
Another difficulty in giving an indication of potential herb-ARV interactions is that there is a 
wide variability in the level of characteristic constituents among various commercial brands 
of the same herb. For example, the amount of hyperforin, the component responsible for the 
pharmacokinetic interactions of SJW with other drugs133, 134, varies widely between different 
brands. Analytical studies have shown significant variation in the amount of hyperforin 
between commercial products purchased in the United States 135, 136. In Germany too, where 
herbal medicines are used as conventional medicines, the concentration of hyperforin and 
hypericin among products and batches of the same product varied widely137.
Herbal medicines are used by HIV patients in America, Europe and Africa. Several studies 
have been done on the European and American herbal medicines, but only six in vitro 
studies have been conducted for African herbal medicines, while on this continent access to 
antiretrovirals and thus potential for herb-ARV interactions is growing. Evidence from these 
studies indicate that some herbal medicines interact extensively with drug metabolizing 
and transporting enzymes involved in ARV metabolism and thereby have the potential to 
interact with antiretroviral metabolism, which may result in treatment failure, resistant HIV 
or toxic drug concentrations. More pharmacokinetic studies to unveil potential interactions 
of American, German and especially African herbal medicines with antiretroviral agents are 
urgently required and the clinical significance of potential herb-ARV interactions should be 
assessed.  This information will also provide HIV-infected individuals and AIDS healthcare 
workers more insight in the potential herb-ARV interactions.
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Abstract
Using the ethnobotanical approach, some Tanzanian plants reported to be used by traditional 
healers for the treatment of oral candidiasis and fungal infections of the skin were collected 
and screened for their antifungal activity against Candida (C.) albicans, C. glabrata, C. tropicalis, 
C. parapsilosis, C. krusei and Cryptococcus neoformans. 
A total of 65 crude methanol extracts belonging to 56 plant species and 38 families were 
screened using the broth microdilution method, according to the guidelines of the Clinical 
and Laboratory Standard Institute (CLSI) (formerly, National Committee for Clinical Laboratory 
Standards) (NCCLS, 2002). Among the tested plant species, 45% (25 species) showed antifungal 
activity against one or more of the test fungi. The most susceptible yeasts were Cryptococcus 
neoformans, followed by C. krusei, C. tropicalis, and C. parapsilosis. The least susceptible were 
C. albicans and C. glabrata. Strong antifungal activity was exhibited by extracts of Clausena 
anisata Oliv., Sclerocariya birrea Sond, Turraea holstii Gurk, Sterculia africana (Lour) Fiori, 
Acacia robusta subsp. Usambarensis (Taub) Brenan, Cyphosterma hildebrandti (Gilg) Desc, 
Elaeodendron buchannanii (Lows), Acacia nilotica (L.) Wild ex Del, Jatropha multifida L., and 
Pteridium aquilinum (L.) Kuhn. 
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Introduction
It has been shown that up to 90% of all HIV/AIDS patients contract fungal infections at some 
point during the course of the disease (Diamond, 1991) and that 10-20% die as a direct 
consequence of fungal infection1. Oral candidiasis is the earliest and most frequent fungal 
infection in the HIV-infected patients2-4. This may extend to the oesophagus and prevent intake 
of adequate oral nutrition, resulting in increased morbidity and mortality, and reduction of the 
length and quality of life5. Candida (C.) albicans is the most common causative agent of oral 
candidiasis, but non-albicans Candida species, such as C. tropicalis, C. glabrata, C. parapsilosis, 
C. krusei, and C. guilliermondii, have also emerged as significant pathogens6, 7.  Infection with the 
pathogenic fungus Cryptococcus neoformans is a more serious infection that often produces 
pneumonia and meningitis in HIV-infected patients. Cryptococcus neoformans is estimated to 
have a prevalence of between 8 to 10% among the AIDS patients group8.
Management of candidiasis and other fungal infections, among HIV/AIDS patients, is facing 
a number of problems including resistance to antifungal agents, drug toxicity, high costs 
of antifungal agents and relapse of infections9, 10. Literature reports show that HIV-infected 
patients often develop resistance to treatment with fluconazole, the most currently used 
antifungal agent11, 12. Sometimes, resistance to fluconazole triggers cross-resistance to other 
azoles or pathogen shift from C. albicans to less sensitive species such as C. glabrata and 
C. krusei7, 13. This reduces the number of available, effective antifungal agents, thus necessitating 
the development of new antifungal remedies.
Plants that are traditionally used in the treatment of fungal infections or related ailments 
could be a good source for new, safe, biodegradable and renewable antifungal drugs. This is 
an important possibility for Tanzania, where medicinal plants have been used for centuries for 
treatment of different ailments.  Both rural and urban populations still depend on traditional 
healers for provision of health care. One report of a survey performed in Dar es Salaam 
showed that 21% of the people that went to seek care from public services had first consulted 
a traditional healer14. Also according to Medicine du Monde, a French non-governmental 
organisation, in Kagera region five out of every six HIV-infected patients receive their medical 
attention from a traditional healer rather than from a hospital or primary health care facility15. 
Despite the broad use of medicinal plants there is very limited scientific support for their use 
in the treatment of fungal infection.
The purpose of this study was to identify and obtain information on the plants that are used 
by traditional healers in the management of fungal infections and to determine their in vitro 
antifungal activities against Candida spp. and Cryptococcus neoformans.
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Materials and Methods
Study areas
The fieldwork was carried out in Tanga, Singida, Coast, and Morogoro regions located on 
north-east, central and eastern Tanzania in February-March 2004. Earlier studies reported 
that some plants used traditionally in these regions possess antifungal activity16. The villages 
that were visited included Nyasa, (Mlalo ward, Lushoto district), on the western Usambara 
highlands with an altitude of 1341-1829 metres. Mwaru, Nduamghangha and Mgori villages 
in Singida rural district bordering Mgori forest reserve, approximately 120 kilometres from 
Singida town. Bwawani, and Mikese village (Morogoro region), Chamakwesa, Chalinze, 
Mabwepande, and Bagamoyo (Coast region).
Interviews with traditional healers
Information on the plants used for treatment of oral candidiasis and fungal infections of 
the skin, parts used, preparations, other uses and adverse effects were obtained through 
interviews with traditional healers using a questionnaire, after obtaining their informed 
consent. Interviews were conducted by the main author in Swahili language. Two traditional 
healers could only understand sukuma and shambaa language, respectively in which case 
close relatives assisted with translation during the interview. Fourteen traditional healers 
were interviewed, eleven men and three women.
Collection and identification of plants
Various plant parts such as leaves, whole plant, fruits, stem, stem barks, roots and root barks 
reported by interviewed traditional healers to be used for treatment of oral candidiasis 
and fungal infections of the skin were collected from the forest by the main and second 
author with the help of a traditional healer. The plants were identified at the Department of 
Botany, University of Dar es Salaam where also voucher specimens were deposited in the 
herbarium.
Extraction of plant materials
All plant samples were air-dried and ground. Approximately 400 grams of the plant materials 
were macerated with 80% methanol at room temperature and after 24 hours filtered 
through Whatman number 1 filter paper. The procedure was repeated three times to ensure 
exhaustive extraction of the plant material. The extracts were pooled together, concentrated, 
and the solvent removed by evaporation under reduced pressure in a rotavapor at 40°C. 
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The extracts were further dried by freeze-drying and kept in a freezer, at -20°C, until used for 
antifungal testing.
Assay for antifungal activity 
The activity of the plant extracts were tested against six American Type Culture Collection 
(ATCC) yeast strains including; C. albicans ATCC 90028, C. glabrata ATCC 90030, C. parapsilosis 
ATCC 22019, C. krusei ATCC 6258, C. tropicalis ATCC 750, and Cryptococcus neoformans.
Candida spp.  and Cryptococcus neoformans were subcultured onto Sabouraud dextrose agar 
(Oxoid Ltd, Hampshire England) and incubated at 35 °C for 24 and 48 h, respectively.
Testing of the plant extracts for antifungal activity was done by the broth microdilution 
method, according to the guidelines of the Clinical and Laboratory Standard Institute (CLSI) 
(formerly, National Committee for Laboratory Standards)17.  All the testing was done in 
duplicate. Stock solutions of dried methanol extracts were prepared by dissolving 100 mg 
of each extract in 1 ml 100% dimethylsulfoxide (DMSO). The resulting 100 mg/ml extract 
solutions were diluted 12.5 times in milli-Q water to obtain a final concentration of 8 mg/ml. 
To avoid bacterial contamination each solution was sterilized by filtration through a 0,22 
µm millipore-filter. Serial dilutions were made in RPMI-1640 medium with L-glutamine but 
without bicarbonate (GIBCO BRL, Life Technologies, Woerden, The Netherlands) Aliquots 
of 100 µl of the diluted extracts were dispensed into the Wells of flat-bottomed 96-wells 
microtitre plates (Costar, Corning, NY). 
The inocula were prepared spectrophotometrically (NCCLS, 2002) to give a final 
concentration of 0.5 to 2.5x103 CFU/ml in RPMI 1640 medium buffered to pH 7 with 0.165M 
morpholinepropanesulfonic acid (MOPS). A constant volume (100 µl) of the inoculum was 
added to each microdilution well containing 100 µl of the serial dilution of the methanol 
extract to reach final concentrations of 4, 2, 1, 0.5, 0.25, 0.125, 0.063, 0.031, 0.016 and 0,008 
mg/ml, respectively. The microtiter plates were incubated at 350C for 48 hours. DMSO 4% to 
0.008% and amphotericin B were used as growth controls.
Minimum inhibitory concentrations (MICs) were determined after 48 h for Candida spp. and 
72 h for Cryptococcus neoformans, after which readings were performed visually by comparing 
with growth in control wells and the extract blank which consisted of uninoculated plates 
(the score of 0-4 was given) or spectrophotometrically with a microplate reader (Anthos htΙΙΙ; 
Anthos Labtec Instruments, Salzburg, Austria) at 405 nm. The optical densities (ODs) of the 
blanks were subtracted from the ODs of the inoculated plates and the percentage growth for 
each well was calculated. MICs of the extracts were defined as the lowest concentration of 
plant extract that inhibited growth by 95-100% (MIC0). Minimum fungicidal concentrations 
3
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(MFCs) were determined by subculturing each optically clear wells (no growth seen). 
Using a micropipette 50µL was removed from clear wells and inoculated onto SDA plates. 
The plates were then streaked with a sterile loop and incubated for 24-48 h at 350C. The MFC 
was defined as the concentration of plant extract at which the number of colony forming 
units was zero18.
Results and Discussion
Ethnomedical information
The results of the field study are presented in Table 1. A total of 65 plant parts belonging to 
56 plant species and 38 families were reported to be used for treatment of oral candidiasis 
and fungal infections of the skin. The most represented family was Euphorbiaceae (6 species), 
followed by Cucurbitaceae, Mimosaceae and Vitaceae (3 species each).  Out of 56 plant species 
three species were mentioned by two or more traditional healers. These included Clausena 
anisata Oliv. (three times), Albizia anthelmintica (A.Rich) Brogn, and Rapanea melanophloeos 
(L.) Mez (two times each). The methods of preparation and administration were generally 
topical (plant parts were ground into powder, mixed with water or sesame oil and used 
as mouthwash or ointment, and juice from leaves and stem topically applied) for 31 plant 
species; infusions taken orally/water decoctions for 20 species; or both topical and water 
decoctions for 5 species. The commonest plant parts mentioned to be used were leaves 
(30%), followed by roots (29%) and the least used were tubers and fruits (3% each). Analysis of 
the data based on their habits showed that 21 species (37%) were trees, 18 species (32%) were 
shrubs, 11 species (20%) were herbs and 6 species (11%) were climbers. Adverse effects were 
only reported for three species; Euphorbia tirucali L. juice from leaves may cause blindness 
when in contact with eyes, and bitter and sour taste for Rhoicissus tridentata (Fresm) Placium 
and Cucumis aculeatus Cogn, respectively. Literature reports (Table 2) showed that 15 (27%) 
plant species have reports of similar ethnomedical uses or proven in vitro antifungal activity. 
Two plants Euphorbia heterophylla19 and Jatropha multifida were reported to be toxic20. 
Antifungal activity
Among the 65 plant extracts tested 26 (40%) extracts, belonging to 25 (45%) plant species, 
completely inhibited the growth of one or more of the tested fungi. Table 3 shows the MICs 
and MFCs of the active methanol plant extracts. Most antifungal activity was found against 
the yeasts. The most susceptible yeasts based on the high number of active plant extracts 
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inhibiting its growth were Cryptococcus neoformans followed by C. krusei, C. tropicalis and 
C. parapsilosis. Out of 26 active plant extracts, 21 (80%) showed activity against Cryptococcus 
neoformans, 17 (65%), 16 (61.5%), 11 (42%) and 5 (19%) against C. krusei, C. tropicalis, 
C. parapsilosis and C. glabrata, respectively. C. albicans was the least susceptible of all the yeasts. 
Only 4 (15%) of the plant extracts, including Clausena anisata Oliv., Sclerocariya birrea Sond, 
Turraea holstii Gurk, and Spirotachys africana Sonder inhibited its growth. The extracts that 
exhibited the broadest spectra of antifungal activity (activity against at least four yeasts) were 
Clausena anisata Oliv., Agauria salicifolia Oliv., Sclerocariya birrea Sond, Acacia robusta subsp 
Usambarensis (Taub) Brenan, Cyphosterma  hildebrandtii (Gilg) Desc, Turraea holstii Gurk, 
Sterculia africana (Lour) Fiori, Zanthoxylum chalybeum L and Acacia nilotica (L) Willd ex Del.
There is no validated criteria for the MIC end points for in vitro testing of plant extracts, 
however, Aligiannis et al (2001) proposed classification for plant materials, based on MIC 
results as follows: Strong inhibitors – MIC up to 0.5 mg/ml; moderate inhibitors – MIC between 
0.6 and 1.5 mg/ml and weak inhibitors – MIC above 1.6 mg/ml42. In our study we tested up 
to maximum concentration of 4 mg/ml. Based on the above classification Clausena anisata 
Oliv. stem bark, Sclerocariya birrea Sond, Turraea holstii Gurk leaves, Sterculia africana (Lour) 
Fiori, Acacia robusta subsp Usambarensis  (Taub) Brenan, Cyphosterma hildebrandti (Gilg) 
Desc Elaeodendron buchannanii (Lows) leaves, Acacia nilotica (L.) Wild ex Del stem, Agauria 
salicifolia, Jatropha multifida L., Pteridyum aquillinum showed strong activity to one or more 
tested microorganisms.
This study shows that information obtained from traditional healers can lead to discovery of 
therapeutically useful agents. From the 56 plant species which were reported by the healers 
only 2 (3.6%) plants, Euphorbia heterophylla 19 and Jatropha multifida20 had previous literature 
reports of toxicity, while 14 plant species had previous reports of confirmed in vitro antifungal 
activity. Among the 14 plant species previously reported to have in vitro antifungal activity 
the results were confirmed in the present study for 8 species; Acacia nilotica, Hymenodictyon 
parvifolium, Clausena anisata, Rhoicissus tridentate, Solanum incanum, Sclerocariya birrea, Tagetes 
minuta and Zanthoxylum chalybeum (Table 2). The antifungal activity for the above plants were 
previously determined by other methods except for Tagetes minuta21 which similar to our study 
used a broth microdilution method, which is the reference method for antifungal susceptibility 
testing recommended by the Clinical and Laboratory Standard Institute (CLSI)17.  
The detection of antifungal activity in nearly 50% of the plant species gives the claims by 
traditional healers a significantly high credibility.  However, 31 plant species (39 extracts) did 
not show activity against any of the test microorganisms. In contrast to previous reports 
several plant extracts did not exhibit in vitro antifungal activity including Salvadora persica 
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L., Securidaca longipedunculata, Acalypha fruticosa, Balanites aegyptiaca, Erythrina abbyssinica 
and Ocimum basilicum22-28. This was also the case for infusions of the bark of Erythrina 
abbyssinica three times a day orally indicated for treatment of candidiasis29. Besides the 
absence of active compounds other reasons could explain the lack of antifungal activity, 
including the parts of the plants used, the solvent used for extraction, the location where the 
plants were collected, and possibly the time of collection. 
Agauria salicifolia Oliv leaves showed activity against all yeasts except C. albicans. The leaves 
also showed fungicidal activity against C. glabrata. Little is known regarding the antifungal 
activity and compounds from leaves of Agauria salicifolia Oliv. Sclerocariya birrea Sond 
roots showed fungistatic activity against all yeasts except C.  glabrata. Moreover, it has 
been reported that the stem bark of Sclerocariya birrea Sond has antifungal activity against 
C. albicans.35. Extracts from leaves of Acacia robusta subsp. Usambarensis (Taub) Brenan and 
Cyphosterma hildebrandti (Gilg) Desc showed fungistatic activity against all yeasts except 
C. albicans, while extracts from leaves of Turraea holstii Gurk was active against all yeasts 
except C. glabrata. Extracts from leaves of Sterculia africana (Lour) Fiori and stem of Jatropha 
multifida L. have shown activity on the yeasts except C. albicans and C. glabrata. Extracts from 
the stem of Spirostachys africana Sonder showed fungicidal activity against C. albicans and 
C. glabrata, the yeasts that showed the least susceptibility of all the tested yeasts in this study. 
Little is known from the literature regarding antifungal activity and the active compounds 
from roots of Sclerocarya birrea Sond, stems of Jatropha multifida L and Spirostachys africana 
Sonder, leaves of Acacia robusta subsp Usambarensis (Taub) Brenan, Cyphosterma hildebrandti 
(Gilg) Desc, Elaeodendron buchannanii (Lows) and Sterculia africana (Lour). Further research is 
warranted to identify their active compounds.
Conclusions
Results of the present study suggest a fairly good correlation between traditional therapeutic 
use and the in vitro antifungal activity. These results corroborate the importance of 
ethnobotanical surveys for screening plants as a potential source for bioactive compounds. 
Hence these could result in discovery of novel antifungal agents.  Further bio-guided 
fractionation will be conducted for roots of Sclerocariya birrea Sond, leaves of Acacia robusta 
subsp Usambarensis (Taub) Brenan, Turraea holstii Gurk, Agauria salicifolia, Sterculia africana 
(Lour) Fiori, Cyphosterma hildebrandti (Gilg), Elaeodendron buchannanii (Lows) and stem of 
Spirostachys africana Sonder to identify the active compounds.
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Abstract 
HIV-infected patients in Sub-Saharan countries highly depend on traditional medicines for 
the treatment of opportunistic oral infections as candidiasis.  Previous investigations on 
antifungal activity of medicinal plant extracts utilized by traditional healers in Tanzania have 
revealed twelve extracts with potent antifungal activity. Although the plants may be good 
candidates for new treatment opportunities, they can be toxic or genotoxic and could cause 
pharmacokinetic interactions when used concomitantly with antiretroviral agents (ARV). 
Therefore, we investigated the cytotoxicity, genotoxicity and cytochrome P450 interaction 
potential of these medicinal plants. Cytotoxicity  was tested by Hoechst 33342, Alamar 
Blue, Calcein-AM, glutathione depletion and O2-consumption assays and genotoxicity by 
a VITOtox assay. Competition of the twelve extracts on substrate metabolism by CYP3A4, 
2C9, 2C19 and 2D6 was tested with high throughput CYP inhibition screening. Pregnane X 
Receptor (PXR) activation was tested using CHO cell lines expressing hPXR. Herbal extracts 
inducing high hPXR activation were tested for enhanced CYP3A4 mRNA levels with QPCR. 
Genotoxicity was found for Jatropha multifida, Sterculia africana and Spirostachys africana. 
All plant extracts showed high cytotoxic effects in almost all tests. Potent competition with 
CYP3A4, 2D6, 2C9 and 2C19 was found for 75% of the herbal extracts. Spirostachys africana 
did not affect CYP2D6 and for Sterculia africana and Turraea holstii no effect on CYP2D6 and 
CYP3A4 (DBF) was found. Nine plant extracts showed significant activation of hPXR, but only 
Agaura salicifolia,  Turraea holstii and Sterculia africana significantly induced CYP3A4 mRNA 
levels. These results indicate the possibility of potential medicinal plant-ARV interactions.
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Introduction
Traditional medicines are commonly used in Sub-Saharan countries like Tanzania, with up 
to 80% of the population depending on traditional medicines for their primary health care 1. 
In Tanzania up to 21% of the people that seeked care from public health care facilities 
first consult a traditional healer 2. Especially, HIV-infected persons who often encounter 
opportunistic infections during their disease course highly depend on this form of health care. 
According to Medicine du Monde, a French non-governmental organisation, in Kagera region, 
five out of every six HIV-infected patients receive their medical attention from a traditional 
healer rather than from a hospital or primary health care facility 3. A survey among 532 HIV 
patients visiting the HIV clinic of Muhimbili National Hospital, Dar es Salaam, Tanzania, reported 
use of traditional medicines by 62 patients (11.7%). Focusing on HIV patients with oral lesions, 
mostly oral candida infections, a prevalence of  traditional medicine use of 40.3% was found 4.
Fungal infections, like oral candidiasis, are commonly seen among HIV-infected patients in 
Sub-Saharan Africa. The problems with effective management of these infections such as 
high costs, drug resistance and toxicity, drives the search for cheap treatment alternatives. 
We previously investigated the antifungal activities of plants used by Tanzanian traditional 
healers for treatment of fungal infections. Twelve medicinal plants were identified with 
potent antifungal activity, which supports the claims by traditional healers on the antifungal 
effectiveness of these Tanzanian medicinal plants 5 (see Table 1). These medicinal plants 
might offer cheap alternative treatment opportunities for HIV-infected patients with 
opportunistic fungal infections. Furthermore, the active compounds may be interesting 
candidates for development of new antifungal agents. However, little is known of the safety 
of these medicinal plant extracts. Some of them were found to contain compounds that 
can be potentially cytotoxic or genotoxic.  For example, Pteridium aquillinum contains the 
carcinogenic compound ptaquiloside 6-10. A case of Agaura salicifolia intoxication, with 
vomiting, arterial hypotension and bradycardia was reported in a 28 year old female due to 
ingestion of tea made of the leaves 11. Therefore cytotoxicity will be tested by Hoechst 33342, 
Alamar Blue, Calcein-AM, glutathione depletion and O2-consumption assays, which focus on 
cellular proliferation, mitochondrial activity, cell membrane integrity, intracellular glutathione 
status and O2 consumption, respectively. This battery of toxicity assays was chosen due to its 
diversity on different aspects of cellular toxicity.
Beside the safety of these medicinal plant extracts in terms of cytotoxicity or genotoxicity, the 
question rises whether usage of these medicines may cause pharmacokinetic interactions 
with concomitantly administered antiretroviral agents (ARV). ARVs are metabolised by 
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enzymes of the Cytochrome P450 enzyme system (CYP450). The protease inhibitors (PIs) 
and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are mainly metabolized by 
CYP3A4 and to a lesser extent by CYP2B6, 2C9, 2C19 and 2D6. Another class of ARVs, the 
nucleoside reverse transcriptase inhibitors are not metabolized through CYP450 enzymes 12. 
Concomitant administration of herbal medicines might induce or inhibit CYP450 enzymes, 
thereby causing subtherapeutic ARV plasma levels with risk of development of HIV resistance 
or high ARV plasma levels with risk for toxicity, respectively. For example, St John´s wort (SJW) 
has been shown to increase the clearance and oral bioavailability of nevirapine with 35% 
in HIV patients 13. This clinical interaction may be due to the inductive capacity of  SJW on 
hepatic and/or intestinal CYP3A4 14. Mills et al. (2005) recently described the potential for 
interaction of two South African medicines with ARVs metabolized by CYP3A4 15. Furthermore 
for Indonesian herbal medicines interaction with CYP3A4 and CYP2D6 has recently been 
reported 16. 
With the plans of WHO to provide worldwide access to antiretroviral agents, also HIV-infected 
patients who formerly depend on traditional medicines will get more access to these Western 
medications. So interactions between medicinal plants and antiretroviral medications are a 
growing concern. The above mentioned survey in Dar es Salaam found that 36 HIV-infected 
patients (58%) on ARVs were concomitantly using traditional medicines underlying the need 
for urgent studies on potential herb-ARV interactions 4. Nothing is known on the eventual 
risk for CYP450 enzyme interaction of the potentially useful Tanzanian herbal extracts. 
Therefore, beside cytotoxicity and genotoxicity, we investigated the extracts of the twelve 
most antifungal active medicinal plants for their competitive activities on CYP2C9, 2C19, 2D6 
and 3A4, the activation of PXR and the induction of mRNA levels of CYP3A4. 
Materials and methodology 
Materials
Ketoconazole, 3-cyano-7-ethoxycoumarin, furafylline, sulfaphenazole were obtained from 
Ultrafine Chemicals (Manchester, UK), Glucose-6-phosphate (G6P), G6P-dehydrogenase 
(G6PDH) and NADP+ were purchased from Roche (Mannheim, Germany). MgCl2 and potassium 
phosphate monobasic were obtained from Merck (Darmstadt, Germany) and potassium 
phosphate dibasic and DMSO from J.T.Baker (Deventer, The Netherlands). Doxorubicin, 
monochlorobimane (MCB), tranylcypromine, quercetin, quinidine, 4-nitrosoquinoline-
1-oxide and benzo[a]pyrene were ordered from Sigma-Aldrich (St. Louis, USA). CYP450 
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supersomes, 7-methoxy-4-methylcoumarin (MFC), 7-benzyloxyquinoline (7-BQ) and 
dibenzylfluorescein (DBF) were obtained from BD Gentest (Woburn, USA), Hoechst 33342 
from Riedel de Haën (Seelze, Germany), Alamar Blue from Sero-Tec (Oxford, UK), Calcein-AM 
from Molecular probes (Eugene, OR, USA), Trypsin from GibcoBRL (Life technologies, USA), 
96-well NUNCLON culture plates from NUNC (Roskilde, Denmark), O2 test kit from Luxcel 
Biosciences (Cork, Ireland),VITOtox test kit from Thermo (Vantaa, Finland), Tularik 0901317 (NV 
Organon, Netherlands), Superscript II Rnase H-Reverse Transcriptase (Invitrogen, Paisley, UK) 
and S9 homogenate from NOTOX B.V. (’s-Hertogenbosch, Netherlands).
The cell culture medium Dulbecco’s Modified Eagles medium, Nutrient mixture F12 (DMEM/
HAM F12 medium in a ratio of 1:1) with phenol red was obtained from GibcoBRL (Invitrogen), 
bovine calf serum from Hyclone (Utah, USA) and 100IU/100µg penicillin/streptomycin from 
GibcoBRL.
Medicinal plants
Plants traditionally used for treatment of fungal infections were collected from Tanga, Singida, 
Coast and Morogoro regions of Tanzania in February-March 2004 and voucher samples were 
deposited at the Herbarium of the Department of Botany, University of Dar es Salaam. Based 
on a previous study on the antifungal activity of the collected plants, the  twelve most potent 
medicinal plant extracts were selected for this study (see Table 1) 5.
Preparation of plant extracts
Methanolic extracts of the plant materials were prepared as described previously5. Methanol 
was used because in 80% methanol all lipophilic and water soluble compounds of the herb, 
thus including those taken up by the body, can be extracted. In short, 400 grams of dried 
and grounded plant materials were extracted with 80% methanol and filtered after 24 h. 
This procedure was repeated three times to ensure exhaustive extraction. The methanol was 
evaporated under reduced pressure in a roto-evaporator at 40 °C. The remaining extracts 
were freeze dried and stored at -20°C until further use. Before the start of the assays, stock 
solutions of plant extracts of 50 mg/ml in DMSO were prepared for Hoechst, Alamar Blue, 
Calcein-AM, glutathione, O2-consumption and PXR assays and of 100 mg/ml in DMSO for 
CYP competition assays and the Vitotox test. Stocks were serially diluted in DMSO by 2-fold. 
The concentration range was based on the antifungal activities that were found (see 5).  
  
Preparation of reference compounds
Stock concentrations of 10-2 M were prepared for the reference compounds in DMSO  and 
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stored at -20°C. Test concentrations were prepared in 100% DMSO in the range of 10-2 to 10-5 
M with √10 dilutions. These dilutions were transported to a deepwell plate and diluted in 
PBS to reach the final test concentrations in the plates for cytotoxicity assays in the range of 
3.16*10-8 to 3.16*10-3 M (0.0183 to 18.3 µg/ml), for vitotox assays of 3.16*10-6 to 10-4 M, for the 
CYP450 enzymes of 10-7 to 10-4 M and for the PXR assay of 3.16*10-10 to 10-4 M. The final DMSO 
concentration in the tests was 0.316% for cytotoxicity assays and 0.1% for the other assays.
 
Cell cultures
HepG2 and HeLa  cells were purchased from the American Type Culture Collection (ATCC, 
Rockville, MD, USA), while CHO-PXR 8G cells were prepared within Organon. This cell line 
contained a promoter luciferase read-out system in combination with the human PXR 
receptor. All three cell lines were cultured in 175 cm2 Roux flasks in low glucose Dulbecco’s 
Modified Eagles medium and Nutrient mixture F-12 supplemented with 10% FBS, 2 mM 
glutamine and 100U/100µg Pen/Strep at 37°C in a humidified atmosphere and flushed with 
5% CO2 in air. Complete medium was refreshed every three to four days with subculturing.
Cytotoxicity assays
The HepG2  cells were trypsinized, counted and resuspended in culture medium to a 
concentration of 5.3x104 cells/ml for Alamar Blue and Hoechst tests, 1.06x105 cells/ml for 
glutathione depletion tests and 104 cells/ml for O2-consumption tests. For Calcein-AM test 
HeLa cells were trypsinized counted and resuspended in culture medium to a concentration 
of 5.3x104 cells/ml. Then 190 µl of this cell suspension was seeded per well and the 96 well 
plate was covered and incubated for 24 h in a humidified atmosphere at 37°C  and 5% CO2. 
For cytotoxicity assays an initial plant extract concentration of 50, 25, 12.5, 6.25, 3.125, 1.56, 
0.8 mg/ml DMSO was used. These extracts were five times diluted with PBS and 10µl was 
added to the pre-incubated 96-well plate. The final test concentrations ranged from 500 to 
8 µg/ml and the final DMSO concentration in the test was 1%. Alamar Blue, Hoechst 33342, 
Calcein-AM and glutathione depletion assays were performed as described by Schoonen 
et al.17, 18. In the O2-consumption assay the 96-well plate was also pre-incubated for 24 hr in a 
humidified atmosphere at 37°C and 5% CO2. Then the medium was removed and replaced 
by 190 µl of serum-free medium containing Luxcel A65N-1 oxygen probe (750x diluted). 
This was followed by the addition of the plant extracts (10 µl) or doxorubicin (10 µl) and 
100µl pre-warmed mineral oil (37°C). Plates were sealed and incubated for another 24 h in 
a humidified atmosphere at 37°C under 5% CO2. The fluorescence was measured at 340 nm 
excitation wavelength and 642 nm emission wave length on a fluorometer at 37°C  (Victor 
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II, Perkin-Elmer, Groningen, The Netherlands). The Minimal Toxic Dose (MTD) is defined as 
the lowest plant extract concentration with an inhibition of the fluorescence/luminescence 
of at least 20% compared to that of doxorubicine at 18.3 µg/ml. The Efficacy (EFF) is defined 
as the percentage of the decrease in fluorescence/luminescence of the plant extract at the 
highest tested dose (500 µg/ml) compared with the fluorescence/luminescence decrease 
by doxorubicin at 18.3µg/ml (100%). The Cumulative Index (CI) is the cumulative sum of the 
percentage of inhibition at the 7 tested concentrations, in which the effect is above MTD. 
Each concentration can obtain a maximal score of 80%, leading to a CI between 0 and 560%. 
A compound is considered toxic when EFF or CI > 50%. Weak toxicity is defined when EFF and 
CI >20. Data of reference compounds were calculated in µg/ml according to their molecular 
weights.
VITOtox test 
The VITOtox test was carried out according to the method of Verschaeve et al. (1999) with 
slight modifications 19. The two bacterial strains were cultured according to manufacturer 
instructions. For testing compounds by metabolic activation, a S9 liver homogenate was 
used from Aroclor 1254-treated rats. Frozen S9 homogenates were diluted in prewarmed 
PBS an hour before the start of the experiment. Then the S9 homogenate is diluted 10 times 
with the bacterial (RecN2-4 and pr1) strains. 10µl of each plant extract dilution (2-fold) was 
transported to a second 96-well plate and 90µl of milliQ water was added. For references 25µl 
of the dilutions were transported to a deepwell plate and 975 µl milli-Q water was added. 
Then 50µl of these dilutions were transferred to a 96-well plate and 75µl milli-Q water was 
added. Then 9µl of these extracts and reference dilutions were transported to 384-well plates 
and 81µl of RecN2-4 strain or pr1 strain with or without S9 homogenate was added. Herbal 
extracts were tested in a concentration range from 1-0.0005 mg/ml in 1% DMSO, while 
for the references a range of 1*10-4- 3.16*10-6mol/l √10 dilutions were used in 0,1% DMSO. 
The plate is sealed and luminescence is measured for each of the wells every 15 min. during 
3 h on a Victor II. The signal to noise ratio (S/N) was calculated for each measurement, 
being the ratio between the sample value and the corresponding blank value. A sample is 
considered to be genotoxic when the max S/N(recN2-4)/max S/N (pr1) >1.5 and when the 
signal is generated after 45 minutes. A compound is considered cytotoxic when the S/N ratio 
for pr1 strain is <0.8. Furthermore the minimal genotoxic dosage with or without metabolic 
activation, defined as the lowest compound concentration with or without S9 mixture with 
a max S/N(recN2-4)/max S/N (pr1) ratio of at least 1.5 is calculated. 
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CYP450 enzyme competition assays
The competitive activities of the plant extracts on human CYP2C9, CYP2C19, CYP2D6 and 
CYP3A4 were assayed with the high throughput fluorometric assays from Gentest (Woburn, 
USA) according to the method of Crespi et al.(1997) with slight modifications. The assay 
conditions are summarized in Table 2. For CYP3A4 assays two fluorometric substrates were 
used. Due to practical issues the plant extracts were tested in slightly different  concentrations 
of 139.00-1.09 µg/ml with 2-fold dilution steps in a 384 well plate in 0.1% DMSO. The cofactor 
solutions were prepared in 25mM phosphate buffer (pH 7.4) containing 1.3 mM NADP+, 3.3 
mM G6P, 3.3 mM MgCl2 and 0.4 U/ml G6PDH, except for CYP2D6. For CYP2D6 the cofactor 
solution contained 0.82 mM NADP+, 0.41 mM G6P, 0.82 MgCl2 and 0.4 U/ml G6PDH.
To the 384 well plates, containing plant extracts and control dilutions, 10 µl of substrate 
solution was added and the plates were covered with a lid and shaken for 20 minutes. 
Then plates were pre-warmed at 37°C in an incubator and 10 µl of enzyme/cofactor solution 
was added leading to a final volume of 40 µl/well. Thereafter the plate was put in the Victor 
II reader, shaked for 20 seconds and pre-incubated for 2 minutes at 37°C. Then the plate 
was measured for 0.1 sec./well after 30 min. of incubation using the excitation and emission 
wavelengths shown in Table 2. Data were exported and analyzed using an Excel spreadsheet. 
The IC50 values were calculated by linear interpolation. Data of reference compounds were 
calculated in µg/ml according to their molecular weights.
PXR induction assay
The plant extracts were serially diluted by 2-fold in PBS and culture medium to obtain final 
concentrations of 0.5-0.0005 mg/ml in 0.1% DMSO. As reference the compound Tularik 
0901317 was used, which is a potent LXR ligand that is also capable of activating human PXR 
20-22. 10µl of the diluted plant extracts or reference were added to a 384 well culture plate. 
Finally, 40µl of CHO-PXR 8G  cell suspension (1.2*104 cells/well) were added to each well. 
After 16 h of incubation at 37°C and 5% CO2, 25 µl of LucLite were added to the wells and cell 
lysis was allowed for 30 min at room temperature. Subsequently, the luciferase light signal 
was measured in a 384-well Topcount NXT (Perkin Elmer). The luminescence is expressed as 
counts per second. The EC50 values of the herbal extracts are calculated by using the spline 
4-parameter calculation. Efficacy of test compounds is defined in percentage by means of 
the maximal compound stimulation at 0.5 mg/ml divided by the maximal stimulation of 
Tularik 0901317 at 1x10-4 M multiplied by 100. Also the induction factor of the tested herbal 
extracts is calculated by means of the maximal induction of the luminescence signal at the 
most active concentration of the 11 tested concentrations with respect to the blank signal.
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CYP3A4 mRNA induction
Eight herbal extracts that showed high PXR activation were tested for CYP3A4 induction. 
The herbs and concentrations are shown in Table 3. HepG2 cells were seeded on  Petri-
dishes with a density of 4500 cells/cm2 in culture medium with 10% dBCS and cultured for 
24 h. Then herbs, and positive controls rifampicin and Tularik 0901317, or vehicle alone were 
added and incubated for 24 h. Final test concentration of DMSO was 0.1% for reference 
compounds rifampicin and Tularik 0901317 and herbs, with exception of Jatropha multifida 
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Table 3  CYP3A4 induction of selected concentrations of herbal medicines 
that showed high PXR activity.
herbs Tested concentration   CYP3A4 Fold induction
 (µg/ml) (mean ± sd)*
Agauria salicifolia 31 0.97 ± 0.21
 63 2.00 ± 0.64 
Clausena anisata 63 -
 125 -
Cyphostemma hildebrandtii 31 0.37 ± 0.10
Elaeodendron buchananii  31 0.95 ± 0.32
 63 -
Jatropha multifida 250 -
 500 -
Sclerocarya birrea  16 1.49 ± 0.19
 31 1.76 ± 0.50
Sterculia africana 63 1.34 ± 0.06
 125 2.01 ± 0.96
Turraea holstii 63 0.39 ± 0.04
 125 3.95 ± 1.15
rifampicin 10 -4 5.38 ± 0.19
 10 -5 2.79 ± 0.59
 10 -6 1.73 ± 0.38
Tularik 0901317† 10 -5 4.89 ± 0.03
 10 -6 3.76 ± 0.84
 10 -7 2.22 ± 0.43 
* induction >2 is considered significant (bolt).
† in M.
- toxic concentration for HepG2 cells.
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for which the final concentration was 1%. The cells were then yielded and RNA was isolated 
using trizol reagent and RNA was precipitated with isopropanol. Thereafter cDNA synthesis 
was performed by adding 0.5 μg  random hexamer primer (GE Healthcare Bio-Sciences Corp, 
Piscataway, USA) to 3 μg RNA. The mixture was heated for 10 min at 70˚C and quickly chilled 
on ice for 2 min. cDNA was then synthesized in a total volume of 25 μl containing 50 mM 
Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 0.5 mM dNTPs and 200 
U Superscript II Rnase H-Reverse Transcriptase. After incubation for 1 hr at 42°C, cDNA was 
diluted to a concentration equivalent to 5 ng/ml RNA.
Quantitative Polymerase Chain Reaction (PCR) was performed using an ABI PRISM 7900 HT 
Sequence Detection system (Applied Biosystems, Inc. Foster City, USA). Specific primers 
were designed using Primer Express software (version 2.0, Applied Biosystems). To avoid 
the influence of DNA contamination, primer pairs were designed over an intron and exon 
boundary. For CYP3A4 and β-actin the following forward and reverse primers were used 
respectively, CAGGAGGAAATTGATGCAGTTTT and GTCAAGATACTCCATCTGTAGCACAGT and 
CTGGCACCCAGCACAATG and GCCGATCCACACGGAGTACT. The PCR reaction consisted of 
cDNA equivalent to 30 ng RNA in a total volume of 25 μl PCR mix containing 37.5 μM CYP3A4 
primers or β-actin primers  and 1x SYBRgreen PCR Mix (Applied Biosystems). The program 
used was 10 min at 95°C, 40 cycles of 15 sec at 95°C and 1 min at 60°C 100%, followed by a 
dissociation curve step. Expression levels were normalized by β-actin.
Results 
Extracts of all 12 plant materials were obtained in methanol:water (v:v; 4:1) as in this way 
most of the lipophilic and water soluble compounds and derivatives will become extracted. 
These obtained extracts were already tested on their specific biological inhibitory potential 
of proliferation of Candida spp. Thus the used concentrations (µg/ml) in the tests below can 
be calibrated on their biological merits with respect to inhibition of proliferation of Candida. 
This implies that a large dilution of extract may be indicative for very high concentrations 
of compounds in the extract or that only one or a few very potent and strong growth 
inhibitors for Candida are present in this extract. A ratio score between the growth inhibitory 
concentration in Candida versus human toxicity, receptor activation or CYP3A4 induction 
levels may than lead to a ranking of the herbs with the largest potential for Candida treatment 
and a reduction in side effects.
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Cytotoxicity 
The effects of the 12 medicinal plant extracts on mitochondrial activity, cellular proliferation, 
damage to the cellular membrane, glutathione depletion and the electron transport chain 
activity were tested with Alamar blue, Hoechst33342, Calcein-AM uptake, Glutathione 
depletion and O2-consumption assays, respectively. All plant extracts were tested in a 
concentration range from 8 to 500 µg/ml. This range was based on the minimal concentrations 
(MIC0) of the herbal extracts that inhibited growth of Candida spp. by 100%. The results of the 
cytotoxicity assays are shown in Table 4 and for a selection of herbs the dose response curves 
are shown in Figure 1. In Figure 1F the interpretation of the results in Table 4 is explained by 
the example curve for doxorubicin in Alamar Blue test.
All herbal extracts, except Pteridium aquillinum and Turraea holstii, reduced the NADPH content 
with Alamar blue. Eleaodendron buchannanii had the highest effect on mitochondrial activity 
with a MTD of 62.5 µg/ml, while Pteridium aquillinum and Turraea holstii showed no effect at 
concentrations up to 500 µg/ml. Seven medicinal plant extracts (Acacia nilotica, Acacia robusta, 
Agauria salicifolia, Cyphostemma hildebrandtii, Elaeodendron buchannanii, Jatropha multifida, 
Spirostachys africana, Sterculia africana) reduced DNA levels with Hoechst 33342 . Cyphostemma 
hildebrandtii had the highest effect on cellular proliferation with a MTD of 62.5µg/ml, while 
again for Pteridium aquillinum and Turraea holstii no effects were found. Eleven medicinal 
herbal extracts induced glutathione depletion, while for Turraea holstii no effect on glutathione 
depletion was found. Eight even scored an activity below 7.18 µg/ml. Nine medicinal plant 
extracts induced cellular membrane damage with Calcein-AM. Jatropha multifida had the 
strongest effect on the membrane integrity with a MTD of 31.3 µg/ml. Except for Sterculia 
africana and Spirostachys africana, all herbal extracts showed toxicity in this O2-consumption 
test. The highest effect was found for Agauria salicifolia with a MTD of 31.3 µg/ml.
VITOtox test
Genotoxic effects were found for Sterculia africana, Jatropha multifida and Spirostachys 
africana with minimal genotoxic dosages of 1.00, 0.5 and 1.00 mg/ml, respectively. However, 
after metabolic activation (addition of S9), no genotoxicity was measured. On the other hand, 
the results also indicated that many of the plant extracts were toxic according to criteria 
mentioned (see M&M). This toxicity could mask the genotoxic response. 
CYP450 enzyme competition assays
The IC50 values for the 12 medicinal plant extracts are shown in Table 5. In Figure 2., the dose 
response curves were demonstrated for a representative set of six plant extracts, i.e. Acacia 
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Figure 1
Effects of Acacia nilotica (–*–), Sterculia africana (– –), Elaeodendron buchananii (– –),  Pteridium 
aquillinum (– –), Sclerocarya birrea (– –), Turraea holstii (– – ) and reference  compound  doxorubicin 
(– –) on mitochondrial activity (A), cellular proliferation (B), damage to cellular  membrane 
(C), glutathione depletion (D) and the electron transport chain activity (E) as measured with  Alamar 
blue, Hoechst33342, Calcein-AM uptake, Glutathione depletion and O2- consumption assays, 
 respectively. In (F) an example curve of doxorubicine in Alamar Blue assay is given for  interpretation 
of efficacy, MTD and CI (see also Table 4). Herbs were tested in dose range of 500 to 8 µg/ml and 
 Doxorubicin in 0.0058 to 18.3 µg/ml. Samples are indexed to 100% at 0.0058 µg/ml point for 
 doxorubicin and 8 µg/ml point for the plant extracts. The mean of duplicate analysis is shown. 
A B
C D
E F
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Figure 2
Competitive activities of Sclerocarya birrea (– –), Sterculia africana (–*–), Cyphostemma  hildebrandtii  
(– –), Jatropha multifida (– –), Pteridium aquillinum (– –), Turraea holstii (– –) and reference  compounds 
(sulfaphenazole (2C9); tranylcypromine (2C19); Ketoconazole (3A4) and Quinidine (2D6)) (– –)  
on CYP2C9 (A), 2C19 (B), 3A4 7BQ (C), 3A4 DBF (D) and 2D6 (E) in a dose range study from 139.00 
to 2.00 µg/ml for plant extracts and 0.010-31.40 µg/ml for sulfaphenazole, 0.004-13.30 µg/ml 
for  tranylcypromine, 0.010-32.40 µg/ml for Quinidine and 0.017-53.10 µg/ml for ketoconazole.  
Reference compound concentrations were converted to µg/ml according to their molecular weights. 
The mean of duplicate analysis is shown. 
A B
C D
E
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nilotica, Cyphostemma hildebrandtii, Jatropha multifida, Sclerocarya birrea, Sterculia Africana 
and Turraea holstii. 
All herbal extracts showed dose dependent competition on the metabolism mediated by 
CYP2C9, CYP2C19, CYP3A4 (7BQ and DBF) and CYP2D6. All herbal extracts were potent 
competitors with IC50 values of less than 100 µg/ml against CYP2C9 and CYP2C19. The most 
potent competitor of CYP2C9 was Acacia nilotica (1.03 µg/ml), while Jatropha multifida is the 
most potent competitor of CYP2C19 (4.26 µg/ml). No competitive activity on CYP2D6 was 
found for Spirostachys africana, Sterculia africana and Turraea holstii, while the IC50 values of 
the other nine herbal extracts ranged from 2.96-79.4 µg/ml. The most potent competitor of 
CYP2D6 was Cyphostemma hildebrandtii (2.96 µg/ml).  Except for Sterculia africana, all herbal 
extracts were potent competitors of CYP3A4 when 7BQ was used as substrate. Furthermore, 
all herbal extracts with exception of Sterculia africana and Turraea holsti, were competitive for 
CYP3A4 when DBF was used as substrate. Cyphostemma hildebrandtii was also found to be 
the most potent competitor of CYP3A4 when DBF and 7BQ were used as substrate (1.26 and 
2.69 µg/ml, respectively).
PXR assay
In Table 6 the activation of the Tanzanian medicinal plants on PXR is shown. Significant 
PXR activation with an induction factor > 2.00 was found for Agauria salicifolia (5.44), 
Cyphostemma hildebrandtii (2.41), Elaeodendron buchannanii  (4.49), Jatropha multifida (5.9), 
Pteridium aquillinum (3.58), Sclerocarya birrea  (3.33), Sterculia africana (2.16), and Turraea holstii 
(4.12). The highest activity was found for Agaura salicifolia with a stimulation factor of 5.44 at 
a dosage of 63 µg/ml. 
 CYP3A4 mRNA induction
The concentrations of the medicinal plants that showed the highest PXR activation were 
used to measure the induction of the mRNA levels of CYP3A4. Significant induction of mRNA 
of CYP3A4 was found for Agaura salicifolia, Turraea holstii and Sterculia africana  (Table 3). 
Discussion 
The VITOtox data indicated that Sterculia africana, Spirostachys africana and Jatropha multifida 
were genotoxic. However, many plant extracts also showed a strong toxic response on the 
bacterial cell line Salmonella typhimurium. Furthermore, all plant extracts showed a relative 
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strong cellular toxicity in one or more assays. The extract of Acacia nilotica had the highest 
toxicity, whereas that of Turraea holstii had the lowest toxicity. Additionally, almost all extracts 
potently competed with CYP2C9, 2C19, 2D6 and 3A4. While 75% of the plant extracts potently 
activated PXR, only for Agaura salicifolia, Turraea holstii and Sterculia africana a high induction 
of mRNA of CYP3A4 could be verified.
Genotoxicity of the plant extracts was evaluated with the VITOtox test. This test is based on 
S. typhimurium TA104 recN2-4 that contains a lux operon followed by the luciferase gene 
4
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Table 6  Inductive activities of Tanzanian medicinal plants on human  
pregnane X receptor (hPXR) .
Herbs Dose range of    hPXR hPXR Highest
 MIC0 against  EC50 Induction PXR
 Candida spp. (μg/ml)a factorb induction
    level
    (µg/ml)
Acacia nilotica 31-1000 250 0.11 -
Acacia robusta subsp. 31-1000 250 0.44 - 
Usambarensis    
Agauria salicifolia 500-4000 31.25 5.44 63
Clausena anisata 63-4000 93.75 3.91 125
Cyphostemma hildebrandtii 250-1000 15.63 2.41 -
Elaeodendron buchananii  31-250   46.88 4.49 63
(Loes) 
Jatropha multifida  250-1000 62.50 5.90 500
Pteridium aquillinum 500 93.75 3.58 250
Sclerocarya birrea Sond 63-250 39.10 3.33 16
Spirostachys africana 1000-2000         250 0.27 -
Sterculia africana 63-1000 31.25 2.16 125
Turraea holstii 63-1000 31.25 4.12 63
Tularik 0901317   1.00x10-6 6.41 1.00x10-4
(mol/L in 0.1%DMSO)
a EC50 = lowest plant extract concentration whereby hPXR activity is inhibited by 50% compared 
to reference compound.
b Stimulation factor is defined by means of maximal induction of the PXR activity at the most 
active concentration of the 11 tested concentrations with respect to the blanc signal.
An induction factor > 2 is considered significant (bolt)
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of Vibrio fischeri. Another control strain S. typhimurium TA 104pr1, that has a constitutively 
expressed luciferase gene, is used for detection of false positive responses due to a toxic 
response of the tested compounds 19. Our results indicate that most of the plant extracts had 
a toxic effect. These toxic effects may be due to the beneficial chemical compounds, but may 
also be the result of impurities with an unwanted effect. Furthermore, bactericidal activity of 
the plant extracts against S. typhimurium may cause the toxicity. Also another study testing 
African plant extracts in the VITOtox test found a high toxic response, which was proposed 
to be caused by interaction of the extracts with the lux operon 23. Although we found three 
plant extracts with genotoxicity, the toxic response of the other extracts might mask the 
genotoxic effects. This may have been the case for Acacia nilotica 24, Clausena anisata 25 and 
Pteridium aquillinum 7, 26 for which previously genotoxicity has been reported.  
With the cytotoxicity assays the effects of the twelve herbal extracts on cellular toxicity were 
studied in human cell lines. These assays are a reliable method for high throughput screening 
of toxicity effects of potential medicinal compounds 17, 18. We found a high toxicity for almost 
all herbal extracts at concentrations that were based on the antifungal activity of the herbs 
found in our previous study 5. This high toxicity may suggest that the potent antifungal 
activities of these herbal extracts are due to a general toxic effect of extract ingredients, 
rather than to a specific growth inhibitory or killing effect on the fungi. However, most of 
the herbal extracts inhibited the growth of Candida spp. by 100%, but had no killing effect 
5. Furthermore, each plant extract had different antifungal effects on the diverse Candida 
spp. tested. For example all herbal extracts potently inhibited C. krusei, while C. albicans was 
only inhibited by Clausena anisata, Sclerocarya birrea , Spirostachys africana and Turraea holstii. 
Thus the toxicity effects of the herbal extracts may be more species specific.
According to the cellular toxicity effects as measured in the five assays, the herbal extracts 
were ranked from high to low toxicity in Table 5. Overall, Acacia nilotica was shown to have the 
highest toxicity. It was previously reported that in rats that were fed an 8% Acacia nilotica diet 
for up to 4 weeks their body weights were significantly reduced and serum cholesterol and 
serum total protein significantly decreased. Symptoms reversed one week after treatment 
termination, leading the authors to conclude that Acacia nilotica had a high toxicity potential 
27, but this toxic effect was not irreversible. These findings illustrate, that in vitro test results 
can be extrapolated directly to in vivo effects. The results of the glutathione depletion assay 
demonstrate that most of the plant extracts show a dramatic effect on the glutathione 
levels. These effects can become dramatic in vivo, but can be prevented by treatment with 
N-acetylcysteine for instance after excessive paracetamol use. On the other hand, such a 
treatment should be in time to prevent liver necrosis. In consistence with the in vitro data 
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for Clausena anisata and Pteridium aquillinum toxicity was reported in animal studies and 
for Agauria salicifolia, Jatropha multifida and Pteridium aquillinum toxicity has been reported 
in humans 7, 11, 26, 28-30. For Acacia robusta, Elaeodendron buchananii and Sterculia africana no 
earlier reports on toxicity have been found. 
Interestingly, the two extracts of Sclerocariya birrea and Turraea holstii that showed no 
cytotoxicity, were among the only four plant extracts that inhibited the growth of C. albicans, 
which is the most common cause of oral candidiasis 5. Moreover, these two extracts exhibited 
the strongest inhibitory activities against C. albicans and had a broad spectra of antifungal 
activity 5. Therefore these plant extracts may be interesting candidates for further fractionation 
and isolation of the active compound.
In a recent review potential interactions between commonly used herbal extracts and 
antiretroviral agents have been described 31. These interactions can be based on inhibition 
or induction of CYPs involved in ARV metabolism. Our results revealed that 75% of the herbs 
potently compete CYP3A4, CYP2C9/19 and CYP2D6. A study on 30 Indonesian medicinal 
plants also revealed that 63% gave significant competition with CYP3A4 and CYP2D6 16. In 
the aforementioned review it was shown that indeed many herbs can inhibit CYP enzymes. 
For example, for 33% of the American 20 Top-selling herbal extracts, the inhibition of CYP’s 
involved in ARV metabolism was shown, and thus potential for interaction with ARVs is 
present 31. CYP3A4 is the most important enzyme involved in the metabolism of all PIs and 
NNRTIs. Our results revealed that, with exception of Sterculia africana and Turraea holstii when 
DBF is used as substrate, all plant extracts potently competed with CYP3A4. Therefore, usage 
of these plant extracts concomitant with ARVs may possibly lead to high plasma levels and 
hence toxicity. Moreover, also potent competitors of CYP2C9, 2C19 and 2D6 were found and 
these enzymes might be involved in potential interactions with atazanavir, nelfinavir and 
ritonavir, respectively.
Turraea holstii and Sterculia africana extracts were shown to be free of competitors for CYP2D6, 
while extract of Turraea holstii only potently competed with CYP3A4 with 7BQ  as substrate. 
Remarkably, although nine plant extracts showed PXR activation, only Agaura salicifolia, 
Turraea holstii and Sterculia africana showed induction of CYP3A4 mRNA. Usage of these 
herbs may possibly lead to induction of the CYP3A4, resulting in subtherapeutic plasma 
levels and development of resistant HIV. To date, the only clinically significant interactions 
with ARVs were found for garlic, SJW and milk thistle and were suspected to be based on 
CYP3A4 induction 31.
Results of in vitro studies might however not correspond with the in vivo activity. For SJW for 
example some in vitro studies reported that SJW extract was a potent inducer of CYP2B6 32, 
4
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CYP2C9, CYP2C19 33and CYP3A4 14, 32-34. Contradictory, crude SJW extracts have been shown 
to inhibit the activities of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 35. In HIV patients SJW led to 
a 35% increase in the clearance of the ARV nevirapine 13. In addition, SJW has been shown to 
decrease plasma concentrations of the ARV indinavir with 57% in healthy volunteers 36. Both 
interactions are suspected to be caused by induction of CYP3A4.
Additionally, the preparation (oral or topical) of each herbal extract influences the in vivo 
toxicity and interaction potential. The potent competition of CYP might be of less importance 
for topical agents, but is very relevant when the herbal extract is used orally. 
Another important consideration remains that the in vivo concentrations of these medicinal 
plant extracts are unknown. However, the in vitro tested concentrations showed antifungal 
activity, in consistence with the claims of the traditional healers, and therefore it contains 
the correct balance of active component(s). On the other hand at these concentrations also 
toxicity and CYP interactions were found in this study. Therefore these medicinal plant extracts 
might potentially give toxic effects and interactions when used by traditional healers. 
In conclusion, the VITOtox test seems less appropriate for testing crude plant extracts for 
genotoxicity. Maybe a separation by analytical techniques into the active components will 
lead to a better prediction. Furthermore, almost all plant extracts have been shown to have 
a relative strong cytotoxicity and high CYP inhibitory potential, which may result in toxic 
side effects and toxic ARV plasma levels, respectively. Agaura salicifolia, Turraea holstii and 
Sterculia africana were the only plant extracts found to significantly induce CYP3A4. Usage 
of these herbs by patients on ARVs might possibly lead to subtherapeutic plasma levels 
and development of drug resistant HIV strains. These results indicate that more research on 
the interaction potential of (African) herbal medicines is urgently needed. Furthermore the 
awareness of HIV/AIDS health care workers and the general public for the risks of medicinal 
plant-ARV interactions needs more attention.
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The use of natural health products, such as herbal medicines, is common among individuals 
with HIV1, 2. Surveys revealed that 26-100% of the HIV-infected patients used natural health 
products (NHP); 16-26% of the patients reported the use of herbal medicines1-3. A cross-
sectional study among HIV-infected patients showed that 67% of the patients who were 
receiving antiretroviral (ARV) treatment were also taking an NHP: 24% of this sample reported 
use of herbal medications3.
Usage of herbal medicines concomitant to ARVs can cause significant drug interactions. 
Protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are 
mainly metabolized by cytochrome P450 enzymes (CYPs). Herbs are often also substrate 
of CYPs. In addition, PIs and NNRTIs have a small therapeutic index4. Herbal medicines can 
interact with ARV metabolism by induction or inhibition of CYPs. Inhibition of CYPs might 
lead to high ARV plasma levels and subsequent risk of serious side effects, whereas induction 
might lead to subtherapeutic plasma levels, leading to therapeutic failure and an enhanced 
risk of developing ARV drug resistance. We describe a case of an HIV-1-infected patient taking 
evening primrose, colayur and rheum frangula concomitant to lopinavir (LPV), which resulted 
in a toxic LPV level. 
In April 2004 HIV-1 infection was diagnosed in a 47-year old man because of oligoarthritis 
and hypergammaglobulinemia. The patients’ CD4 lymphocyte count was 120 cells/mm³ 
and his viral load was >100,000 HIV RNA copies/ml. Treatment with stavudine (40 mg BD), 
lamivudine (150 mg BD) and lopinavir/ritonavir soft gel capsules (533/133 mg BD) was directly 
started. Later on stavudine was changed to tenofovir (245 mg QD), because of lipodystrophy. 
His CD4 lymphocyte count recovered to 220 cells/mm³, and the viral load became 
undetectable (<40 copies/ml). Every three months random LPV plasma levels were checked 
and ranged between 4-9 mg/L (normal: 5-10 mg/L). In July 2006, the patient presented with 
persistent diarrhea (>5 times per day), which was interfering with daily life. The patient turned 
out to have a high LPV level of 15.2 mg/L  6.75 hr after intake (time-adjusted population level: 
9 mg/L). The patient history revealed that he was taking herbal medications including Efamol 
(2 tablets TID), Rheum Frangula (2 tablets BD) and Colayur (1 teaspoon a day) for 2 months 
and he has had persistent diarrhea since then. Six weeks after discontinuation of the herbals 
his trough LPV plasma level recovered to 5.3 mg/L and all his complaints disappeared. 
We rechallenged the patient with efamol for 1 week and his trough LPV plasma level increased 
from 6.69 mg/L to 8.11 mg/L. Thereafter the patient discontinued herbal medications and his 
LPV levels remained within normal range at the consecutive visits. There were no adverse 
events reported by the patient during the week of rechallenge.
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This case illustrates a potential herbal medicine-LPV interaction. The patient developed 
diarrhea and toxic LPV levels when he was taking herbal medicines, then recovered upon 
discontinuation of the herbal medications. Before usage of the herbals his LPV levels were 
always within normal ranges and remained within normal ranges during all consecutive 
determinations after rechallenge. 
The diarrhea in this patient can possibly be accounted to the high LPV levels5, although 
Rheum Frangula and/or Colayur, which are laxative intestinal cleaners, could also have been 
responsible. 
Lopinavir is metabolized through CYP3A4 and in less extent CYP2D65. Evening primrose 
(Oenothera biennis), an ingredient of efamol, has in vitro be found to inhibit both CYP3A4 
and CYP2D66. Inhibition of CYP3A4 by evening primrose could be a plausible explanation for 
the toxic LPV level, although during rechallenge only a slight rise in LPV level was observed. 
The patient discontinued the primrose after one week so we do not know what would have 
happened after longer combined administration in this rechallenge. 
Evening primrose is a frequently used herbal medicine, appearing on the 12th place of the 
20 top-selling herbal dietary supplements in the US7. Nothing is known on usage of Rheum 
frangula or Colayur.
Numerous commonly used herbal supplements, especially those in Africa, have not 
been studied for potential clinical interactions with ARVs8. Many HIV-infected patients on 
antiretroviral therapy use herbal medicines, but often do not report usage of these agents 
to their physician9. As a result there is a great potential for interactions between ARVs and 
herbal medicines. Physicians should be aware of the risk for herb-ARV interactions and 
should routinely discuss the usage of concomitant herbal medications with their patients. 
Two recent reviews on clinical10 and potential8 interactions between herbs and ARVs might 
be helpful in this. Furthermore, there is demand for rigorous clinical research to investigate 
whether commonly used African and Western herbal medicines interact with ARVs in vivo.
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Abstract 
Vitamin D regulates bone metabolism but has also immunoregulatory properties. In HIV-
infected patients bone disorders are increasingly observed. Furthermore, low 1α,25(OH)2D3 
levels have been associated with low CD4+ counts, immunological hyperactivity and AIDS 
progression rates. Few studies have examined the vitamin D status in HIV-infected patients. 
This study will specifically focus on the effects of antiretroviral agents on vitamin D status. 
Furthermore, the effect of vitamin D status on CD4 cell recovery after initiation of HAART will 
be evaluated.
Among 252 included patients the prevalence of vitamin D deficiency (<35 nmol/L from 
April-September and <25 nmol/L from October-March) was 29%. Female sex, younger age, 
dark skin and NNRTI treatment were significant risk factors in univariate analysis, although 
in multivariate analyses skin pigmentation remained the only independent risk factor. 
Median 25(OH)D3 levels were significantly lower in White NNRTI treated patients (54.5 (27.9-
73.8) nmol/L) compared to White PI treated patients (77.3 (46.6-100.0) nmol/l, p = 0.007), 
while among non-whites no difference was observed. Both PI and NNRTI treated patients 
had significant higher blood PTH levels than patients without treatment. Moreover, NNRTI 
treatment puts patients at risk of elevated PTH levels (>6.5 pmol/L). Linear regression analysis 
showed out that vitamin D status did not affect CD4 cell recovery after initiation of HAART. 
In conclusion, 29% of the HIV-1-infected patients had vitamin D deficiency, with skincolor as 
independent risk factor. NNRTI treatment may add more risk for vitamin D deficiency. Both 
PI and NNRTI treated patients showed higher PTH levels and might therefore be at risk of 
bone problems. Evaluation of 25(OH)D3 and PTH levels, in especially NNRTI treated and dark 
skinned, HIV1 infected patients is necessary to early detect and treat vitamin D deficiency.
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Introduction
Vitamin D is required for bone health and calcium homeostasis and has important 
immunoregulatory properties. In HIV-infected patients bone disorders, like osteopenia and 
osteoporosis, are increasingly observed 1, 2. Furthermore, low 1α,25-dihydroxyvitamin D3 
(1α,25(OH)2D3) levels and polymorphisms in vitamin D receptor have been associated with low 
CD4+ counts, immunological hyperactivity and AIDS progression rates 3-6. However, only few 
studies have examined the vitamin D status in HIV-infected patients (as recently reviewed 7). 
Plasma concentrations of 25-hydroxyvitamin D3 (25(OH)D3) are the best indicator of vitamin 
D status 8. Vitamin D is obtained from the diet and produced in the skin under influence 
of sunlight. All reactions in vitamin D metabolism are catalyzed by enzymes from the 
cytochrome P450 (CYP450) enzyme system (Figure 1). Previtamin D3 is 25-hydroxylated in 
the liver to 25(OH)D3 and then 1α-hydroxylated in the kidney to 1α,25(OH)2D3, the active 
metabolite 9. Inactivation of vitamin D metabolites occurs mainly by renal 24-hydroxylation, 
which is stimulated by 1α,25(OH)2D3 and high calcium. 
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Figure 1  Vitamin D metabolism
7-dehydrocholesterol is, under influence of sunlight, in the skin converted to previtamin D3, which 
is transported to the liver by vitamin D-binding protein, where it is 25-hydroxylated (CYP27A1) to 
25(OH)D3. 25(OH)D3 is then 1α-hydroxylated (CYP27B1) in the kidney to 1α,25(OH)2D3, the active  
metabolite 9. Inactivation of vitamin D metabolites occurs mainly by renal 24-hydroxylation, which is 
stimulated by 1α,25(OH)2D3 and high calcium.
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Vitamin D deficiency can be caused by several factors. The synthesis of previtamin D3 in 
the skin decreases with age and skin pigmentation 8, 10. Also low sunlight exposure, obesity 
and insufficient vitamin D intake are known risk factors for vitamin D deficiency 11, 12. In HIV- 
infected patients, HIV itself might lead to low 1α,25(OH)2D3 levels by inhibition of renal 
1α-hydroxylase, possibly induced by an inhibitory effect of TNFα 5. Alternatively, 1α,25(OH)2D3 
might be low due to utilization for maturation and proliferation of T lymphocytes during 
HIV infection 7. In addition, highly active antiretroviral therapy (HAART) might interact with 
vitamin D metabolism: protease inhibitors (PIs) and non nucleoside reverse transcriptase 
inhibitors (NNRTIs) can respectively inhibit or induce CYP450 enzymes. In vitro, PIs exerted 
strong inhibition of 1α- and 25-hydroxylase activities, while exerting mild inhibition of 
24-hydroxylase 13, which may in vivo result in low 1α,25(OH)2D3 levels. Also other drugs 
like anti-epileptic agents and tuberculostatics can lead to reduced vitamin D levels and 
subsequent low bone mineral density by either inducing or inhibiting CYP450 14-16.
In this study, we examined the prevalence and causes of vitamin D deficiency among 
HIV-1-infected patients in the Netherlands. We examined, in particular, whether and if so 
which antiretroviral agents interfere with vitamin D metabolism. Additionally the effect of 
vitamin D status on CD4+ T-cell recovery after initiation of HAART has been investigated.
Patients and Methods
Study Subjects 
From January 2006 to August 2006, a cross-sectional survey on vitamin D deficiency was 
done among 254 adult HIV1-infected patients visiting the Radboud University Nijmegen 
Medical Centre, The Netherlands. We excluded subjects with pregnancy, renal disorders 
(serum creatinine >220 µmol/L)) and hepatic disorders (ASAT >200 or ALAT >225 IU/L). Two 
hundred fifty-two patients (99.2%) could be included. 
The study received approval by the local ethics committee and all subjects provided written 
informed consent.
Study design
During their routine visit the vitamin D status of the patients was screened. Blood samples 
were collected for measurement of: 25(OH)D3, intact parathyroid hormone (PTH), serum 
calcium, phosphate, creatinine, albumin, alkaline phosphatase, ASAT and ALAT, CD4 and CD8 
cell counts and viral load (VL). Patients’ age, sex, weight, length, skin color/ethnicity, duration 
and stage of HIV infection (according to 1993 Centers for Disease Control (CDC) criteria 17), 
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duration and kind of antiretroviral therapy and medications were collected from patients’ 
medical history or the database of HIV monitoring foundation. BMI was calculated as weight 
in kg/length2 (in m) for each subject. 
Laboratory measurements
25(OH)D3 was measured by High Pressure Liquid Chromatography (HPLC) with UV detection, 
after prior extraction on small SepPak columns. Tritiated 25(OH)D3, collected from the HPLC 
system during passage of the UV peak, was used to correct for procedural losses. 
Serum intact-PTH in the first 33 patients was measured using the Advantage PTH-N kit 
(Nichols, San Juan Capistrano, CA, USA) and in the last 219 patients using the ELSA-PTH 
kit (CIS Bio International, Gif-sur-Yvette, France). The CIS BIO assay was recalibrated on the 
Advantage assay to give identical measurement results.  
Serum calcium, phosphate, creatinine, albumin, alkaline phosphatase, ASAT and ALAT, 
cholesterol, triglycerides and glucose were determined by automated standard laboratory 
techniques. Corrected calcium was calculated as follows: [Calcium]- (0.025*[albumin])+1.
CD4 and CD8 cell counts were determined by standard flow cytometry (FACS Count System, 
Becton Dickinson, USA). Viral load was measured with Cobas Amplicor HIV-1 monitor test, 
with a minimal detection threshold before January 2000 of <400 HIV-1 RNA copies/ml and 
after January 2000 of <40 HIV1 RNA copies/ml. 
Questionnaire
For further evaluation of risk factors associated with vitamin D deficiency an invalidated 
questionnaire on dietary vitamin D intake, intake of vitamin D supplements and average 
sunlight exposure (hr/day) was taken by face to face interview. Two hundred and one patients 
(79.8%) participated in this questionnaire. Data on dietary questions were processed in a 
special developed spreadsheet (Microsoft Excel 2000) in order to calculate the daily vitamin 
D intake. The mean dietary vitamin D intake per patient was calculated by using the Dutch 
Food table 2004 18.  The recommended daily intake (RDI) of vitamin D is >2.5 µg for people 
aged 18-50 year , >7.5 µg for 51-70 and >12.5 µg for people >70 yrs 18.
Definition of vitamin D deficiency and elevated PTH levels
Vitamin D deficiency was defined as circulating plasma 25(OH)D3 levels <35 nmol/L in April-
September, or <25 nmol/L in October-March. These levels are corrected for season, because 
sunlight radiation differs between summer and winter and can thereby directly influence the 
vitamin D levels. 
Elevated PTH levels were defined as serum intact PTH >6.5 pmol/L.
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Effects of vitamin D deficiency on CD4 cell recovery
For this part only patients receiving HAART for >24 weeks were included. Patients were 
excluded when pregnant during initiation of HAART. As HIV-1 can induce a decline in 
CD4 cells only patients with undetectable HIV-1 viral loads, measured 24 weeks after the 
initiation of HAART, were included. Also patients that had <3 CD4 measurements available 
for regression analysis were excluded. One hundred and five patients could be included. CD4 
cell counts and VL of included patients were retrospectively collected from the database of 
HIV Monitoring Foundation starting 8 weeks after initiation of HAART for as long as the viral 
load remained undetectable. The first 8 weeks of CD4 cell recovery were excluded, because 
then CD4 cells increased rapidly, which is due to a release of memory CD4 cells trapped in 
the lymphoid tissue19.
Statistical Analysis
Continuous variables are expressed as median (Q1-Q3) and categorical variables as number 
of cases (percentage). Continuous variables were compared by the Mann-Whitney U test or 
Kruskal-Wallis test when appropriate. Frequencies were compared by the χ2 test or Fishers’ 
exact test when appropriate. Correlation between 25(OH)D3 levels and PTH and CD4 cell 
count and low calcium and elevated PTH was tested using Spearman correlation.
Logistic regression analysis was used to identify significant risk factors for vitamin D deficiency. 
The following variables were entered: age, gender, BMI, skincolor (White, Mediterranean, 
Asian or Black), type of HAART (PI based, NNRTI based, PI+NNRTI based, triple NRTI based, or 
no HAART), vitamin D intake and sunlight exposure. 
For CD4 cell analysis, a linear regression line of the CD4 cell response to HAART was calculated 
for each individual patient. The obtained slopes of each line represented the, second phase, 
CD4 cell recovery rate of each patient. Because the CD4 cell recovery will probably stop 
around normal physiological levels, with a lower limit of 500, the CD4 cell recovery rates for 
each patient were calculated until a recovery of 500 and 600 cells was reached. Within these 
two groups, median CD4 cell recovery rates were compared between vitamin D deficient 
group versus patients with normal vitamin D levels using Mann-Whitney U test. Also, baseline 
CD4 cell values can influence the CD4 cell recovery rate, therefore the patients were stratified 
according to their baseline CD4 cell count in 0-200 and >200 CD4 cells and the former 
comparison was replied.
All analyses were performed using SPSS statistical software package release 14.0.2 (SPSS 
Software, Chicago, IL). A p-value ≤0.05 was considered statistically significant.
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Results 
Subject sample and characteristics 
Overall, vitamin D status was determined for 254 patients. Two patients were excluded 
because of pregnancy and HIV-2 co-infection, respectively. Subsequently 252 patients could 
be included. In Table 1 the population characteristics are summarized. 
Prevalence and risk factors of vitamin D deficiency  
Data for patients according to presence or absence of vitamin D deficiency are shown in 
Table 1. The prevalence of vitamin D deficiency was 29.0% (73/252). Females had a significantly 
higher prevalence of vitamin D deficiency (58.1%) compared to males (24.7%) (p = 0.010). 
The median (Q1-Q3) 25(OH)D3 levels were significantly lower in females 32.3 (22.6 -51.6) 
nmol/L compared to males 56.0 (30.0-78.5) nmol/L (p<0.001). Postmenopausal females are 
on risk of developing vitamin D deficiency and therefore we compared the age of female 
patients with or without vitamin D deficiency. The median age of females with vitamin D 
deficiency was 36.5 (31.5-41.25) yrs and females without vitamin D deficiency were 35.5 
(29.5-43.75) yrs old; this difference was not statistically significant.
The prevalence of vitamin D deficiency was 19% in White, 33% in Mediterranean, 44% in 
Asian and 62% in Black patients. Black patients were at a significant higher risk of developing 
vitamin D deficiency compared to the other groups (OR 6.22, 95% CI 3.20-12.08). Median 
(Q1-Q3) serum levels of 25(OH)D3 in White, Mediterranean, Asian and Black patients were 
59.5 (36.2-82.8), 57.0 (22.8-64.0), 32.0 (21.5-57.5) and 27.1 (16.8-37.0) nmol/L, respectively; the 
differences were statistically significant between White and Black (p < 0.001) and between 
Mediterranean and Black patients (p = 0.026). Non-White patients were significantly younger 
(median(Q1-Q3): 34 (30-39.75) yrs) than Whites (45 (39-53) yrs), which may explain the 
significant younger age of the vitamin D deficient patients. 
The prevalence of vitamin D deficiency was 24.5% in patients without treatment and 30% 
in patients receiving HAART; 23.0% in patients that received PI based HAART and 36.5% in 
patients on NNRTI based HAART. Prevalence tended to be higher among NNRTI treated 
patients compared to PI treated patients (p = 0.070). Usage of NNRTIs was of significant 
influence on vitamin D deficiency (OR 1.86, 95% CI 1.07-3.22). Median (IQR) 25(OH)D3 levels 
did not differ between patients with and without treatment (48.0 (27.0-76.0) vs 50.3 (34.6-
72.2) respectively, p = 0.750). Median (IQR) 25(OH)D3 levels were significantly lower  for NNRTI 
treated patients (42.5 (22.3-67.8) nmol/L) compared to PI treated patients (60.0 (29.0-89.20) 
nmol/L, p = 0.017). In Figure 2 plasma 25(OH)D3 levels according to the therapy groups 
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Table 1  Patient characteristics of HIV1 seropositive patients: overall and 
with and without vitamin D deficiency.
  Vitamin D Normal 
  deficient  vitamin D 
Variables Overall (n=252) (N=73, 29%) (N=179, 71%) p value‡
Clinical data
Male sex*  190 (75.4) 47 (64.4) 143 (79.9) <0.001
Female sex* 62 (24.6) 26 (35.6) 36 (20.1) <0.001
Age (years) †  41.00 (35-50)  38.0 (32.0-46.5) 43.0 (37.0-52.0) 0.005
BMI (kg/m2)* 23.57(21.6-25.7) 23.39 (21.51-25.60) 23.73 (21.64-26.02) 0.740
CD4 cell count  420 (290-600)  420 (310-560) 420 (280-625) 0.931
(cells/ml) † 
CD8 cell count  780 (580-1150) 670 (515-950) 860 (590-1205) 0.009
(cells/ml) † 
CD4/CD8 ratio † 0.54 (0.30-0.82) 0.62 (0.38-0.90) 0.51 (0.28-0.76) 0.055
VL (copies/ml) † 40 (40-400) 40 (40-500) 40 (40-400) 0.790
  285 (136-518) 275 (116-516) 0.781
HIV stage (1993 CDC criteria)
A* 126 (50) 39 (53.4) 87 (48.6) 0.786
B* 52 (20.6) 14 (19.2) 38 (21.2) 
C* 74 (29.4) 20 (27.4) 54 (30.2) 
Immune stage (1993 CDC criteria)
CD4 > 500  95 (37.7) 30 (41.1) 65 (36.5) 0.682
cells/mm3* 
CD4 200-499 131 (52.0) 37 (50.7) 93 (52.2) 
cells/mm3 *  
CD4 <200   26 (10.3) 6 (8.2) 20 (11.2)
cells/mm3 * 
Skincolor
White* 184 (73) 35 (47.9) 149 (83.2) < 0.001
Mediterranean*  9 (3.6) 3 (4.1) 6 (3.4) 0.721
Asian* 9 (3.6) 4 (5.5) 5 (2.8) 0.287
Black* 50 (19.8) 31 (42.5) 19 (10.6) < 0.001
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stratified for White and non-White skincolor are shown. Within the White population the 
median 25(OH)D3 levels of PI treated patients (77.3 (46.9-100.0) nmol/l) were significantly 
higher compared to NNRTI treated (54.5 (27.9-73.8) nmol/L; p = 0.007) or no treatment 
groups (57.0 (68.0-78.4) nmol/l; p = 0.049). Interestingly, no significant differences in 25(OH)
D3 levels were found among non-White patients treated with PI, NNRTI or without treatment 
(29.0 (20.4-57.0), 22.0 (14.7-38.4), 33.3 (23.3-44.5) nmol/L, respectively). 
Beside female gender, younger age, lower CD8 cell count, black skin color and NNRTI treatment 
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  Vitamin D Normal 
  deficient  vitamin D 
Variables Overall (n=252) (N=73, 29%) (N=179, 71%) p value‡
Antiretroviral treatment 
No Treatment * 53 (21) 13 (17.8) 40 (22.3) 0.497
PI based regimen * 61 (24.2) 14 (19.2) 47 (26.3) 0.260
NNRTI based 104 (41.3) 38 (52.1) 66 (36.9) 0.034
regimen* 
PI and NNRTI based 11 (4.4) 2 (2.7) 9 (5.0) 0.518
regimen * 
Triple NRTI based  23 (9.1) 6 (8.2) 17 (9.5) 1.000
regimen *
HAART duration 238 (108-363) 264 (134-380) 213 (102-355) 0.236 
(weeks) † 
Metabolic parameters 
25-hydroxy  49.00 (27.45-74.83) 20.4 (16-26.15) 62.00 (46.8-84.5) <0.001
vitamin D (nmol/L) † 
Parathyroid hormone 4.1 (2.8-5.3) 5.1 (3.89-7.61) 3.57 (2.60-4.79) <0.001
(pmol/l) † 
Calcium (mmol/L) † 2.34 (2.27-2.39)  2.30 (2.23-2.36) 2.36 (2.30-2.41) <0.001
Corrected Calcium  2.32 (2.26-2.38)  2.29 (2.25-2.36) 2.33 (2.27-2.40) 0.022
(mmol/L) † 
Phosphate (mmol/L) † 0.93 (0.82-1.08) 0.95 (0.81-1.08) 0.92 (0.83-1.09) 0.760
Albumin (g/L) † 41 (38-43) 40 (38-42) 41.5 (39-44) 0.017
Univariate analysis: data presented as * N (%), † Median (Q1-Q3). 
‡ p-value of comparison of prevalence or values between vitamin D deficient patients and patients 
with normal vitamin D with Chi-square test or Mann-Whitney U test, respectively.
BMI, body mass index; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; 
NRTI, nucleoside reverse transcriptase inhibitor; HAART, highly active antiretroviral therapy.
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also higher PTH, lower calcium and lower albumin levels, were significantly associated with 
vitamin D deficiency in univariate analysis (Table 1).
Results of the questionnaire are shown in Table 2. There was no significant difference in either 
dietary vitamin D intake or sunlight exposure between the two groups. Overall, 25.9% of the 
patients (52/201) used non-prescribed vitamin D supplements, for example multivitamins. 
Usage of vitamin D supplement was not significantly different between vitamin D deficient 
and not deficient patients (p = 0.532). When the total intake of vitamin D from food and 
supplements is considered, 55 patients (27.3%) consumed less than the RDI. When patients 
consuming vitamin D supplements were excluded, 54 patients (36.2%) consumed less than 
the RDI. Again, no significant difference was found in percentage of subjects consuming less 
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Figure 2  Plasma 25-hydroxyvitamin D3 levels for White and non-White 
patients in the different therapy groups
Box plots show median (horizontal line in center of each box), 25th and 75th percentiles (bottom and 
top of each box), and 10th and 90th percentiles (bottom and top of error bars). Plasma 25(OH)D3 levels 
differed only significantly within the White group for PI treated patients compared to NNRTI treated 
patients (*,p = 0.007) and patients that received no treatment (**, p = 0.049). 
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than RDI between patients with and without vitamin D deficiency (34.1% (n=14) and 37.0% 
(n=40), respectively; p = 0.743). 
Multiple logistic regression analysis was used to identify significant risk factors for vitamin D 
deficiency in HIV-1-infected persons. Because the food questionnaire was only done in 201 
patients, the multivariate analysis could only be conducted for that population. Only skin 
color remained a significant risk factor for vitamin D deficiency (AOR = 5.4, 95% CI 2.3-12.2, p 
< 0.001). After stratification of the population in White and non-White no independent risk 
factor for vitamin D deficiency remained. 
Prevalence of elevated PTH levels and effect of HAART
For two patients (with normal vitamin D) the PTH levels were missing. Overall 42 patients 
(16.8%) had elevated PTH levels. Among the patients with vitamin D deficiency, 27 patients 
(37%) had elevated PTH levels. No patients (0/13, 0.0%) without treatment, five patients 
(5/14, 35.7%) receiving PI based HAART and 19 patients (19/38, 50%) on NNRTI based HAART 
developed elevated PTH levels in addition to vitamin D deficiency. Patients treated with 
6
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Table 2  Questionnaire results of HIV-1 infected patients stratified for  
vitamin D deficiency.
 Vitamin D Normal p value‡
 deficient  vitamin D
 (N = 53, 26%) (N =148, 74%) 
Supplement
Use of Vit D supplement* 12 (22.6) 40 (27.0) 0.532
Vit D supplement intake (µg/day) † 5.00 (5.00-5.00) 5.00 (5.00-5.00) 0.311
Diet
Dietary Vit D intake (µg/day) † 4.3 (2.7-5.5)  4.5 (3.1-6.3) 0.143
Total Vit D intake (µg/day) † 4.64 (2.83-7.30) 5.57 (3.7-7.98) 0.131
Total Vit D intake < RDI * 14 (26.4) 41 (27.7)  0.857
Total Vit D intake > RDI * 39 (73.6) 107 (72.3) 
Sunlight
Sunlight exposure (min/day) † 60 (30-150) 90 (60 -180) 0.168
* N (%) ; † Median (Q1-Q3)
‡  p-value of comparison of prevalence or values with Chi-square test or Mann-Whitney U test, 
respectively.
Vit D, vitamin D; RDI, recommended daily intake. 
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NNRTIs had a significant higher risk of developing elevated PTH levels in addition to vitamin 
D deficiency (OR 3.93, 95% CI 1.65-9.37). 
Among the patients with normal vitamin D levels, 15 (15/177, 8.5%) patients developed 
elevated PTH levels; one patient (1/39, 2.6%) had no treatment, 4 patients (4/47, 8.5%) received 
PI based HAART and 9 patients (9/65, 13.8%) received NNRTI based HAART. There was no 
significant difference in prevalence of elevated PTH levels among these treatment groups 
(p = 0.212). In Figure 3, the PTH levels of patients without, and with PI or NNRTI treatment 
according to 25(OH)D3 levels are shown. The upper left quadrant, with low vitamin D3  and 
high PTH blood levels, shows an overrepresentation of  NNRTI and PI treated patients.
There was a significant inverse correlation between serum PTH and 25(OH)D3 levels (r -.394, p 
< 0.001). PTH levels of patients on PI treatment (4.27 (3.26-5.46) pmol/L) or NNRTI treatment 
(4.61 (3.30-6.89) pmol/L) were significantly higher than patients without treatment (2.98 
(2.15-3.68) pmol/L; p <0.001 and <0.001, respectively). The PTH level of patients on NNRTIs 
was non-significantly higher than that of patients on PI treatment (p = 0.098). 
There is a significant relationship between low calcium levels and elevated PTH (r 0.153 p = 
0.031). 
 
Effects of vitamin D deficiency on CD4 cell recovery
One hundred and five patients could be included in regression analysis with CD4 cell counts 
up to 500 cells, 31 patients (29.5%) had vitamin D deficiency and 74 patients (70.5%) had 
normal vitamin D levels. There was no significant difference in median CD4 cell recovery 
rates between patients with and without vitamin D deficiency (Median(IQR) 1.17 (0.69-2.91) 
and 1.10 (0.29-2.25), respectively; p = 0.177). Also with cutoff of 600 CD4 cells/ml no statistical 
differences in CD4 cell recovery rates were found. 
When patients were stratified according to their baseline CD4 cell count, also no statistically 
significant differences in CD4 cell recovery rate were found (data not shown). Overall, there was 
no significant correlation between CD4 cell counts and 25(OH)D3 levels (r 0.059, p = 0.351).
Discussion
We found a prevalence of  29% vitamin D deficiency among HIV-1-infected patients. 
In univariate analysis, female sex, dark skin color, younger age and NNRTI treatment were 
found as significant contributors. Skin color remained the only independent risk factor for 
vitamin D deficiency in multivariate analysis.
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The 25(OH)D3 levels were signifi cantly lower among NNRTI treated patients as compared to 
PI treated patients. When the group was stratifi ed into Whites and non-Whites, the 25(OH)
D3 levels remained signifi cantly lower for White NNRTI treated patients compared to White 
PI treated patients, while among the non-whites no signifi cant diff erences were found. 
These results suggest that NNRTI treatment may have add more risk for vitamin D defi ciency. 
Interestingly, NNRTI as well as PI treated patients had higher levels of PTH compared to 
patients without treatment. Moreover, NNRTI treatment puts patients at risk of elevated 
PTH levels. No eff ect of vitamin D status on CD4 recovery rate after initiation of HAART was 
found.
Vitamin D defi ciency among HIV infected patients has previously been reported in only 
two studies20, 21.  Kuehn et al. found a prevalence of 50% vitamin D defi ciency (<50 nmol/L) 
6
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Figure 3  PTH levels of patients with NNRTI based, PI based or no Antiretroviral 
treatment according to serum 25(OH)D3 levels (nmol/L). 
Reference lines show low vitamin D levels (<35 nmol/L) and elevated PTH levels (>6.5 pmol/L). 
In upper left corner patients with elevated PTH levels and vitamin D deficiency can be found.
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among 21 HIV-infected patients with advanced AIDS and hypocalcemia21. Coodly et al found 
17% vitamin D deficiency (average 25(OH)D-2SD) among adult HIV-infected patients20. 
These results cannot easily be compared with our study as the study populations are small, the 
patients also had hypocalcaemia and different definitions of 25(OH)D deficiency were used. 
Whether the incidence of vitamin D deficiency in our study population is high can however 
not firmly be concluded, as we lack a HIV-negative control group. Also in the literature there 
are no other reports that compared vitamin D status between HIV-positive and HIV-negative 
controls. One study by Teichmann et al. reported that 25(OH)D levels were significantly lower 
in HIV-positive compared to HIV-negative individuals6. 
In univariate analysis female sex, pigmented skin, younger age and NNRTI treatment were 
significant contributors to the prevalence of vitamin D deficiency in our patient population. 
In the study by Teichmann et al., lower 25(OH)D3 levels were found among females compared 
to males, however no information on prevalence of vitamin D deficiency was given 6. 
In the literature the prevalence of vitamin D deficiency among adult HIV-negative females 
in Europe ranged from 26-80% and causes were being menopausal or veiling traditions 22, 23. 
In our study, median age of females was younger than 50 and showed no differences 
between patients with and without vitamin D deficiency. None of the females in the present 
study wore a veil.
Skin pigmentation is a known contributor to development of vitamin D deficiency8. 
A study by Grootjans-Geerts reported high levels of vitamin D deficiency among non-
western immigrants in the Netherlands 24. The younger age of Black patients in this study 
contributed to the significant younger age of the vitamin D deficient group. In consequence, 
in multivariate analysis only skin pigmentation remained a significant risk factor for vitamin 
D deficiency. 
Although HAART was no significant contributor for vitamin D deficiency in multivariate 
analysis, our results suggest that antiretroviral agents may affect 25(OH)D3 levels. At first 
sight, we found  no significant differences in 25(OH)D3 levels between patients with and 
without antiretroviral therapy. In contrast, Ramayo et al. found significantly lower 25(OH)D3 
levels among naïve compared to HAART treated HIV-infected patients. This was most likely 
caused by undernourishment associated with HIV disease progression, given the fact that 
lower albumin levels were found among naïve patients25.  We specifically looked then at 
the effects of PIs and NNRTIs on the 25(OH)D levels, after correction for skincolor, and found 
among Whites significant lower 25(OH)D3 levels in patients treated with NNRTIs compared 
to PI treated patients. Furthermore, NNRTI treated patients had significantly higher PTH levels 
compared to patients without treatment. The low vitamin D levels may have been caused by 
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increased catabolism of 25(OH)D3 or 1α,25(OH)2D3 through induction of CYP450 by NNRTIs. 
On the other hand we found that White PI treated persons had significantly higher 25(OH)
D3 levels compared to White NNRTI treated patients and White patients without treatment. 
In vitro, PIs have been found to inhibit 1α-hydroxylation of 25(OH)D3 to 1α,25(OH)2D313. 
This may explain the elevated PTH levels that were found in our study. In addition, Maddedu et 
al. reported significantly lower 1α,25(OH)2D3 levels within all HIV-infected patients compared 
to controls, with the lowest levels found among PI treated patients26.  
Within the non-White population no significant differences in 25(OH)D3 levels were found, 
which emphasizes the great contribution of skin pigmentation in vitamin D deficiency.
Low 1α,25(OH)2D3 levels have been associated with low CD4+ counts 3-6. However, in the 
present study and in that of  Teichmann et al., no associations between 25(OH)D3 levels and 
CD4 cells were found 6. Also no differences in CD4 recovery rates after initiation of HAART 
between patients with and without vitamin D deficiency were found. 
This is the first study evaluating the prevalence of vitamin D deficiency among a large 
cohort of adult HIV-1-infected patients. One drawback of the present study is the lack of a 
HIV-negative control group, which limits firm conclusions on incidence levels in HIV-infected 
patients. Nevertheless, this is the first study evaluating the effect of antiretroviral therapy on 
vitamin D status. In the present study was shown, that NNRTI treated patients may be at  risk 
for vitamin D deficiency. Both, PI and NNRTI treated patients showed higher PTH levels and 
might therefore be at risk for increased bone mass loss. 
An adequate vitamin D status is necessary for maintenance of good bone mineral density. 
Therefore the vitamin D status of HIV-infected patients, especially those having a dark skin 
color or receiving NNRTI or PI containing HAART, should be evaluated by measuring 25(OH)
D3 and PTH levels. Doing so vitamin D deficiency could be early detected and treated. 
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The effect of colecalciferol  supplementation 
on vitamin D levels and insulin 
sensitivity is dose related in vitamin D 
deficient HIV-1-infected patients
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Abstract 
Objective: To explore the effects of colecalciferol supplementation on vitamin D levels, bone 
mineral density (BMD), body fat distribution and insulin sensitivity in vitamin D deficient 
HIV-1-infected patients.
Methods: Twenty vitamin D deficient HIV-1-infected patients were prospectively treated with 
2000 IU colecalciferol/day for 14 weeks, where after treatment was continued with halved 
dosage until 48 weeks. BMD, body fat distribution, 1,25-dihydroxy-vitamin D3 (1α,25(OH)2D3), 
fasting glucose, insulin, adiponectin, leptin, IL-6 and TNFα were measured at baseline, 24 and 
48 weeks. PTH, 25(OH)D3, cholesterol and triglycerides were measured at baseline, 12, 24 and 
48 weeks.
Results: Colecalciferol supplementation significantly increased 25(OH)D3 and 1α,25(OH)2D3 
levels and decreased PTH and insulin sensitivity as was observed after 24 weeks. After 48 
weeks, however, only 25(OH)D3 levels remained significantly different from baseline, while the 
other parameter levels returned to baseline, suggesting a dose response effect. Colecalciferol 
had no effect on BMD, adipokines and triglycerides. 
Conclusions: The effect of colecalciferol treatment in this cohort appears to be dose 
dependent. Colecalciferol dosages of ≥2000 IU are necessary to achieve 1α,25(OH)2D3 levels, 
that significantly decrease PTH, but also negatively affect insulin sensitivity. The results of this 
hypothesis driven explorative study need to be confirmed in larger clinical trials.
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Introduction
Vitamin D deficiency has been observed in 29% of HIV-1-positive patients in The Netherlands. 
The main risk factor is dark skin color, but also use of non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) may increase the risk for vitamin D deficiency1. Also by other investigators low 
25-hydroxy vitamin D3 (25(OH)D3) levels have been reported among HIV-infected patients2.
Vitamin D is mainly known for its function in regulation of calcium homeostasis and 
maintenance of bone mineralization. Serum 25(OH)D3 levels are the best indicator of vitamin 
D status3. The optimal 25(OH)D3 level needed for maintenance of adequate bone mineral 
density (BMD) is unknown. A significant positive association between 25(OH)D3 levels and 
BMD has been observed in both younger and older white adults4. This finding suggests that 
25(OH)D3 levels at the upper end of normal are preferable for achieving and maintaining an 
optimal bone density. In HIV-1-infected patients low BMD is increasingly observed, especially 
after the introduction of highly active antiretroviral treatment (HAART)5, 6. Since we earlier 
observed that many HIV-infected patients have low vitamin D levels, there might be an 
association with low BMD. 
Another emerging problem associated with the widespread use of HAART is the lipodystrophy 
syndrome, which is characterized by altered fat distribution (central fat accumulation and 
peripheral fat loss) and metabolic alterations (dyslipidemia, insulin resistance and diabetes 
mellitus). The vitamin D receptor (VDR) has also been found on adipocytes, suggesting a role for 
vitamin D in fat metabolism7. Indeed in vitro, it was demonstrated that 1,25-dihydroxyvitamin 
D3 (1α,25(OH)2D3) inhibits adipocyte differentiation, among others through inhibition of 
peroxisome proliferator-activated receptor-γ (PPARγ)7-9.  On the other hand, 1α,25(OH)2D3 can 
elicit a non-genomic action on adipocytes in vitro, resulting in a stimulation of intracellular 
calcium levels and corresponding, stimulation of adipogenesis and inhibition of lipolysis10. 
A number of genetic polymorphisms in the VDR gene and low 25(OH)D3 levels have been 
associated with insulin resistance and with diabetes mellitus type 1 and 211-15. Vitamin D may 
alter glucose and insulin metabolism by several mechanisms (see recent review13).The VDR 
has also been found on pancreatic β-cells, suggesting that 1α,25(OH)2D3 may exert a direct 
effect on these cells. In animal studies was demonstrated that 1α,25(OH)2D3 treatment of 
vitamin D deficient animals increases insulin secretion and reduce blood glucose response 
after intravenous glucose administration. Furthermore, also studies in human suggest that in 
vitamin D deficient patients, vitamin D treatment may increase insulin secretion13. 
As vitamin D deficiency may interfere with bone and glucose metabolism and adipocyte 
function, we hypothesize that an adequate vitamin D status is beneficial for HIV-1-infected 
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patients. Therefore we supplemented colecalciferol for 48 weeks to vitamin D deficient 
HIV-1-infected patients and explored  the effects on 25(OH)D3, 1α,25(OH)2D3 and PTH levels, 
on BMD, body fat percentage and distribution, insulin resistance and on levels of adipokines, 
cholesterol and triglycerides in the blood.
Materials and Methods
Patients
We conducted a prospective clinical pilot study in which we supplemented colecalciferol to 
20 vitamin D deficient HIV-1-infected patients for a period of 48 weeks to explore the effects 
on vitamin D levels, PTH, BMD, fat percentage and distribution, insulin sensitivity and on levels 
of adipokines, cholesterol and triglycerides in the blood. All patients were recruited from the 
outpatient clinic of the Radboud University Nijmegen Medical Centre, the Netherlands. The 
inclusion criteria were: 25(OH)D3 deficiency, HIV-1 seropositivity and age >18 years. Subjects 
with hypercalcaemia (calcium >2.60 mmol/l), renal disorders (serum creatinin >220µmol/L), 
hepatic disorders (ASAT >200 IU/L or ALAT >225 IU/L), pregnancy, drug or alcohol abuse or 
non adherence to HIV related therapy were excluded. Vitamin D deficiency was defined as 
25(OH)D3 levels <35 nmol/L from April-September and <25 nmol/L from October-March. 
Patients received 2000 IU colecalciferol per day for 14 weeks, after which the dosage was 
lowered to 1000 IU per day, if patients’ 25(OH)D3 levels were normalized (this was the case 
in all patients). Total follow up of the patients was 48 weeks. The study was approved by the 
local ethical review board and all patients signed written informed consent.
Methods
Clinical evaluations were performed at baseline (before start of supplementation), and at 6, 12, 
24, 36 and 48 weeks to assess adverse events. At baseline and at 12, 24 and 48 weeks, 25(OH)
D3, PTH, CD4+ and CD8+ T cell count, viral load, calcium, phosphate, alkaline phosphatase, 
albumin, creatinine, ASAT, ALAT, antiretroviral plasma concentrations and fasting cholesterol, 
triglyceride, adiponectin and leptin concentrations were determined. Fasting glucose and 
insulin and 1α,25(OH)2D3 was measured at baseline, and at 24 and 48 weeks. The duration 
of HIV-1-infection, CDC stage, current antiretroviral treatment regimen and duration and 
dosage of concomitant medication were recorded. At 6 weeks after the start of colecalciferol 
treatment calcium and albumin were measured to assess adverse events.
Plasma circulating IL-6 and TNFα were measured at baseline, and at 24 and 48 weeks.
chapter 7
VandenBout.1044-Proefschrift.indd   148 02-03-2009   14:54:24
149
At baseline, 24 and 48 weeks a DEXA scan was performed to measure the bone mineral 
density (BMD),  fat mass and fat distribution.  
Laboratory measurements
Calcium, phosphate, alkaline phosphatase, albumin, creatinine, ASAT and ALAT, glucose, 
cholesterol and triglycerides were measured by standard laboratory techniques. Normal 
ranges for cholesterol and triglycerides were 4.7-6.5 and 0.8-2.0 mmol/L, respectively. 
Corrected calcium was calculated using the formula: corrected calcium = [Calcium]- 
(0.025*[albumin])+1. 
25(OH)D3 was measured by HPLC with UV detection as described before 1. 1α,25(OH)2D3 was 
measured by radioreceptor assay (RRA) after chromatographic prepurification as described 
previously 16. Within- and between-run cv’s were 9.2% and 16.1% at a level of 122 pmol/l.
PTH measurements were done with ELSA-PTH assay of CIS BIO and Intact PTH assay performed 
on the Abbot Architect analyzer, as described previously 17. Elevated PTH levels were defined 
as >6.5 pmol/L.
Insulin was measured by an in-house radioimmunoassay (RIA), using Guinea pig anti-human 
insulin antibody and 125I-labelled human insulin tracer. Bound-free separation is performed 
by second antibody/polyethylene glycol precipitation antibody-bound insulin. The assay is 
calibrated on WHO I.S. 83/500. Within- and between- assay precision was 4.6% and 9.4% at a 
level of 8.5 mU/l, 4.0% and 5.8% at 32.7 mIU/l and 4.2% and 8.2% at 80.2 mU/l respectively.
Plasma adiponectin and leptin were measured by ELISA (R&D Systems, Minneapolis, USA).  
CD4 and CD8 cell counts were determined by standard flow cytometry (FACS Count System, 
Becton Dickinson, USA). Viral load was measured with Cobas Amplicor HIV-1 monitor test, 
with a minimal detection threshold <40 HIV-1 RNA copies/ml.
IL-6 and TNFα were measured using bio-plex kit based on Luminex bead array technology 
(Bio-Rad, Hercules, CA).
Insulin sensitivity
Insulin sensitivity was estimated using the homeostasis model assessment method (HOMA). 
The HOMA-index was calculated from the fasting concentrations of insulin and glucose by 
the formula: (fasting plasma insulin (mU/L) x fasting plasma glucose (mmol/l)/ 22,5 18. 
Measurement of BMD and fat distribution
BMD of whole body, right femoral neck and lumbar spine (L1-L4) and fat mass and distributions 
were measured by dual-energy x-ray absorptiometry (DEXA)(Hologic QDR 4500W, software 
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version 12.1, Inc., Waltham MA). Total BMD (g/cm2) and BMD status at right hip and lumbar 
spine were determined. BMD status was defined according to the WHO criteria, considering 
T- scores between –1 and –2.5 as osteopenia and T-scores below –2.5 as osteoporosis. 
Fat mass was determined for total body, arms, legs and trunk. 
Statistical analysis
Values are given as mean ± SD, when normally distributed or as median (Interquartile range 
(IQR)) when not normally distributed. Continuous variables were compared with students 
t-test or Mann-Whitney U test. The paired t-test or Wilcoxon signed-rank test were used 
when baseline data was compared with those evaluated during follow up. Frequencies 
were compared with χ2 or Fisher’s exact test. Correlation between 25(OH)D3 and PTH, BMD, 
cholesterol, adiponectin and leptin levels was tested using Pearson and Spearman correlation 
when appropriate. A 2-tailed P value of <0.05 was considered significant. All statistical analyses 
have been done with SPSS version 14.0 (SPSS software, Chicago, Ill).
Results
Study population 
Twenty HIV-1-infected patients with vitamin D deficiency received colecalciferol therapy, 19 
for 48 weeks and one for 24 weeks. After 12 weeks all patients achieved 25(OH)D3 levels within 
the normal range and therefore the treatment dose was halved. No adverse effects were 
observed during the trial.  The mean age of the study participants was 45 years [Standard 
deviation (SD), ± 10]. Sixteen (80%) patients were male, 3 patients (15%) were Black, 15 (75%) 
patients were Caucasian, 1 patient (5%) was Asian and 1 (5%) patient Mediterranean. The 
mean time since HIV infection was 512 (± 291) weeks. Five patients (25%) had developed 
AIDS, five patients (25%) were in CDC disease stage B and the other five (25%) in stage A. The 
median CD4 lymphocyte count was 369 cells/µl [Interquartile range (IQR), 262-603]; 5 (25%) 
patients had CD4 cell counts <200 cells/µl. The median plasma HIV RNA count was <40 (<40-
4750) copies/ml; 14 patients had an undetectable viral load. Eighteen patients (90%) were 
receiving highly active antiretroviral therapy for a median duration of 386 (273-478) weeks. 
Four patients (22%) were receiving a PI, 10 patients (56%) were receiving a NNRTI, 3 patients 
(17%) were receiving triple NNRTI and 1 patient (6%) had both PI and NNRTI based treatment. 
Other laboratory baseline parameters are outlined in Table 1.
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Effects of colecalciferol on Vitamin D metabolites and PTH
As compared  to baseline (26.4 (19.0-26.4) nmol/L), median (IQR) 25(OH)D3 levels significantly 
increased to normal levels after 12 (101.0 (93.0-109.8) nmol/L; p<0,001), 24 (98.5 (68.3-103.5) 
nmol/L; p = <0.001) and 48 weeks (79.8 (62.9-98.4) nmol/L; p = <0.001) of colecalciferol 
supplementation (Fig 1a). Also the median (IQR) 1α,25(OH)2D3 levels significantly increased 
after 24 weeks (186 (108-215) pmol/L; p = 0.005) of supplementation, but after 48 weeks 
(132 (99-144) pmol/l) the levels were not significantly different from baseline (142 (106-167), 
p = 0.339) (Fig 1b). Furthermore, the median (IQR) PTH levels significantly decreased after 
12 (4.02(2.91-5.93) pmol/L) and 24 weeks (4.20 (2.92-4.82) pmol/L) as compared to baseline 
(4.70 (4.03-6.91) pmol/L, p = 0.009 and 0.021, respectively). However, after 48 weeks the PTH 
level was not significantly different from baseline (5.00 (3.42-6.37) pmol/L, p = 0.398) (Fig 1c). 
There was no correlation between all measured 25(OH)D3 or 1α,25(OH)2D3 levels and PTH 
(r -0.148, p = 0.262 and r 0.191, p = 0.159). Five patients had elevated PTH levels at baseline. 
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In three of these patients, PTH levels decreased to normal levels when the 25(OH)D3 levels 
became normal. In contrast, in the remaining two patients PTH levels remained elevated, 
despite normal levels of vitamin D. Even when the patients with elevated PTH levels and 
normal 25(OH)D3 levels at 48 weeks were excluded, there was no significant difference in 
median (IQR) PTH levels at 48 weeks (4.42 (3.24-5.64) pmol/L) as compared to baseline (4.48 
(3.75-5.51) pmol/L; p =  0.313). Also the correlation between vitamin D metabolites and PTH 
levels remained insignificant.
Colecalciferol supplementation had no effect on CD4 cell count, plasma HIV RNA, albumin, 
phosphate, alkaline phosphatase and ALAT levels. The calcium and corrected calcium levels 
were found to be significantly higher after 48 weeks of supplementation, although they were 
still within normal range (Table 1).
Effects of colecalciferol on bone mineral density 
Frequencies of patients with osteopenia, osteoporosis or normal BMD according to T-scores 
in lumbar spine and femoral neck are summarized in Table 2. No significant differences were 
observed in percentage of osteopenic, osteoporotic or patients with normal BMD at baseline 
compared to 24 or 48 weeks of supplementation.
There were no significant differences in lumbar spine, femoral neck or total body bone mineral 
density after 48 weeks of colecalciferol supplementation (Table 3). Although there was no 
significant difference in BMD after 48 weeks of colecalciferol supplementation compared to 
baseline, the mean (± SD) T-score of femoral neck was significantly lower at 48 weeks (–0.9 ± 
0.8)  in comparison to baseline (–0.8 ± 0.8; p = 0.040). Also when patients with and without 
osteopenia were analysed separately, no significant changes in BMD or T-scores in lumbar 
spine, femoral neck or total body BMD or T-scores were found (data not shown).
Additionally, no significant correlation between 25(OH)D3 and lumbar spine, total body or 
femoral neck bone mineral density was found (r = -0.066; r = -0.002; r = -0.082, respectively).
Effects of colecalciferol on BMI, fat percentages and distribution 
The mean weight of the patients after 24 (69.6 ± 10.2 kg) and 48 (71.8 ± 10.1 kg) weeks was 
not significantly different from baseline (70.4 ± 9.6 kg; p = 0.458 and 0.098, respectively). 
In Table 4 the fat percentage in limbs, trunk and total body at baseline and after 24 and 
48 weeks of colecalciferol supplementation are summarized. The median trunk/limb fat % 
ratio was significantly lower after 24 weeks of colecalciferol supplementation as compared to 
baseline (p = 0.048). No other significant differences were found.
Ten patients (10/20, 50%) had lipodystrophy as defined by self-report. When patients 
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with and without lipodystrophy were analysed separately no significant differences in fat 
distribution were found between baseline and 48 weeks of colecalciferol supplementation 
(data not shown).
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Table 2 Percentage of normal, osteopenic or osteoporotic patients and T-scores at   
 baseline and after 24 and 48 weeks of supplementation of colecalciferol.
  Baseline 24 weeks 48 weeks p value p value
  n = 20 n = 20 n = 19 0 vs 24 wks 0 vs 48 wks
Femoral Normal* 13 (65%) 13 (65%) 11 (58%) n.s.
neck Osteopenia* 7 (35%) 7 (35%) 8 (42%) 
 Osteoporosis* 0 0 0 
 T-score ‡ -0.8 ± 0.8 -0.8 ± 0.8 -0.9 ± 0.8 n.s. 0.040
Spine Normal* 15 (75%) 15 (75%) 13 (69%) χ 2 : n.s.
 Osteopenia* 3 (15%) 3 (15%) 5 (26%) 
 Osteoporosis* 2 (10%) 2 (10%) 1 (5%) 
 T-score ‡ -0.6 ± 1.1 -0.6 ± 1.1 -0.7 ± 1.1 n.s. n.s.
* n (%)
‡ mean ± SD
n.s. = not significant
Table 3 Bone mineral density in right femoral neck, spine and total body measured   
 at baseline and after 24 and 48 weeks of colecalciferol supplementation.
  Baseline 24 weeks 48 weeks p value p value
  n = 20 n = 20 n = 19 0 vs 24 wks 0 vs 48 wks
Femoral BMD (g/cm2) ‡ 0.804 ±  0.807 ± 0.800 ± n.s. n.s.
neck  0.103 0.101 0.098   
spine BMD (g/cm2) ‡ 1.013 ± 1.019 ± 1.010 ± n.s. n.s.
  0.115 0.116 0.115
Total Body BMD (g/cm2) ‡ 1.156 ± 1.161 ± 1.151 ± n.s. n.s.
  0.087 0.087 0.082
* number, %
‡ Mean ± SD
n.s. = not significant
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Effects of colecalciferol on glucose levels and insulin sensitivity
After 24 weeks of colecalciferol supplementation the median HOMA-index and fasting 
glucose levels were significantly higher compared to baseline. However, after 48 weeks there 
was no difference anymore (Table 1). One patient developed diabetes during this study and 
received treatment. After exclusion of this patient, the same results remained.
Effects of colecalciferol on inflammatory markers
Seven patients had detectable circulating IL-6 plasma levels at two or more time points. There 
were no significant differences in the median circulating IL-6 plasma levels of these patients 
after 24 (2.14 (2.14-3.95) pg/ml) and 48 (2.14 (2.14-3.50) pg/ml) weeks of supplementation 
as compared to baseline (2.14 (2.14-3.81) pg/ml). The circulating TNFα plasma level was only 
detectable in one patient. His TNFα level was 20, 29 and 22 pg/ml at baseline and after 24 and 
48 weeks of colecalciferol supplementation, respectively.
Effects of colecalciferol on cholesterol, triglycerides, adiponectin and leptin levels
There was no significant difference in cholesterol levels after 24 and 48 weeks of treatment as 
compared  to baseline values (Table 1). A significant positive correlation between 25(OH)D3 
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Table 4 Percentage of fat in limbs, trunk en total body at baseline and after 24 and 
 48 weeks of colecalciferol supplementation.
  Baseline 24 weeks 48 weeks p value p value
  n = 20 n = 20 n = 19 0 vs 24 wks 0 vs 48 wks
Limbs  33.7  35.8  32.7  n.s. n.s.
  (21.8-39.7) (22.4-45.4) (19.6-44.5)
Trunk  18.2 18.2 20.3 n.s. n.s.
  (13.3-24.1) (14.4-25.4) (14.5-33.6)
Total body 18.3 17.9 18.5 n.s. n.s.
  (13.1-21.1) (13.9-22.8) (13.4-23.2)
Trunk/ limb fat % ratio 0.61  0.55 0.59 0.048 n.s.
  (0.46-0.84) (0.46-0.67) (0.47-0.71)
Total body fat in kg 12.9 12.5 13.6 n.s. n.s.
  (8.4-16.6) (8.6-16.7) (7.8-19.2)
n.s.= not significant
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levels and cholesterol was observed (r = 0.313, p = 0.019). Median (IQR) triglyceride levels did 
not significantly change after 24 or 48 weeks as compared to baseline (p = 0.356 and 0.938, 
respectively)(Table 1). There were no significant changes in median (IQR) adiponectin or leptin 
levels after 12, 24 and 48 weeks of colecalciferol supplementation (3.5 (1.9-5.7), 3.6 (2.4-7.1), 
3.9 (2.3-5.6) µg/ml and (4.5 (1.4-8.4), 4.6 (1.8-9.6), 5.5 (1.8-11.8) ng/ml, respectively) compared 
to baseline (3.5 (2.0-5.3) and 4.6 (1.5-8.5), respectively) (Figure 2). Also when lipodystrophy 
patients were analysed separately there was no significant change in these adipokines (data 
not shown). Furthermore, no correlation was found between 25(OH)D3 levels and leptin or 
adiponectin (r = 0.049, p = 0.609 and r = 0.065, p = 0.502, respectively).
Discussion
Treatment with colecalciferol at dosages of 2000 IU colecalciferol per day for 14 weeks led 
to normalization of 25(OH)D3 levels, a significant increase in 1α,25(OH)2D3 levels, a decrease 
in PTH, insulin sensitivity and trunk-limb fat % ratio as was observed after 24 weeks. After 48 
weeks, however, only 25(OH)D3 levels remained significantly different from baseline, while 
the levels of the other parameters returned to baseline levels. This was probably due to the 
lowered colecalciferol dosage (1000 IU/day) after 14 weeks. These results suggest a dose 
response effect.
Supplementation of colecalciferol had, however, no effect on BMD, although the mean 
T-score of the femoral neck was significantly lower after 48 weeks of supplementation as 
compared to baseline. The significance of this observation is however questionable, as the 
difference in T-score is very low, the BMD is stable and the SDs show a large overlap. Serial 
measured 25(OH)D3 levels were positively correlated with cholesterol levels.
Effect of colecalciferol supplementation on 25(OH)D3 and 1α,25(OH)2D3 levels have not 
been evaluated in HIV-1-infected patients before. To our knowledge, two other studies by 
Mc Comsey et al. and Mondy et al. supplemented vitamin D in combination with calcium 
and alendronate to HIV-infected patients but did not evaluate the 25(OH)D3 or 1α,25(OH)2D3 
levels19, 20. Studies are described among not HIV-infected elderly in which supplementation 
of 400-800 IU vitamin D3 per day led to a significant rise in 25(OH)D3 and 1α,25(OH)2D3 
levels21, 22. The results of the present study indicate that supplementation of 2000 IU 
colecalciferol/ day is necessary to achieve a significant increase in 1α,25(OH)2D3 level, which 
is also sufficient to influence other parameters as PTH levels. However, when only 1000 
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IU per day was supplemented the 25(OH)D3 levels normalizes, but no effect on 1,25(OH)
D3 was found, suggesting that 1α-hydroxylation may be the rate limiting step (Figure 2). 
Indeed,  1α-hydroxylation might be impaired by the HIV infection itself 23 as well as through 
polymorphisms in 1α-hydroxylase (CYP27B1)24, 25 or protease inhibitors26.
Remarkably, although all our patients had vitamin D deficiency, the BMD was relatively normal, 
and, only a low prevalence of osteopenia (32%) and no osteoporosis in the femoral neck was 
observed. For example, among elderly and among younger women with a poor vitamin D 
status a positive correlation of vitamin D levels with BMD of the proximal femur and vertebrae 
have been reported3, 21. However, the duration of vitamin D deficiency might have influenced 
these results, as we do not know for how long our patients had vitamin D deficiency. In 
addition some of the patients were suffering mild vitamin D deficiency with no secondary 
hyperparathyroidism, although 25% of the subjects had elevated PTH levels. In other studies 
among HIV-1-infected patients 14- 84% osteopenia and 0-45% osteoporosis have been reported, 
which is within the range of our study27. In only one study, 25(OH)D3 and 1α,25(OH)2D3 levels 
were considered as risk factors for osteopenia. However, no differences in the levels of these 
metabolites between patients with and without osteopenia were found28. However, Maddedu 
et al. reported a positive correlation between 1α,25(OH)2D3 levels and  bone mineral density in 
protease inhibitor treated HIV-1-infected patients29. In the present study a correlation between 
vitamin D metabolite levels and bone mineral density was missing. 
Supplementation of colecalciferol for 48 weeks did not result in an increase of BMD. This 
might be explained by the fact that at baseline, a relatively normal BMD and low prevalence 
of osteopenia in femoral neck was found probably due to the relatively mild vitamin D 
deficiency. Also the duration of vitamin D treatment might have been too short and/or the 
colecalciferol dosage too low. However, two other studies by Mondy et al. and McComsey et 
al. evaluated the effect of 1 year supplementation of 400 IU vitamin D and 1000 mg calcium 
per day on BMD in HAART treated HIV-infected patients with lumbar spine osteopenia. 
McComsey et al. reported a significant increase of 1.31% in total hip and 1.24% in femoral 
neck BMD, while Mondy et al., observed only a non-significant increase of 1.3% in lumbar 
spine BMD19, 20. Above results suggest that supplementation of >400 IU of colecalciferol 
daily together with calcium might be enough for increasing BMD in HIV-1-infected patients. 
This is also in line with the recommendations for treatment of osteoporosis in postmenopausal 
women and in the elderly3, 30. In these groups, oral vitamin D supplementation of 700-800 IU 
daily increases BMD and reduces significantly the risk of fractures 3, 30. In our study, we did not 
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supplement calcium because we wanted to study the effects of supplementation of solely 
vitamin D on the vitamin D metabolites and calcium also affects the vitamin D metabolism.
Surprisingly, colecalciferol supplementation at dosages of 2000IU/day leaded to increased 
insulin resistance. Few human studies and case reports described the effect of vitamin D 
supplementation on insulin resistance and reported conflicting results, as recently reviewed 
by Tai et al13. In these studies several vitamin D formulations were used as supplement. Only 
one human study and one report of three cases used colecalciferol as supplement, as we 
did31, 32. In the human study, ten women with diabetes, of which 70% was vitamin D deficient, 
were treated with 1332 IU colecalciferol per day for 1 month, which resulted in an increase 
in insulin sensitivity31. Interestingly, a decrease in insulin sensitivity was found in three 
cases of diabetic Asian/British people with vitamin D deficiency that received colecalciferol 
supplementation32. The results remain however difficult to compare with our study as other 
treatment dosages were used and the study population is different.
The significant increase in insulin resistance and fasting glucose found in present study may 
be explained by the inhibition of the expression of the PPAR-γ receptor by 1α,25(OH)2D3, 
which has been described in in vitro studies7, 8, 33. The PPAR-γ receptor is involved in the 
regulation of genes involved in adipogenesis, glucose, and lipid metabolism and its activation 
leads to improved insulin sensitivity34. Inhibition of PPARγ by 1α,25(OH)2D3 might also lead 
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Figure 2 
Vitamin D is metabolized by 25-hydroxylase to 25(OH)D3 and then further 1α-hydroxylated to the 
 active 1,25(OH)2D3 metabolite. Inactivation of 25(OH)D3 and 1,25(OH)2D3 occurs by 24-hydroxylase.  
The 1α-hydroxylation of 25(OH)D3 might be inhibited by HIV infection, CYP27B1 and protease inhibitors. 
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to triglyceride accumulation and diminishing of adipokines secretion and lipid metabolism7, 
8. In the present study no effects on leptin, adiponectin and triglyceride levels were found, 
although a trend to higher cholesterol levels was found. In addition, cholesterol was found to 
be positively correlated with 25(OH)D3 levels. Vitamin D and cholesterol are both produced 
from 7-dehydrocholesterol and  one may speculate that as colecalciferol is supplemented, 
more 7-dehydrocholesterol is left for production of cholesterol. 
Above results indicate that colecalciferol treatment in vitamin D deficient HIV-1 infected 
patients may increase insulin resistance. However, given the fact that the effect is lost after 24 
weeks, it might be dose or time dependent. 
The results also showed that supplementation of 2000 IU colecalciferol leaded to a decrease 
in trunk/ limb fat % ratio. This is remarkable since the literature suggests that an increase in 
trunk/limb fat % ratio is associated with improved insulin sensitivity35. Also, in HIV-infected 
patients with lipodistrophy loss of limb fat and central fat accumulation is associated with 
increased insulin resistance36. The significance of this observation is however questionable 
since we observed no effects of colecalciferol supplementation on trunk or limb fat, or ALAT, 
which is a marker for increased liver fat. In addition, the differences in trunk/limb fat % ratio 
were very small and the SDs overlap for an important part suggesting that the significance 
of the observation is low.
To our knowledge, this is the first study investigating the effects of colecalciferol on vitamin 
D metabolites, PTH, BMD, fat metabolism, insulin sensitivity, adipokines, cholesterol and 
triglyceride levels in vitamin D3 deficient HIV-1-infected patients. The effects of colecalciferol 
supplementation in vitamin D deficient in HIV-1 infected patients seemed to be dose 
dependent. Optimalisation of the vitamin D levels in the blood of HIV-1-infected patients 
can only be reached by daily administration of >2000 IU colecalciferol. In consequence, these 
patients may risk development of insulin resistance. The results of this explorative study need 
to be confirmed in larger clinical trials.
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Chapter 8
Vitamin D supplementation causes a dose 
dependant change in circulating CD4+CD25high 
regulatory T cell numbers in vitamin D 
deficient HIV-1-infected patients
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Abstract
Background: Regulatory T cells (Treg) suppress activation and proliferation of T cells and 
possibly play an important role in HIV pathogenesis. Vitamin D is not only known for its role 
in bone metabolism, but also has strong immunomodulatory properties. Vitamin D status 
may therefore affect HIV infection by influencing Treg. 
Objective: To determine the effects of colecalciferol (vitamin D) supplementation on numbers 
of circulating CD4+CD25high Treg in 25-hydroxyvitamin D (25(OH)D3) deficient HIV-1 infected 
patients in the Netherlands. 
Design: HIV infected subjects (n=20) received 2000 IU colecalciferol daily. In case of 
normalization of 25(OH)D3 after 12 weeks, the dosage was lowered to 1000 IU. Circulating 
CD4+CD25high Treg, 25(OH)D3, 1,25-dihydroxyvitamin D (1α,25(OH)2D3), parathyroid hormone 
(PTH), CD4 count and viral load were determined at baseline, after 24 and 48 weeks. 
Results: After 24 weeks circulating CD4+CD25high Treg numbers decreased significantly  (Mdn= 
19 and 9 cells/µL, p = 0.0005). 25(OH)D3 and 1α,25(OH)2D3  concentrations increased and 
PTH decreased. Since all subjects had normal 25(OH)D3 concentrations after 12 weeks, the 
colecalciferol dose was halved, Subsequently, after 48 weeks, Treg numbers, 1α,25(OH)2D3, 
PTH did not differ significantly anymore from baseline, whereas 25(OH)D3 still did. CD4 count 
and viral load did not differ significantly as compared to baseline.
Conclusions: Colecalciferol supplementation in vitamin D deficient HIV-patients decreased 
the number of circulating CD4+CD25high Treg and changed concentrations of 1α,25(OH)2D3 
and PTH in a dose dependant manner. This could have implications for future clinical HIV 
management, considering the immunomodulatory role of vitamin D and the role of T cells 
in HIV pathogenesis. 
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Introduction
Several studies (reviewed in 1) have documented 25-hydroxyvitamin D3 (25(OH)D3) deficiency 
in HIV-1 infected patients. The serum 25(OH)D3 concentration is the best indicator of vitamin 
D status and  depends mainly on sunlight exposure of the skin and partly on dietary intake 2. 
1,25-dihydroxyvitamin D3  (1α,25(OH)2D3) is the active vitamin D metabolite and acts through 
the vitamin D receptor (VDR) expressed by target cells. 1α-hydroxylase converts 25(OH)
D3 into 1α,25(OH)2D3. Highly active antiretroviral therapy (HAART) and HIV-related factors 
can influence the activity of 1α-hydroxylase and possibly also of other cytochrome P450 
enzymes that are involved in vitamin D metabolism 3, 4. This, together with other known risk 
factors such as dark skin and little sunlight exposure, may contribute to an increased risk for 
HIV patients to develop vitamin D deficiency (Figure 1).
Vitamin D is not only important for bone metabolism, but also has immunomodulatory 
properties5-11. Several mononuclear cells express VDR and can also produce the VDR ligand 
1α,25(OH)2D3, by expressing 1α-hydroxylase 12-16.Therefore a role for vitamin D in immune 
8
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regulation has been postulated. More specifically, 1α,25(OH)2D3 decreases the pro-
inflammatory T helper 1 (Th1) immune response, increases the T helper 2 (Th2) immune 
response and induces regulatory T cells (Treg)  17-20. Treg suppress effector T cell activation 
and proliferation and shift the balance from Th1 to Th2 response, which ultimately results 
in more tolerogenic immune responses. Treg are important for limiting immune responses 
against pathogens and for maintaining tolerance for self antigens 21.
Lately, Treg have been subject of great interest in transplantation medicine, autoimmune 
diseases, cancer immunology as well as in HIV infection 22. At present their possible beneficial 
or detrimental role in HIV pathogenesis is subject of debate (reviewed in 23, 24). Treg may be 
beneficial in HIV by suppressing T cell expansion and activation and thereby limiting viral 
replication and CD4+ cell depletion. On the other hand, Treg can inhibit specific immune 
responses against HIV itself and against other pathogens, which results in ongoing HIV 
infection and an increased risk for other infections 25-30. Progression of HIV infection is 
associated with decreasing numbers and function of Treg, as well as with chronic immune 
activation, increased viral replication and CD4+ cell depletion. There is growing evidence 
that changes in circulating Treg numbers during the course of HIV infection, may be due 
to an altered distribution of Treg (homing). Recent studies show that increasing viral load is 
associated with accumulation of Treg in secondary lymphoid tissues, which may explain the 
decrease in Treg in the blood during progression of HIV infection 31-35. 
In summary, HIV-1 infected individuals are at risk for vitamin D deficiency, whereby the 
interaction mechanisms between HIV related factors and vitamin D metabolism are not fully 
elucidated yet. Considering the effect of vitamin D on T cell function and the central role for T 
cells in HIV infection, vitamin D deficiency may affect immunity in HIV infection. 
In the present study we therefore supplemented 25(OH)D3 deficient HIV infected subjects 
with colecalciferol (vitamin D3); first daily 2000 IU, then daily 1000 IU once normalization of 
25(OH)D3 concentration was achieved. We analyzed the effect on circulating CD4+CD25high 
Treg numbers. 
Subjects, materials and methods
Subjects 
An observational study has was done among vitamin D deficient HIV-1 seropositive patients 
visiting the Radboud University Nijmegen Medical Centre, The Netherlands as described in 
36. We prospectively studied the effect of colecalciferol supplementation on circulating Treg 
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numbers, 25(OH)D, 1α,25(OH)2D3 and PTH. In addition, we determined concentrations of 
circulating and ex-vivo production of pro inflammatory and anti-inflammatory cytokines.
The inclusion criteria were: HIV-1 seropositivity, 25(OH)D3 deficiency at the time of screening, 
age >18 years and ability to give informed consent. We excluded subjects with hypercalcaemia 
(serum calcium >2.60 mmol/L), renal disorders (serum creatinine >220 µmol/L), hepatic 
disorders (ASAT or ALAT >200 and 225 IU/L, respectively), pregnancy, drug or alcohol abuse 
or nonadherence to HIV related therapy. Vitamin D deficiency was defined as serum 25(OH)
D3 levels <25 nmol/L in October-March or <35 nmol/L in April-September.
The subjects daily received an oral solution which initially contained colecalciferol 2000 IU, for 
a total duration of 48 weeks. At baseline and after 12, 24, 36 and 48 weeks of supplementation, 
serum concentrations of 25(OH)D3 1α,25(OH)2D3 and parathyroid hormone (PTH), CD4+ T 
cell count, CD8+ T cell count, viral load were determined and calcium, phosphate, creatinine, 
liver enzymes, and anti-retroviral drug concentrations were monitored. In case 25(OH)D3 
concentrations normalized after 12 weeks, the dose was halved to 1000 IU. At baseline and 
after 24 and 48 weeks, circulating Treg, defined as CD4+CD25high T cells, were determined as 
absolute numbers and as a percentage of the CD4+ T cell subset. In addition, FoxP3+CD127low 
regulatory T cell analysis was performed for a number of samples drawn at 24 and 48 
weeks. We determined the percentage of CD4+CD25highFoxP3+CD127low T cells within the 
CD4+CD25high cell T subset as well as the absolute numbers of CD4+CD25highFoxP3+ CD127low 
T cells as a control for our method used to define CD4+CD25high cells as Treg.
This study was approved by the local ethics committee and written informed consent was 
given by all participating subjects.
25(OH)D3, 1α,25(OH)2D3 and PTH determination
Serum 25(OH)D3 was measured by high pressure liquid chromatography (HLPC) with UV 
detection, after prior extraction on small SepPak columns. Tritiated  25(OH)D3, collected from 
the HPLC system during passage of the UV peak, was used to correct for procedural losses. 
Serum 1α,25(OH)2D3 was measured by radioreceptor assay (RRA) with prior extraction and 
chromatographic purification with correction for recovery according to van Hoof et al 37. For 
PTH assays the ELSA-PTH assay by CIS BIO was used at first. This method was switched into 
the intact PTH assay performed by the Abbott Architect analyzer, when the CIS BIO assay was 
no longer available. The Abbott Architect assay was recalibrated on the CIS BIO assay to give 
identical measurement results.
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Flow cytometric analysis of and CD8+, CD4+, CD4+CD25high T cells 
CD8+, CD4+ and CD4+CD25high T cells were determined in flow cytometric (FCM) analysis 
using a hematology analyzer cell count combined with the data from FCM analysis. Briefly, 
venous blood was drawn into a 3 mL EDTA tube. White blood cell counts and morphological 
differentiations were performed on a hematology analyzer (Advia, Bayer). Heparinized blood 
cells were stained with directly fluorochrome-labeled antibody using CD3 PE-Cy5 , CD4 
FITC, CD8 PE, CD45 ECD (Beckman Coulter) and CD25 PE (clone M-A251; Becton Dickinson). 
Next, all erythrocytes were lysed according to the lyse/no wash method. Staining of cells 
was determined in 4-color analysis by using a Beckman Coulter Epics XL flow cytometer 
(Beckman Coulter, Hileah, FL). All measurements were performed on minimally 50,000 cells. 
Thereafter absolute numbers of the lymphocyte subsets were calculated from the white 
blood cell count and the FCM analysis. 
Flow cytometric analysis of CD4+CD25highFoxP3+CD127low cells
For CD4+CD25highFoxP3+ CD127low Treg analysis, venous blood was drawn into a 8.5 mL 
ACD-A tube. PBMCs were isolated by density gradient centrifugation. Subsequently, 250,000-
500,000 cells were washed twice with FCM-buffer (PBS/0.2% BSA) and labeled with the 
following conjugated monoclonal antibodies (mAb); CD127 (clone hIL-7R-M21; Beckman 
Coulter, USA), CD4 PE-CY5 (clone 13B8.2; Beckman Coulter) and CD25-biotin (clone 4E3; 
Miltenyi Biotec GmbH). Biotin labeled antibodies were visualized by streptavidin PE-CY7 
staining (eBioscience, San Diego, USA). Intracellular FoxP3 expression using anti-FoxP3 mAb 
(clone PCH101) FITC (eBioscience), was analyzed after fixation and permeabilisation (Fix 
and Perm reagent, eBioscience) of the cells. After washing twice with FCM-buffer the cells, 
minimal 100,000 events within the live gate, were analyzed by 5 color flow cytometry with a 
Coulter FC500 flow cytometer (Beckman Coulter, Hileah, FL). CPX software (Beckman Coulter) 
was used for analysis. By using the CD4+ cell count, the number of CD4+CD25high cells and 
the percentage of FoxP3+CD127low expressing cells within the CD4+CD25high subset, we 
calculated the absolute number CD4+CD25highFoxP3+CD127low  T cells.
Cytokine assays
Plasma circulating cytokine concentrations of TNF-α, IFN-γ, IL-6 and IL-10 were determined at 
baseline and after 24 and 48 weeks. We also determined the soluble receptors CD25 (sCD25) 
and TNF receptors (sTNFR) I and II, as a measure for the level of immune activation. Venous blood 
was drawn in a 10 mL EDTA tube and centrifuged at 2200 g for 10 minutes. Supernatants were 
centrifuged in an Eppendorf centrifuge for 5 minutes at 2100 g and stored at –20 0C until assay. 
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In addition, the ex vivo production of cytokines was determined in whole blood stimulated 
with lipopolysaccharide (LPS), the synthetic lipopeptide Pam3Cys or sonicated Mycobacterium 
Tuberculosis (MTBson), which are ligands of respectively Toll-like receptor (TLR)4, TLR2 and 
both 38. Venous blood was collected in 4 mL lithium heparin tubes. Whole blood (200 µL) 
was diluted 1:5 in 24 wells plates with 700 µL RPMI+ 1640 (Dutch modification 1% Glutamine 
200 mM/L, 1% Pyruvate 100 mM/L, 1% Garamycine 5 mg/mL) and with 100 µL 10 ng/mL LPS 
(E.coli  serotype 055:b5; Sigma Zwijndrecht, the Netherlands), 1 µg/mL Pam3Cys or 10µg/
mL MTBson.  After incubation for 24 and 48 hours at 37 oC and 5% CO2, supernatants were 
obtained from the well, centrifuged in an Eppendorf centrifuge for 5 minutes at 2100 g and 
thereafter stored at –20 oC until assay. Incubation with RPMI+ alone was used as a negative 
control. Concentrations of TNF-α, IL-4, TGF-β (24 hrs stimulation), and IL-10 and IFN-γ (48 
hrs stimulation) were determined in the supernatants. ELISA kits were used according to 
the manufacturer’s protocol for determination of TNF-α, IL-4, IL-6, IFN-γ and IL-10 (Pelipair, 
Sanquin, Amsterdam, The Netherlands), TGF-β and sCD25 (RnD systems, Minneapolis, USA), 
sTNFR I and sTNFR II (Bender MedSystems, Burlingame, USA). 
Statistical analysis
For describing non parametric distributed data we used the median (Mdn) and the 
interquartile range (IQR). The Wilcoxon signed-rank test was used when applicable, with 
p< 0.05 considered as significant. SPSS 12.0 for Windows was used to perform these analyses.
Results
Included subjects
During the spring and summertime of 2006, 20 subjects received colecalciferol 
supplementation for 24 weeks and 18 subjects for a total of 48 weeks. 2 subjects drop out for 
other medical reasons, after 24 weeks. All subjects daily received 2000 IU colecalciferol and 
had normal 25(OH)D3 concentrations after 12 weeks, so their dose was lowered to 1000 IU 
after 14 weeks. No adverse effects were reported or observed during the supplementation. 
Baseline characteristics are shown in Table 1.
Effects of colecalciferol supplementation on vitamin D metabolites and PTH
As compared  to baseline (26.4 (19.0-29.1) nmol/L), median (IQR), 25(OH)D3 serum 
concentration significantly increased after both 24 (98.5 (68.3-103.5) nmol/L; p = <0.001) and 
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48 weeks (79.8 (62.9-98.4) nmol/L; p=<0.001) of colecalciferol supplementation (Figure 2). 
Also the median (IQR) 1α,25(OH)2D3 levels significantly increased after 24 weeks (186 (108-
215) pmol/L; p = 0.005) of supplementation, but after 48 weeks (132 (99-144) pmol/l) the 
levels were not significantly different from baseline (142 (106-167), p = 0.339) (Figure 3). 
Furthermore, the median (IQR) PTH levels significantly decreased after 24 weeks (4.2 (2.92-
4.82)) as compared to baseline (4.70 (4.03-6.91), p =0.021), but at 48 weeks the difference was 
not statistically significant (5.0 (3.42-6.37), p=0.398) (Figure 4). 
Circulating CD4+CD25high Treg numbers decreased after daily 2000 IU colecalciferol 
supplementation and returned to baseline after daily 1000 IU colecalciferol.
Next, we analyzed the effect of colecalciferol supplementation on the number of CD4+CD25high 
Treg. Surprisingly, this number was significantly lower after 24 weeks of supplementation as 
compared to baseline (Mdnbaseline = 19; IQR= 12-28, Mdn24weeks = 9; IQR= 6-14 cells/µL) 
p = .005, (Figure 5). Not only the absolute number of  CD4+CD25high Treg, but also the 
percentage of CD4+CD25high Treg within the CD4+ subset decreased  (Mdnbaseline = 4.3; IQR= 
2.3-5.7 and Mdn24weeks = 2.0; IQR= 1.5-3.1 %CD25high cells in CD4+ T cell subset), p = .001, 
(Figure 6). The decrease in absolute Treg numbers and the percentage of Treg within the 
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Table 1 Patient characteristics at baseline.
 Baseline
Age (years) † 47 (38-52)
Male sex (%) ‡ 16 (80.0%)
CDC stage of infection 
         A (%) ‡ 10 (50%)
         B (%) ‡ 5  (25%)
         C (%) ‡ 5  (25%)
CD4 count (cells/μL) † 369 (262-603)
CD8 count (cells/ μL) † 479 (365-788)
CD4/CD8 ratio † 0.8 (0.4-1.1)
Plasma HIV RNA (copies/ml) 40 (40-4750)
Plasma HIV RNA >40 (copies/mL) ‡ 6 (30%)
on HAART treatment ‡ 17 (85%)
Data are † median (interquartile range) or ‡ counts (%).
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Figure 2  Effect of colecalciferol supplementation in 25(OH)D3 deficient  
HIV-1-infected patients on 25(OH)D3 serum concentration. 
Figure 3  Effect of colecalciferol supplementation in 25(OH)D3 deficient  
HIV-1-infected patients on 1,25(OH)2D3 serum concentrations. 
* p< .05 as compared to baseline. 
* p< .05 as compared to baseline, ** p< .05 as compared to 24 weeks. 
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Figure 4  Effect of colecalciferol supplementation in 25(OH)D3 deficient  
HIV-1-infected patients on PTH levels. 
Figure 5  Number of CD4+CD25high regulatory T-cells (cells/μL) after 24 and  
48 weeks of colecalciferol supplementation. 
* p< .05 as compared to baseline.
Initially 2000 IU/day was given for 14 weeks, where after dose was lowered to 1000 IU/day. 
(p values: 0 vs 24, 0.005; 0 vs 48, 0.129; and 24 vs 48, 0.002)
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Figure 6  Percentage of CD4+CD25high regulatory T-cells in CD4 after 24 and 
 48 weeks of colecalciferol supplementation.  
Figure 7  Number of CD4+CD25highFoxP3+ CD127low T cells after 24 and  
48 weeks of colecalciferol supplementation
Initially 2000 IU/day was given for 14 weeks, where after the dose was lowered to 1000 IU/day.  
(p values: 0 vs 24, 0.001; 0 vs 48, 0.068; and 24 vs 48, 0.001)
Initially 2000 IU/day was given for 14 weeks, where after the dose was lowered to 1000 IU/day.  
(p values: 24 vs 48,  0.754)
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CD4+ T cell subset was observed in all supplemented subjects that showed increase in 25(OH)
D3 concentration, which was n=19/20. After 48 weeks of supplementation no significant 
differences in Treg numbers (Mdn48weeks= 24; IQR= 11-38 cells/µL) or in percentage of Treg 
within the CD4+ subset  (Mdn48weeks= 5.6; IQR= 2.4-10.1% CD25high cells in CD4+ T cell 
subset) were observed as compared to baseline.
Effect of colecalciferol on percentage and number of CD4+CD25highFoxP3+CD127low 
T cells
During the study FoxP3 and CD127 analysis became available. For 10 patients Foxp3 
measurements were available at 24 and 48 weeks en for 1 patient only at 24 weeks.
Figure 7 and 8 show that the percentage of the CD4+CD25highFoxP3+CD127low T cells within 
the CD4+CD25high cell T subset was significantly lower at 48 weeks (Mdn48weeks= 87.8; IQR= 
87.1-91.2%) as compared to 24 weeks supplementation (Mdn24weeks= 75.4; IQR= 61.3-86.1%), 
p = .03, There were no differences in the absolute numbers of CD4+CD25highFoxP3+ CD127low 
T cells (Mdn24weeks= 10; IQR= 6-15 cells/µL; Mdn48weeks= 13; IQR= 5-17 cells/µL). 
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Figure 8  Percentage of CD4+CD25highFoxP3+CD127low T cells within the 
CD4+CD25high T cell subset after 24 and 48 weeks of colecalciferol 
supplementation. 
Initially 2000 IU/day was given for 14 weeks, where after the dose was lowered to 1000 IU/day. 
(p value 24 vs 48, 0.03)
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Other calcium metabolism and immunological parameters did not change after 
colecalciferol supplementation
Calcium, phosphate, creatinine, liver enzymes, CD4+ T cell count, CD8+ T cell count and 
viral load did not change significantly (data not shown) . No hypercalcaemia occurred. In 
6 patients viral load was detectable at baseline and it was unchanged (n=2) or decreased 
(n=4) after 2000 IU daily colecalciferol supplementation. Three of these patients were not on 
HAART, while all the other subjects in the trial were. 
Circulating cytokine concentrations and ex vivo cytokine production were not affected 
by changes in 25(OH)D3 levels
Plasma circulating concentrations of TNF-α, IFN-γ, IL-6 and IL-10 were mostly undetectable 
before and after treatment. Soluble receptors sCD25 and sTNFR I and II did not change. 
Concentrations of TNF-α, IFN-γ, IL-4, IL-10 and TGF-β in whole blood stimulated with Pam3Cys, 
LPS or MTBson did not change significantly after colecalciferol supplementation of the 
subjects (data not shown). 
Discussion
This study demonstrates that daily supplementation of 2000 IU colecalciferol in vitamin D 
deficient, HIV-1-infected patients results in decreasing numbers of circulating CD4+CD25high 
Treg, while 1α,25(OH)2D3 levels significantly increase. This effect is dose-dependent, since the 
Treg numbers, as well as the 1α,25(OH)2D3 concentrations, return to baseline values, when 
subjects receive a maintenance dose of 1000 IU colecalciferol. This can be explained by the 
fact that 1α,25(OH)2D3, unlike 25(OH)D3, is the active metabolite which has a high affinity for 
the VDR. In fact, in contrast to 1α,25(OH)2D3 which was inversely related to the Treg numbers, 
the concentration of 25(OH)D3 hardly decreased due to the lowering of the colecalciferol 
dose. Therefore, our data show that 25(OH)D3 is of limited value to study immunological 
effects of vitamin D. This may be of clinical significance since 25(OH)D3 as mostly used to 
assess vitamin D status.
Prior to the study and based on in vitro data, we hypothesized an increment of Treg numbers 
as result of increasing vitamin D concentrations. However, the opposite trend was observed. 
This may be explained by increased homing of Treg, whereby the expression of different 
chemokine receptors on Treg alters the site of action, which may be clinically relevant in 
HIV infection 39-42. Homing of Treg might be induced by higher vitamin D concentrations. 
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Whether this could be due to altered expression of chemokine receptors on Treg by vitamin 
D is the subject of present studies. Secondly, Treg proliferation may be influenced by different 
vitamin D metabolite concentrations, although possible mechanisms are unclear at present. 
Finally, differences in 1α,25(OH)2D3 concentrations in vitro versus in vivo could attribute to a 
different effect of vitamin D on circulating Treg.
In this study we specifically analyzed the effect of colecalciferol supplementation 
on the number of circulating Treg in HIV-1-infected individuals. We focused on the 
CD4+CD25highCD127lowFoxP3+ and CD4+CD25high Treg subset. To date, with regard to human 
Treg, there is no unique marker. Most Treg reside in the CD4+CD25high T-cell population, but a 
number of other markers have been described. Unfortunately all of these markers can also be 
transiently expressed by activated T-cells, which complicates the identification of pure Treg 
populations. In contrast to most markers, FoxP3, a transcription factor, is clearly associated 
with the immunosuppressive functions of Treg and is at present, in combination with lack 
of CD127 expression, considered to be an accurate marker for Treg 43, 44. Although FoxP3 and 
CD127 determination were not available for all samples in this study, in the samples analyzed 
we found a high percentage of CD4+CD25high cells to express FoxP3 in combination with low 
CD127 levels. This indicates that the freshly isolated CD4+CD25high subset mainly consisted 
of Treg and not of activated T cells. Phenotypic analysis does clearly not allow conclusions 
concerning the influence of vitamin D supplementation on the function of Treg or on their 
distribution, which is recommended for future studies.
In addition to the number of circulating Treg, we studied circulating cytokine concentrations, 
which were not detectable. Concentrations of circulating cytokines are often not detectable 
and do not always reflect the local cytokine production. This can be partly solved by 
determining the ex vivo cytokine production of stimulated whole blood 45. We stimulated 
TLR2 (Pam3Cys), TLR4 (LPS) or both (MTBson) in diluted whole blood. We found no differences 
in ex vivo cytokine production after TLR2 and/or TLR4 stimulation between whole blood of 
vitamin D deficient of HIV-1-patients drawn before and after colecalciferol supplementation, 
whereas the circulating Treg numbers decreased significantly. Probably the stimulation of 
diluted whole blood was not sensitive enough to detect differences in ex-vivo cytokine 
production due to changes in Treg numbers, since whole blood only consists for a small part 
of Treg. Therefore, the cytokine production of other blood components may have masked a 
possible difference in pattern and amount of cytokine production that was due to a decrease 
in Treg.
To our knowledge this is the first human study in which the effect of vitamin D supplementation 
on Treg is investigated. Treg play a key role in establishing a balance between immunity and 
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tolerance in for example autoimmune diseases and infections. The possible beneficial or 
detrimental role of Treg in HIV infection is still unknown, thus we can not conclude whether 
the decrease in circulating Treg induced by vitamin D supplementation is beneficial for 
the immune status or not. However, it is known that in several infectious diseases, such 
as tuberculosis (TB) 46  vitamin D deficiency undermines the adaptive immune responses. 
TB and other infections often occur simultaneously in HIV infection. Considering this, it is 
noteworthy that after starting HAART, TB and other concurrent infections can become 
clinically relevant and autoimmunity becomes more prevalent 47. HAART usually establishes 
a rapid reconstitution of the immune system in general, and more specifically, a change in 
Treg distribution as well 48. Based on the above information, we speculate that in HIV infection 
the tolerance for self antigens and infectious agents can be altered. Treg may be crucial in 
these processes 49, 50.Supported by the observations in the current study, we hypothesize that 
high dose vitamin D supplementation can have a adjunctive role in optimizing the immune 
system in HIV-infected patients in the future. Apart from speculations on the role of vitamin 
D for immunity in HIV patients,  vitamin D is certainly crucial for maintaining adequate 
bone metabolism. Since bone disorders are common among people with HIV infection, we 
consider it to be important to achieve normal vitamin D levels in these patients by vitamin 
D supplementation.
In summary: Colecalciferol supplementation established a dose-dependant decrease of 
absolute numbers of circulating CD4+CD25high Treg and a decrease of the percentage of 
CD4+CD25high Tregs in the CD4+ cell subset in 25(OH)D3 deficient HIV-1-infected subjects. 
We speculate about a role for vitamin D supplementation to optimize the immune status of 
HIV-infected-patients.
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Summary and discussion
In 2007, WHO estimated that there are 33.2 million HIV-infected subjects worldwide whereby 
Sub-Sahara Africa is the most affected region. The acces to highly active antiretroviral therapy 
(HAART) in these countries is limited, and many patients will consult a traditional healer and 
receive treatment with herbal medicines. Herbal medicines, like HAART, can be considered 
as xenobiotics and may be metabolized by the Cytochrome P450 (CYP450) enzyme system. 
Apart from xenobiotics, also endogenous compounds may be metabolized by this enzymatic 
metabolizing system. Vitamin D for example is extensively metabolized by different enzymes 
of CYP450.
This thesis focuses on the interaction between compounds that are substrate of CYP450, 
such as antiretroviral drugs, medicinal herbs and vitamin D. We hypothesized that insufficient 
vitamin D levels may develop in HIV-infected subjects not only because of insufficient 
intake, dark skin or possibly HIV itself, but also as a result of Cytochrome P450 interactions. 
This hypothesis was explored and the consequences of vitamin D deficiency in HIV infection 
were studied. 
In this chapter the main results of our studies are summarized and discussed and future 
research questions are formulated.
Herbal medicines are widely used by HIV-infected patients in all parts of the world and 
various herbal medicines may be metabolised by CYP450 just like other drugs. Various 
antiretroviral drugs are also substrate for CYP450 and we anticipated therefore an interaction 
between some of the antiretroviral drugs and medicinal herbs. These interactions might 
lead to either high or low antiretroviral levels with as consequence respectively toxicity or 
insufficient treatment. In chapter 2, we provide an overview of the modulating effects of 
the most commonly used European, American and African herbal medicines on ARV drug-
metabolizing and transporting enzymes, focusing on potential herb-ARV drug interactions. 
It was found that several American and German, and some African herbal medicines may 
modulate CYPs involved in ARV metabolism and  thereby cause interactions with ARVs. 
Evidence from clinical trials with ARVs and drugs with the same metabolic route as ARVs 
indicates that interactions with antiretroviral agents may occur with St John’s wort (SJW), 
allicin-containing garlic, Echinacea, ginkgo and milk thistle. SJW, allicin-containing garlic and 
milk thistle may reduce PI and NNRTI concentrations, thereby increasing risk of therapeutic 
failure, while Echinacea and ginkgo may increase PI and NNRTI concentrations, thereby 
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risking toxic concentrations. Indeed, subtherapeutic ARV levels as a consequence of SJW use 
has been described, but for most other possible interactions, no in vivo data are available. 
Most physicians are aware of the interaction with SJW, but rarely consider the use of other 
herbs, such as the ones mentioned above. Herb-drug interactions are mostly not considered 
important by patients and physicians, and the concurrent intake of ARVs and herbs is 
therefore seldom recorded (personal observation). Apart from the above-mentioned herbs, 
other herb-ARV interactions may occur, although current evidence, especially for African 
herbal medicines, is mostly based on in vitro investigations and therefore limited. Moreover, 
the African herbal medicines are the least investigated while on the African continent, many 
patients still use this form of health care. In recent years, the access to antiretroviral agents 
has increased but, as a result of that, also the risk for herb-ARV interactions. More research to 
unveil potential interactions between commonly used European, American and especially 
African herbal medicines is urgently required.
In chapter 3, herbs that are traditionally used for the treatment of fungal infections in 
Tanzania were studied for their anti fungal effect. Oral fungal infections are very common in 
HIV infection in Tanzania and most patients will at first visit a traditional docter and try the 
effect of medicinal herbs. Very little is known however about the in vitro efficacy of these 
herbs. A total of 65 crude methanol extracts belonging to 56 plant species and 38 families 
were therefore screened using the broth microdilution method, according to the guidelines 
of the Clinical and Laboratory Standard Institute (CLSI) (formerly, National Committee 
for Clinical Laboratory Standards) (NCCLS, 2002). Among the tested plant species, 45% 
(25 species) showed antifungal activity against one or more of the following isolates: 
Candida (C.) albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. krusei and Cryptococcus 
neoformans. The most susceptible isolates were Cryptococcus neoformans, C. krusei, 
C. tropicalis and C. parapsilosis, according to the high number of active plant extracts inhibiting 
their growth. Remarkably, C. albicans was shown to be the least susceptible yeast, as only 
4 plant extracts, including Clausena anisata, Sclerocariya birrea, Turraea holstii and 
Spirostachis africana inhibited its growth. Based on classification criteria for MIC endpoints as 
proposed by Alligianis et al., the following herbal extracts exhibited strong inhibitory activities 
to one or more of the tested isolates: Sclerocarya birrea Sond (root), Elaeodendron buchananii 
(Loes) (stem bark), Pteridium aquilinum (L.) (leaves), Agauria salicifolia Oliv. (leaves), Jatropha 
multifida L. (stem), Acacia robusta subsp. Usembarensis (leaves), Acacia nilotica (L.) Wild ex Del. 
(stem), Turraea holstii Gurk (leaves), Clausena anisata Oliv.(stem bark), Sterculia africana (Lour) 
Fiori (leaves), Cyphostemma hildebrandtii (Gilg) Desc. (leaves)1. 
For some of the herbs, we could not confirm in vitro antifungal activity as has been reported 
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before. Beside the absence of active compound(s), this could be due to factors as place and 
season of collection, the used plant parts and the extraction solvent. Interestingly, parts of 
Spirostachys africana that may be used traditionally as toothbrush indeed showed fungicidal 
activity against C. albicans and C. glabrata. Further bio-guided fractionation to identify the 
active compounds of these herbs may contribute to the discovery and development of 
novel antifungal agents. On the other hand these herbs might be good candidates for cheap 
treatment opportunities in Tanzania. 
The ideal antifungal treatment should have strong antifungal activity against the most 
common pathogens, be cheap,  widely available, non-toxic and should not interfere with the 
metabolism of other drugs such as ARVs. We tested therefore the above mentioned 11 herbs 
with strong inhibitory activities and Spirostachys africana Sonder (stem), selected because of 
its fungicidal activity against C. albicans, for their CYP450 competition and CYP3A4 inducing 
effects and their cytotoxicity and genotoxicity (Chapter 4). This study revealed that Jatropha 
multifida, Sterculia africana and Spirostachys africana were genotoxic. Overall, a high cytoxicity 
for almost all herbal extracts was found. Only Turraea holstii and Sclerocariya birrea  showed 
very low toxicity. Interestingly, these two herbs were among those four reported to have 
antifungal activity against C. albicans and may therefore be interesting candidates for further 
fractionation and isolation of the active compounds.
Regarding the question whether herbs may cause CYP450 interaction, we indeed found 
potent competitive activities (IC50 <100 µg/ml) with CYP2C9, CYP2C19, CYP2D6 and CYP3A4 
in 75% of the herbal extracts. These herbs may have potential to cause high ARV plasma 
levels and hence toxicity. 
Induction of hPXR and CYP3A4 mRNA was found for Agauria salicifolia, Sterculia africana 
and Turraea holsti. Usage of these herbal medicines by HIV-1-infected patients on ARVs may 
potentially lead to subtherapeutic ARV levels and possibly development of resistant HIV. 
Herbal supplements are frequently used not only in Africa, also in Europe the intake of herbal 
medicines and other supplements such as vitamins is common. Especially HIV-infected 
patients are well known users of alternative medicines as herbs and dietary supplements2-6. 
For example, in our study population some 10% of the patients was using herbal supplements 
(unpublished data). In Chapter 5 we describe a significant clinical interaction in a HIV-1-
infected patient who developed toxic lopinavir concentrations while taking several herbal 
medicines. This case indicates that physicians should be aware of herb-ARV interactions 
and they should routinely discuss usage of concomitant alternative medications with their 
patients.
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Apart from herbs also dietary supplements as vitamin D are commonly used by HIV-
infected patients. Within our study population 26% was using vitamin D supplements. As 
a substantial part of the Dutch population of HIV-1-infected patients is from African origin, 
intake of vitamin D might even be necessary. Patients with a dark skin have an increased risk 
for vitamin D deficiency. Besides, HIV itself and the usage of HAART may add more risk for 
vitamin D deficiency. In Chapter 6, we investigated the prevalence and causes of vitamin D 
deficiency among HIV-1-infected patients in the Netherlands. The results revealed that 29% 
of our HIV-1-infected patients (n=252) had vitamin D deficiency. About 25% of these patients 
were from African/ Surinam origin and 62% of them had vitamin D deficiency. Indeed, skin 
color was found to be the only independent risk factor. The results also pointed towards an 
additional effect of NNRTIs on risk for low vitamin D levels. This can probably be explained by 
an increased vitamin D metabolism through induction of CYPs. In addition, higher PTH levels 
were found in patients using NNRTI or PI treatment. Therefore these patients have a higher 
risk for bone demineralization. 
In Chapter 7 and 8 the metabolic and immunological effects of one year vitamin D 
supplementation was analysed in HIV-1-infected patients with a vitamin D deficiency. 
Colecalciferol (2000 IU/day) was supplemented for a minimum of 12 weeks and until vitamin 
D levels normalised, thereafter a maintenance dose of 1000 IU/day was given. 
In chapter 7 we demonstrate that supplementation of 2000 IU colecalciferol per day 
leaded to increased 25-hydroxy vitamin D3 (25(OH)D3) and 1α,25-dihydroxyvitamin D3 
(1α,25(OH)2D3) levels and decreased PTH and insulin sensitivity at 24 weeks. Probably due 
to the lowering of colecalciferol to 1000 IU/ day after 14 weeks, only significantly different 
25(OH)D3 concentrations were found after 48 weeks, while 1α,25(OH)2D3, PTH and insulin 
sensitivity returned to baseline levels. These results indicate that the effects of colecalciferol 
supplementation on vitamin D levels, PTH and insulin sensitivity seemed to be dose 
dependent in HIV-1-infected patients with vitamin D deficiency. No effect on bone mineral 
density and adipocyte function was found. 
The reduction in PTH levels can be explained by the rise in 1α,25(OH)2D3, which regulates 
the negative feedback to PTH. The decrease in insulin sensitivity may be explained by 
the inhibition of the expression of the PPAR-γ receptor by 1α,25(OH)2D3, which has been 
described in vitro7-9. A few human studies and case reports described the effect of vitamin D 
supplementation on insulin resistance and reported conflicting results10, 11. 
Chapter 8 describes the effects of 2 doses of coleciferol, as outlined in chapter 7, on circulating 
CD4+CD25high regulatory T cell numbers (Treg). Treg are important for limiting immune 
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responses against pathogens and for maintaining tolerance for self antigens. Contrary to our 
expectations, a significant decrease in circulating CD4+CD25high Treg number and percentage 
of CD4+ T cell subset was found after 2000 IU calciferol supplementation, while no difference 
compared to baseline was found with 1000 IU calciferol supplementation, indicating that 
1α,25(OH)2D3 affects regulatory T-cells in a dose responsive manner. Based on the in vitro 
observation that 1α,25(OH)2D3 leads to an increase in Treg, it was expected that the number 
of circulating CD4+CD25high Treg would increase after colecalciferol supplementation. The 
opposite finding illustrates that in vitro results cannot directly be extrapolated to the in vivo 
situation. Differences in 1α,25(OH)2D3 concentrations in vitro versus in vivo may be attributed 
to a different effect of colecalciferol supplementation on circulating Treg. It is however likely 
that in vivo the Treg indeed increased, but disappear from the circulation, as redistribution of 
Treg has been described in HIV-1-infected patients before12-16. 
The results of this hypothesis-driven explorative study, as described in chapters 7 and 8, 
need to be confirmed in larger clinical trials. At present however, we conclude that the effect 
of colecalciferol treatment appears to be dose dependent and that colecalciferol dosages 
of ≥2000 IU are necessary in HIV-infected subjects to achieve 1α,25(OH)2D3 levels, that 
significantly decrease PTH and circulating CD4+CD25high Treg. However such dosages also 
decrease insulin sensitivity. 
Future research 
Herbal medicines are often used in African countries for treatment of opportunistic infections 
as oral candidiasis but the effectivity and safety of these agents need more studies. The 
improving access to ARVs in developing countries urges us to explore the interaction between 
commonly used herbal medicines and antiretroviral agents. The research on Tanzanian 
herbs in this thesis sheds some light on potential interactions. Clinical trials are needed to 
reveal pharmacokinetic interactions between commonly used Western and African herbal 
medicines with ARVs. In the design of such studies, it should be taken into account that the 
prevalence of genetic polymorphisms in Cytochrome P450  between subjects from Africa, 
Europe and America differ and these differences  influence drug metabolism as well. 
Vitamin D has several functions that might benefit HIV infected patients. Future research 
should deal with the question whether vitamin D  plays a role in host defence against HIV 
itself. This thesis showed that vitamin D decreases the T-reg number in HIV-1-infected patients. 
Larger clinical trials should be conducted to confirm these results. It is a challenging question 
whether vitamin D plays a role in immune phenomena, such as the immune reconstitution 
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syndrome, that occurs in HIV infected patients after initiation of HAART. In addition, the 
question whether vitamin D substitution influences the chance of development of an 
immune reconstitution syndrome is an intriguing one.
An often debated topic is the definition of vitamin D deficiency and still no consensus is 
reached. It is, however, even more important to answer the question: What is the optimal 
vitamin D status?
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Samenvatting en discussie
In 2007 heeft de WHO de schatting gemaakt dat 33.2 miljoen mensen in de wereld leven met 
een HIV infectie, waarbij Sub-Sahara Afrika het meest aangedaan is. In ontwikkelingslanden 
is de toegang tot HAART beperkt en zullen vele HIV-geinfecteerde patiënten de traditionele 
dokter bezoeken en kruiden geneesmiddelen voorgeschreven krijgen. Kruiden, zijn 
net als “Westerse geneesmiddelen” lichaamsvreemde stoffen (xenobiotics) waarvan de 
stofwisseling plaatsvindt door gespecialiseerde enzymsystemen zoals het Cytochroom P450 
enzymsysteem (CYP450). De stofwisseling van lichaamseigen stoffen kan echter ook door 
het CYP450 systeem plaatsvinden en vitamine D is een voorbeeld van een lichaamseigen 
stof die door verschillende CYP450 enzymen wordt omgezet.
Dit proefschrift richt zich op de interactie tussen componenten die substraat zijn voor CYP450. 
Antiretrovirale geneesmiddelen, en vitamine D worden door CYP450 gemetaboliseerd 
en we hypothetiseerden dat HIV-patiënten een insufficiënte vitamine D status kunnen 
ontwikkelen tengevolge van interactie in het CYP450 systeem. Deze hypothese is getoetst 
en de consequenties van vitamine D tekort in HIV-seropositieve patiënten zijn onderzocht. 
In dit hoofdstuk worden de belangrijkste resultaten samengevat en bediscussieerd en 
toekomstvragen worden geformuleerd.
Door het gelijktijdig gebruik van medicinale kruiden naast antiretrovirale geneesmiddelen, 
ontstaan risico’s voor CYP450 interacties waardoor te hoge of te lage geneesmiddelen 
spiegels kunnen ontstaan met als gevolg toxiciteit dan wel insufficiënte behandeling. In 
hoofdstuk 2, hebben we een overzicht gegeven van de modulerende effecten van de meest 
gebruikte Europese, Amerikaanse en Afrikaanse kruidengeneesmiddelen op de enzymen die 
antiretrovirale middelen metaboliseren en transporteren, gericht op potentiële interacties 
tussen kruiden en antiretrovirale geneesmiddelen. Verschillende Amerikaanse en Europese, en 
sommige Afrikaanse kruidengeneesmiddelen bleken inderdaad CYP enzymen te moduleren die 
betrokken zijn bij de stofwisseling van sommige antiretrovirale geneesmiddelen. Een significante 
interactie tussen kruiden en  deze geneesmiddelen zou hierbij dus kunnen ontstaan. Klinische 
trials met antiretrovirale middelen en geneesmiddelen die via dezelfde route als antiretrovirale 
middelen gemetaboliseerd worden, laten zien dat er potentiële interacties van antiretrovirale 
middelen zijn met St. Janskruid, knoflook (met allicine), Echinacea, ginkgo en mariadistel (milk 
thistle) . St. Janskruid, knoflook (met allicine) en mariadistel kunnen de concentraties van 
protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) verlagen 
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met een verhoogd risico op therapiefalen als gevolg. Echinacea en Ginkgo biloba kunnen 
de PI en NNRTI concentraties verhogen en daarbij een toxische concentraties riskeren. In de 
literatuur zijn inderdaad subtherapeutische antiretrovirale spiegels, tengevolge van het gebruik 
van St. Janskruid beschreven, terwijl dergelijke data ontbreken  voor het gebruik van vele 
andere kruiden die ook via CYP450 worden gemetaboliseerd.  Vaak zijn gezondheidswerkers 
zich nauwelijks bewust van het mogelijke gevaar van het gebruik van medicinale kruiden, 
anders dan St. Janskruid.  Het gebruik van antiretrovirale middelen tezamen met kruiden wordt 
daarom zelden gedocumenteerd (persoonlijke waarneming). Behalve St. Janskruid, knoflook, 
Echinacea, ginkgo en mariadistel, zouden ook nog andere kruidengeneesmiddelen een 
CYP450 interactie kunnen geven, maar het huidige bewijs is, met name voor de Afrikaanse 
kruidengeneesmiddelen, gebaseerd op in vitro data en daarom beperkt. Bovendien zijn de 
Afrikaanse kruidengeneesmiddelen het minst onderzocht, terwijl op het Afrikaanse continent 
veel patiënten vaak een beroep doen op deze vorm van gezondheidszorg. De afgelopen jaren 
is de toegang tot antiretrovirale middelen daar toegenomen, maar hierdoor neemt ook het 
risico op interactie tussen kruiden en antiretrovirale middelen toe. Onderzoek naar potentiële 
interacties tussen de meest gebruikte Europese, Amerikaanse en, in het bijzonder, Afrikaanse 
kruiden geneesmiddelen en antiretrovirale geneesmiddelen, is hard nodig. Om tegemoet te 
komen aan het tekort aan informatie over Afrikaanse kruidengeneesmiddelen en hun potentieel 
interactierisico, hebben wij onderzoek gedaan naar kruiden die traditioneel gebruikt worden 
voor de behandeling van gist infecties in Tanzania. Orale Candida infecties komen vaak voor bij 
HIV patiënten in Tanzania. De meeste van deze patiënten zullen zich eerst door de traditionele 
dokter laten behandelen met kruidengeneesmiddelen. Er is echter maar weinig bekend over 
de in vitro effectiviteit van deze kruiden. In totaal zijn daarom 65 ruwe methanol extracten 
behorende tot 56 plant species  en 38 families gescreend met de ‘broth microdilutie methode’ 
(volgens de richtlijnen van het Clinical and Laboratory Standard Institute (CLSI) (voorheen het 
National Committee for Clinical Laboratory Standards) (NCCLS, 2002). 
De resultaten, beschreven in hoofdstuk 3, lieten zien dat 25 planten species anti-schimmel en 
gist activiteit hadden tegen een of meerdere van de volgende isolaten: C. albicans, C. glabrata, 
C. tropicalis, C. parapsilosis, C. krusei. and Cryptococcus neoformans. Cryptococcus neoformans, 
C. krusei, C. tropicalis en C. parapsilosis waren het meest gevoelig, gezien het hoge aantal 
actieve plantextracten dat hun groei remden. Opmerkelijk genoeg bleek C. albicans de minst 
gevoelige gist en we vonden maar vier plant extracten, namelijk Clausena anisata, Sclerocariya 
birrea, Turraea holstii en Spirostachis africana, die groei remden. Gebaseerd op de classificatie 
criteria voor minimaal remmende concentratie (MRC) eindpunten, zoals opgesteld door 
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Alligianis et al. 1, hebben de volgende kruiden extracten een sterke remmende activiteit 
(MRC ≤ 0,5 mg/ml) tegen één of meer van de isolaten: Sclerocarya birrea Sond (wortel), 
Elaeodendron buchananii (Loes) (schors), Pteridium aquilinum (L.) (bladeren), Agauria salicifolia 
Oliv. (bladeren), Jatropha multifida L. (stem), Acacia robusta subsp. Usembarensis (bladeren), 
Acacia nilotica (L.) Wild ex Del. (stem), Turraea holstii Gurk (bladeren), Clausena anisata Oliv.
(stem bark), Sterculia africana (Lour) Fiori (bladeren), Cyphostemma hildebrandtii (Gilg) Desc. 
(bladeren). Voor sommige kruiden, waarvoor in de literatuur de in vitro anti-schimmel en gist 
activiteit beschreven was, konden wij dit resultaat niet bevestigen. Naast de afwezigheid 
van actieve componenten, kan dit worden veroorzaakt door factoren als plaats en seizoen 
van verzamelen, de gebruikte plantendelen en het extractie middel. Het is interessant dat 
Spirostachys africana, dat in Afrika wel gebruikt wordt om de tanden te reinigen, gistdodende 
activiteit liet zien tegen C. albicans en C. glabrata. Het fractioneren en identificeren van 
de actieve componenten van deze kruiden zou kunnen leiden tot de ontdekking en 
ontwikkeling van nieuwe anti- Candida geneesmiddelen. Daarnaast zouden deze kruiden 
goede kandidaten kunnen zijn voor goedkope behandelmogelijkheden in Tanzania.
De ideale antimicrobiële behandeling moet een aantal eigenschappen bezitten zoals 
sterk dodende activiteit tegen de meest voorkomende pathogenen, goedkoop zijn, 
gemakkelijk verkrijgbaar, niet toxisch en niet interfererend met het metabolisme van ander 
geneesmiddelen. De hierboven genoemde elf kruiden met sterke anti-schimmel and gist 
activiteit plus Spirostachys africana Sonder (stam), vanwege zijn dodende activiteit tegen 
C. albicans, zijn daarom getest op competitie met CYP2C9, CYP2C19, CYP2D6 en CYP3A4, 
en CYP3A4 inducerende effecten, cytotoxiciteit en genotoxiciteit (Hoofdstuk 4). Over het 
algemeen lieten alle kruidengeneesmiddelen een hoge cytotoxiciteit zien. AlleenTurraea 
holstii en Sclerocariya birrea hadden een lage toxiciteit. Het is opmerkelijk dat deze twee 
kruiden bij de vier kruiden behoorden met dodende activiteit tegen C. albicans. Deze twee 
kruiden zijn daarom interessante kandidaten voor het verder fractioneren en isoleren van 
de actieve componenten. Voor meer dan 75% van de plant extracten werden potente 
competitieve activiteiten (inhibirende concentratie <100 µg/ml) met CYP2C9, CYP2C19, 
CYP2D6 en CYP3A4 gemeten. Deze kruiden kunnen daarom mogelijk aanleiding geven tot 
hoge antiretrovirale plasma spiegels , met toxiciteit tot gevolg.
Inductie van de humane pregnane X receptor en CYP3A4 mRNA is gevonden voor Agauria 
salicifolia, Sterculia africana and Turraea holsti. Het gebruik van deze kruidengeneesmiddelen 
door HIV-geïnfecteerde patiënten zou daarom mogelijk kunnen leiden tot subtherapeutische 
ARV spiegels en mogelijk tot ontwikkelen van HIV resistentie. 
Kruidengeneesmiddelen worden niet alleen in Afrika veel gebruikt, maar ook in Europa is de 
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inname van kruidengeneesmiddelen en andere supplementen zoals vitamines algemeen. 
In het bijzonder zijn HIV-patiënten bekende gebruikers van alternatieve geneesmiddelen 
als kruiden en voedingssupplementen2-6. In onze studie populatie bijvoorbeeld, gebruikte 
ongeveer 10% van de patiënten kruidengeneesmiddelen (ongepubliceerde data). In hoofdstuk 
5 hebben we een significante klinische interactie beschreven in een HIV-geïnfecteerde patiënt 
die een toxische lopinavir concentratie ontwikkelde tijdens het gebruik van verschillende 
kruidengeneesmiddelen. Deze casus illustreert dat artsen beducht moeten zijn op interacties 
tussen kruiden en antiretrovirale geneesmiddelen. Tevens zouden ze regelmatig het gebruik 
van alternatieve geneesmiddelen met hun patiënten moeten bespreken.
Naast kruiden worden voedingssupplementen zoals vitamine D veel gebruikt door HIV-
patiënten. In onze studie populatie bleek dat 26% van de patiënten niet door een arts 
voorgeschreven vitamine D supplementen te gebruiken. Voor deze suppletie is ook een 
mogelijke rationale: een substantieel deel van de patiënten die in Nerderland worden 
behandeld voor een HIV infectie is van Afrikaanse origine, en hebben met een donkere 
huidskleur een verhoogd risico op vitamine D tekort. Daarnaast, zouden HIV zelf en het 
gebruik van antiretrovirale therapie ook kunnen zorgen voor een hoger risico op vitamine 
D tekort. In hoofdstuk 6 hebben we de prevalentie en oorzaken van vitamine D tekort in 
HIV-patiënten in Nederland onderzocht. De resultaten wezen uit dat 29% van onze HIV-
geïnfecteerde patiënten (n=252) vitamine D tekort had. Ongeveer 25% van deze patiënten 
was van Afrikaanse/ Surinaamse origine en 62% van deze mensen had een vitamine D 
deficiëntie. Huidskleur werd als de enige significante risicofactor voor vitamine D tekort 
gevonden. De resultaten wezen verder ook uit dat NNRTIs een aanvullend effect hebben op 
het risico op lage vitamine D waarden. Dit kan mogelijk worden verklaard door een verhoogd 
vitamine D metabolisme door inductie van CYP enzymen. Daarnaast werden er hoger PTH 
waarden gevonden bij patiënten die NNRTI of PI behandeling ontvingen. 
In hoofdstuk 7 en 8 zijn de metabole en immunologische effecten van 1 jaar vitamine D 
suppletie in HIV-1-patienten geanalyseerd. Cholecalciferol (2000IE per dag) werd voor 
een minimum van 12 weken toegediend, totdat de vitamine D waarden genormaliseerd 
waren. Daarna werd een onderhoudsdosering van 1000IE per dag gegeven. Hoofdstuk 7 
beschrijft dat het dagelijks suppleren van 2000IE cholecalciferol leidt tot toegenomen 
vitamine D waarden op 24  weken, zo wel van de 25-hydroxy vitamine D3 (25(OH)D3) als 
van de 1α,25-dihydroxy vitamine D3 (1α,25(OH)2D3) waarden met verder ook een afname 
van parathormoon (PTH) en van insuline gevoeligheid. Waarschijnlijk door het verlagen van 
de cholecalciferol dosering naar 1000IE/dag na 14 weken, werd er op 48 weken alleen een 
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significant verschil waargenomen in de 25(OH)D3 spiegel, terwijl de andere parameters weer 
terug op baseline niveau waren. Deze resultaten suggereren dat de effecten van colecalciferol 
suppletie op vitamine D waarden, PTH en insuline gevoeligheid dosis-afhankelijk zijn in HIV-
1-geinfecteerden patiënten met vitamine D tekort. Er werd geen effect van colecalciferol 
suppletie op de botdichtheid en vetcel functie gevonden. 
De afname in PTH waarden kan worden verklaard door de stijging in 1α,25(OH)2D3, dat de 
negatieve feedback op PTH reguleert. De afname in insuline gevoeligheid kan mogelijk worden 
verklaard doordat de PPAR-γ receptor door 1α,25(OH)2D3 wordt geremd, zoals ook in vitro is 
beschreven7-9. Enkele humane studies en casussen hebben het effect van vitamine D suppletie 
op insuline resistentie beschreven, maar rapporteerden tegenstrijdige resultaten10, 11. 
Hoofdstuk 8 beschrijft de effecten van 2 cholecalciferol doseringen, zoals uitgelegd in 
hoofdstuk 7, op de circulerende CD4+CD25high regulatoire T cel aantallen. Regulatoire T 
cellen zijn belangrijk voor het begrenzen van het immuunrespons tegen pathogenen 
en voor het onderhouden van de tolerantie tegen lichaamseigen antigenen. De definitie 
van een regulatoire T cell is niet eenduidig tot nu toe maar de meeste Tregs behoren tot 
de CD4+CD25high T-cell populatie. In tegenstelling tot onze verwachtingen, werd er een 
significante afname in het aantal circulerende regulatoire T cellen  en percentage CD4+ T 
cellen gevonden na suppletie van 2000 IE cholecalciferol, terwijl geen verschil ten opzichte 
van baseline werd gevonden na toediening van 1000 IE. Dit suggereert dat 1α,25(OH)2D3 
ook een dosis respons effect lijkt te hebben op de regulatoire T cellen. Gebaseerd op de 
in vitro waarneming dat 1α,25(OH)2D3 leidde tot een toename in regulatoire T- cellen, was 
de verwachting dat het aantal circulerende CD4+CD25high regulatoire T-cellen zou stijgen na 
cholecalciferol suppletie. De tegenovergestelde vinding laat zien dat in vitro observaties niet 
altijd direct naar de in vivo situatie geëxtrapoleerd kunnen worden. Een mogelijke verklaring 
voor deze bevinding is dat de regulatoire T cellen in vivo wel toegenomen zijn, maar uit de 
circulatie verdwenen zijn en zich herverdeeld hebben. Deze redistributie van regulatoire T 
cellen is namelijk eerder in HIV-1-patienten beschreven12-16. 
De resultaten van deze hypothesis gedreven explorerende studie, zoals beschreven in 
hoofdstuk 7 en 8, dienen bevestigd te worden in grotere klinische studies. Op dit moment, 
kunnen we concluderen dat het effect van cholecalciferol behandeling dosis afhankelijk lijkt 
te zijn en dat cholecalciferol doseringen van ≥2000IE noodzakelijk zijn om in HIV-patienten 
die 1α,25(OH)2D3 waarde te bereiken, die zorgt voor een significante afname in PTH en 
circulerende CD4+CD25high regulatoire T cellen maar dat deze dosering ook een negatief 
effect op insuline gevoeligheid lijkt te hebben. 9
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Toekomst onderzoek
Kruiden medicijnen worden effectief gebruikt in Afrikaanse landen voor de behandeling 
van opportunistische infecties als orale Candida-infecties. Desalniettemin is er meer 
onderzoek nodig om de effectiviteit en veiligheid van deze geneesmiddelen te bewijzen. 
De verbeterende toegang tot antiretrovirale geneesmiddelen in ontwikkelingslanden 
zou het verder onderzoeken van de interacties tussen veelgebruikte kruiden- en 
antiretrovirale geneesmiddelen moeten aansporen. Het onderzoek onder de Tanzaniaanse 
kruidengeneesmiddelen in dit proefschrift geeft iets meer inzicht in potentiële interacties. 
Klinische studies zijn nodig om pharmacokinetische interacties tussen de veelgebruikte 
Westerse en Afrikaanse kruiden geneesmiddelen met antiretrovirale middelen aan het licht 
te brengen. Gedurende deze studies moet rekening worden gehouden met de verschillen 
in de prevalentie van genetische polymorfismen in CYP enzymen tussen personen uit Afrika, 
Europa en Amerika, die het geneesmiddelmetabolisme kunnen beïnvloeden.
Vitamine D heeft verschillende functies die voor HIV patiënten van groot belang zouden 
kunnen zijn. Met name, wat is de rol van vitamin D bij de immuunresponse op HIV zelf en 
speelt vitamine D een rol bij het ontstaan van diabetes of het immuun reconstitutie syndroom, 
dat bij HIV-geïnfecteerde patiënten regelmatig wordt gezien. 
In de literatuur is er discussie over de definitie van vitamine D deficiëntie, en daarover is nog 
geen consensus. Mogelijk is het nog belangrijker om de volgende vraag te beantwoorden: 
Wat is de optimale vitamine D status?
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Dankwoord
Met maar liefst 65 plantextracten kwamen we terug uit Tanzania. Trots op zoveel mooi 
materiaal. Het moment, Mei 2004, waar het promotieonderzoek geboren werd. Aangestoken 
en gemotiveerd door een enthousiaste André van der Ven. De subsidies moesten nog 
binnengesprokkeld worden, maar het besluit stond. Ik ga ervoor! Mede dankzij de subsidie 
van de AIDS werkgroep van dit ziekenhuis kon in Juli 2005 het echte werk beginnen. In 
samenwerking met diverse afdelingen startte de VIDI-trial. Daarnaast gaf Organon mij de 
mogelijkheid het kruidenonderzoek voort te zetten. Het waren intensieve jaren. Ik wil hier 
graag allen bedanken die een bijdrage hebben geleverd aan het onderzoek in dit proefschrift.
Prof. dr. van der Meer, promotor, beste Jos, dank voor je steun aan het onderzoek en het delen 
van je kennis tijdens de leerzame cytokinebesprekingen.
Dr. van der Ven, co-promotor, beste André, je enthousiasme voor het onderzoek heb ik als 
stimulerend ervaren. Ik ben onder de indruk van je kennis en het (schijnbare) gemak waarmee 
je nieuwe ideeën genereert. Dank voor je begeleiding, inzet en de mogelijkheden die je mij 
bood om onderzoek te doen. Het traject was niet altijd makkelijk, maar we zijn er gekomen!
Dr. Koopmans, co-promotor, beste Peter, dank je voor het begeleiden en meedenken, en de 
goede samenwerking bij het opzetten en uitvoeren van de VIDI studie.  
In Tanzania I would like to thank Prof. dr. Matee for giving me the opportunity to work at 
MUCHS, Dar es Salaam, Tanzania. Thank you for supervising me and Omar during our project. 
I also thank Prof. Moshi for his support and the change to work at the Institute of Traditional 
medicine, MUCHS, Tanzania. Haji O. Selemani, our botanist, your knowledge about the herbs 
and traditional healers was of great help. I very much enjoyed our forest walks!
Special thanks to my colleague Omar Hamza, dear Omar, Asante sana (thank you very much) 
for the pleasant cooperation. I really enjoyed my stay in Tanzania. I will never forget the funny 
and scary experiences during the forest walks. Especially that time we walked in the forest 
when the evening was already falling. We had ensured with the healer that the walk should 
not take longer than an hour. However, as usually, it took much longer. In the afternoon, we 
had heard on the news that, in the same forest, tourists were attacked by lions. The healer 
had no worries, but we were scared by every crack we heard. And now, although our research 
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paths separated through the years, we safely arrived at the end to finish our PhD on the 
same day! Dear Omar, I wish you all the best and really hope you can use all your skills and 
knowledge to make a difference for the HIV patients in Tanzania. 
Special thanks also for dr. Edda Vuhahula Wandwi for her kind hospitality and interest in 
my studies. I really appreciated that I could live with you and your family during my stay in 
Tanzania. It gave me a real view into the Tanzanian way of living. Asante Sana! 
Bij NV Organon (Schering-Plough Corporation), Oss: Willem Schoonen, dank je wel voor 
de goede samenwerking en mogelijkheden die je gaf om een deel van mijn onderzoek bij 
jullie te kunnen uitvoeren. Bedankt voor het delen van je kennis en de bijdrage die je met 
Walter geleverd hebt aan de artikelen. Daarnaast dank ik Walter Westerink en Joe Stevenson 
voor de hulp bij het uitvoeren van de testen. Ook de andere medewerkers dank ik voor de 
gezelligheid tijdens de lunch en koffiepauzes.  
De medewerkers van de medische microbiologie, Hein van der Lee en Ton Rijs, dank voor jullie 
hulp en alle gezelligheid. Elke keer als ik weer even kwam buurten op de microbiologie was het 
weer gezellig en leefden jullie  mee! 
Ik dank Peter de Smet voor de samenwerking tijdens het schrijven van het review 
artikel. Ik ben onder de indruk van je kennis en waardeer je bevlogenheid over 
kruidengeneesmiddelen en de alternatieve geneeskunst.
Marjolein Bosch, HIV-verpleegkundige en research verpleegkundige, dank je wel voor al 
je hulp en de goede samenwerking tijdens de VIDI-trial. Je was meelevend, oplettend en 
je zorgt goed voor je patiënten. Dat heb ik zeer gewaardeerd! 
Ook de HIV verpleegkundigen Bert Zomer en Karin Grintjes, bedankt voor al jullie hulp 
en de goede samenwerking. 
Verder dank ik Annemarie Goedhart-Camp en de andere medewerkers van Post blauw 
voor het afnemen en verzamelen van alle bloedmonsters. Ook dank ik Minny Meeuwissen 
voor de hulp bij het verzamelen van de gegevens voor de VIDI-trial. 
Ik dank Hadewich ter Hofstede, die als trial-arts een onmisbare bijdrage heeft geleverd 
aan de VIDI-trial. 
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Dr. Monique Keuter dank ik voor haar goede medewerking aan de VIDI-trial. 
Ik wil graag alle patiënten bedanken die hebben deelgenomen aan de VIDI-trial. 
De extra bloedafnames en onderzoeken die jullie hebben ondergaan zijn van onmisbare 
waarde bij het onderzoek in dit proefschrift. Bedankt!
Binnen het ABTI dank ik Hans Koenen, voor de prettige samenwerking tijdens de VIDI-
trial en het delen van zijn kennis om “de regulatoire T-cel” te kunnen meten. Daarnaast 
dank ik Ronald van Beek voor de vele metingen die, soms ad hoc, toch maar weer gedaan 
werden! 
Ik dank Prof. dr. Hermus, Prof. dr. Sweep, Prof. dr. Oyen en dr. Preijers voor de goede 
samenwerking tijdens de VIDI-trial. Ik vond het prettig dat ik bij jullie terecht kon met 
vragen en jullie kritische bijdrage aan de artikelen heb ik zeer gewaardeerd.  
De analisten van het Algemeen Klinisch Chemisch Lab, Centraal Hematologisch Lab, 
Chemisch Endrocinologisch Lab en Lab Klinische Farmacie dank ik  voor het uitvoeren 
van de vele labbepalingen, de onmisbare data voor het onderzoek.
Ik dank de medewerkers van Nucleaire Geneeskunde, in het bijzonder Marjo van der Ven, 
voor de goede samenwerking bij het uitvoeren van alle DEXA-scans. 
Ik dank Lydia Fievez, die voor haar onderzoeksstage de vele CD4 data heeft uitgezocht. 
Veel succes met je verdere opleiding.
Medewerkers lab interne, in het bijzonder Johanna, Trees, Liesbeth, Helga en Anneke, 
bedankt voor jullie hulp en assistentie en de gezelligheid op het lab.
Maartje van den Bos en Meta Michels, hartelijk dank voor jullie hulp als stagiaires tijdens de 
VIDI-trial. Dankzij jullie inzet kon ik met een gerust hart op zwangerschapsverlof. Maartje, veel 
succes in Mexico toegewenst. Meta, leuk dat je ook na je stage nog zo enthousiast met het 
T-reg onderzoek bent verder gegaan. Ik wens je veel succes met je opleiding en hoop dat je 
ook verder kunt in het onderzoek!
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Mijn collega-onderzoeker, Quirijn de Mast, dank voor je gezelligheid als kamergenoot. 
Veel succes met je opleiding en promotie.
Oud-collega’s, Clara Blaauw en José dank voor jullie meeleven en gezelligheid.
Ik dank Carla Ysenbrandt en Mieke Daalderop voor jullie meeleven, gezelligheid en  praktische 
hulp.
De collega’s van interne dank ik voor het delen van jullie kennis, het meeleven en de 
gezelligheid die we met elkaar tijdens lunches of uitstapjes mochten hebben!
De leden van de manuscriptcommissie, Prof dr. Hekster, Prof dr. Galama en Prof dr. Brinkman 
wil ik bedanken voor het beoordelen van dit proefschrift.
Meta en Hein, ik vind het geweldig dat jullie als paranimfen achter mij willen staan, bedankt 
voor jullie ondersteuning en inspanningen.
Vrienden en familie, dank jullie wel voor alle steun en interesse in mijn onderzoek. 
Lieve Arnoud, Tanzania was al niet te ver om mij achterna te reizen en samen avonturen te 
mogen beleven. De afgelopen drie jaar waren een mooi, maar soms ook moeilijk avontuur 
met bergen en dalen waar je mij doorheen geholpen hebt. Je steunde mij altijd en dat 
waardeer ik heel erg. We hebben het samen gehaald! 
Lieve Rosalie en Noortje, nog te klein om het echt te ervaren hebben jullie in dit traject voor 
heel wat leuke en ontspannende momenten gezorgd.  Ik houd van jullie! 
Samen gaan we nog heel wat mooie avonturen beleven!
Afgelopen jaren heb ik niet aan mensen alleen te danken. De grootste dank komt toe aan 
mijn God en Vader in de hemel, “daar Hij zelf aan allen, leven en adem en alles geeft” 
(Handelingen 17:25c).
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Cornelia Johanna Petra (Carolien) van den Bout- van den Beukel werd op 6 augustus 
1980 geboren in Delft. Zij groeide op in Monster en behaalde het HAVO diploma aan de 
interconfessionele scholengemeenschap “Het Westland” in Naaldwijk. Aansluitend startte zij 
met de studie Biologie en Medisch Laboratorium Onderzoek aan de Hogeschool Rotterdam 
en Omstreken in Rotterdam. In het laatste studiejaar deed zij onderzoek naar de rol van de IL-1 
en TLR-4 receptor bij invasieve pulmonaire aspergillose (Laboratorium interne geneeskunde, 
UMC St Radboud, Nijmegen). In juli 2002 behaalde ze het bachelor examen. Daarna 
studeerde zij Biomedische Wetenschappen aan de Radboud Universiteit Nijmegen, waar zij 
zich specialiseerde in pathobiologie en geneesmiddelenonderzoek. Tijdens de laatste jaren 
deed zij onderzoek naar de relatie tussen nevirapine plasmaconcentraties en hepatotoxiciteit 
(Afdeling Klinische Farmacie, UMC St Radboud, Nijmegen) en antifungale activiteit en 
interacties met cytochrome P450 van traditionele kruidengeneesmiddelen uit Tanzania 
(MUCHS, Tanzania en Afdeling Medische Microbiologie, UMC St. Radboud, Nijmegen). 
Na het behalen van het doctoraalexamen in Juni 2005, startte zij in Juli 2005 met haar 
promotieonderzoek bij de afdeling Algemene Interne Geneeskunde van het UMC 
St Radboud te Nijmegen. Na het afronden van het promotieonderzoek, werkte zij van 
Juli 2008 tot Januari 2009 als Pharmacovigilance Manager bij Synthon BV in Nijmegen. 
Carolien is op 31 augustus 2005  getrouwd met Arnoud en is moeder van Rosalie en Noortje 
van den Bout. 
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